Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:amino acid amide
go back to main search page
Accession:CHEBI:22475 term browser browse the term
Definition:An amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.


show annotations for term's descendants           Sort by:
anagliptin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CCL2 mRNA] CTD PMID:31586451 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ctsk cathepsin K multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CTSK mRNA] CTD PMID:31586451 NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550 		JBrowse link
G Ctss cathepsin S multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CTSS mRNA] CTD PMID:31586451 NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483 		JBrowse link
G Cyba cytochrome b-245 alpha chain multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CYBA mRNA] CTD PMID:31586451 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of CYBB mRNA] CTD PMID:31586451 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 decreases activity ISO anagliptin results in decreased activity of DPP4 protein CTD PMID:31586451 NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of ICAM1 mRNA] CTD PMID:31586451 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP2 mRNA] CTD PMID:31586451 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of MMP9 mRNA] CTD PMID:31586451 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anagliptin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; anagliptin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; anagliptin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein] CTD PMID:31586451 NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166 		JBrowse link
G Vcam1 vascular cell adhesion molecule 1 multiple interactions ISO anagliptin inhibits the reaction [Hydrogen Peroxide results in increased expression of VCAM1 mRNA] CTD PMID:31586451 NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958 		JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca2 ATP binding cassette subfamily A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases expression
decreases activity		 ISO [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein		 CTD PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein		 CTD PMID:20977926 PMID:33775688 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238 		JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283 		JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927 		JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061 		JBrowse link
G Abi1 abl-interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792 		JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284 PMID:17495969 PMID:21195056 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065 		JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131 		JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309 		JBrowse link
G Adam10 ADAM metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889 		JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression		 ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA		 CTD PMID:20471514 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654 		JBrowse link
G Aff1 ALF transcription elongation factor 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729 		JBrowse link
G Aff4 ALF transcription elongation factor 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751 		JBrowse link
G Afg2a AFG2 AAA ATPase homolog A increases expression ISO Bortezomib results in increased expression of AFG2A mRNA CTD PMID:20977926 NCBI chr 2:120,306,417...120,497,707
Ensembl chr 2:120,306,412...120,497,705 		JBrowse link
G Ager advanced glycosylation end product-specific receptor multiple interactions
increases expression		 EXP Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] CTD PMID:35121005 NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078 		JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934 		JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003 		JBrowse link
G Agtpbp1 ATP/GTP binding carboxypeptidase 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr17:5,120,540...5,238,874
Ensembl chr17:5,120,609...5,238,869 		JBrowse link
G Agtrap angiotensin II receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 affects localization
multiple interactions		 ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein		 CTD PMID:12893773 PMID:16024631 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Aifm2 apoptosis inducing factor, mitochondria associated 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr20:29,654,283...29,679,239
Ensembl chr20:29,652,927...29,679,236 		JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975 		JBrowse link
G Airim AFG2 interacting ribosome maturation factor increases expression ISO Bortezomib results in increased expression of AIRIM mRNA CTD PMID:20977926 NCBI chr 5:137,198,688...137,205,912
Ensembl chr 5:137,198,720...137,204,026 		JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B1 increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157 		JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852 		JBrowse link
G Akr1c1 aldo-keto reductase family 1, member C1 multiple interactions
increases expression		 ISO [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA
Bortezomib results in increased expression of AKR1C1 mRNA		 CTD PMID:21215737 PMID:25913414 NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326 		JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases activity
decreases expression		 ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein		 CTD PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890 		JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677 		JBrowse link
G Aldh6a1 aldehyde dehydrogenase 6 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656 		JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542 		JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr10:105,875,209...105,886,307 JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression		 ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA		 CTD PMID:17895889 PMID:20977926 NCBI chr12:33,748,709...33,781,709
Ensembl chr12:33,748,735...33,781,781 		JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923 		JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670 		JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713 		JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 1:95,384,306...95,414,170
Ensembl chr 1:95,384,309...95,414,147 		JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528 		JBrowse link
G Apol9a apolipoprotein L9a decreases expression ISO Bortezomib results in decreased expression of APOL4 mRNA CTD PMID:20977926 NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649 		JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:77,377,723...77,443,672
Ensembl chr  X:77,377,781...77,443,900 		JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720 		JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796 PMID:30818834 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Arf6 ADP-ribosylation factor 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114 		JBrowse link
G Arfgap1 ADP-ribosylation factor GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933 		JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396 		JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023 		JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318 		JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513 		JBrowse link
G Arl8a ADP-ribosylation factor like GTPase 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr13:46,585,845...46,594,851
Ensembl chr13:46,585,845...46,594,851 		JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061 		JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754 		JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908 		JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression		 ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA		 CTD PMID:12393500 PMID:20977926 NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236 		JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions		 ISO
EXP		 ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]		 CTD PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance		 ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16928686 PMID:20022965 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707 		JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases cleavage		 ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437 		JBrowse link
G Atp1a3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918 		JBrowse link
G Atp2a1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance		 ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib		 CTD PMID:25576094 NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838 		JBrowse link
G Atp6v0e1 ATPase H+ transporting V0 subunit e1 increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434 		JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766 		JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273 		JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247 		JBrowse link
G Bag3 BAG cochaperone 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775 PMID:17659339 PMID:20471514 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression		 ISO [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein		 CTD PMID:12902978 PMID:17326159 PMID:20850924 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression		 ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein		 CTD PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295 PMID:20051518 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bbln bublin coiled coil protein decreases expression ISO Bortezomib results in decreased expression of BBLN mRNA CTD PMID:20977926 NCBI chr 3:15,674,577...15,677,322
Ensembl chr 3:15,674,580...15,677,374 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein		 CTD PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions
increases expression		 ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein		 CTD PMID:18223231 PMID:20051518 NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance		 ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More... NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression
increases activity
increases response to substance		 ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib		 CTD PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 More... NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624 		JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA		 CTD PMID:20471514 PMID:20977926 NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607 		JBrowse link
G Bcl6 BCL6, transcription repressor increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389 		JBrowse link
G Bcl7a BAF chromatin remodeling complex subunit BCL7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:33,211,978...33,243,903
Ensembl chr12:33,223,931...33,243,886 		JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016 		JBrowse link
G Becn1 beclin 1 multiple interactions
decreases response to substance		 ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:22842577 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions		 ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]		 CTD PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More... NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity		 ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein		 CTD PMID:16446371 PMID:18566236 NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296 		JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein		 CTD PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732 		JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions		 ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA		 CTD PMID:17626072 PMID:24085292 PMID:25522274 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression		 ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein]
Bortezomib results in increased expression of BIRC5 protein		 CTD PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More... NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression		 ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606 		JBrowse link
G Bles03 basophilic leukemia expressed protein BLES03 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804 		JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031 		JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375 		JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination		 ISO Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein		 CTD PMID:21917757 PMID:25522274 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304 		JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA		 CTD PMID:21917757 PMID:25913414 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567 		JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080 		JBrowse link
G Brf2 BRF2, RNA polymerase III transcription initiation factor subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr16:64,928,334...64,933,057
Ensembl chr16:64,928,300...64,933,059 		JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092 		JBrowse link
G C17h6orf62 similar to human chromosome 6 open reading frame 62 increases expression ISO Bortezomib results in increased expression of C6ORF62 mRNA CTD PMID:20977926 NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020 		JBrowse link
G C1h9orf85 similar to human chromosome 9 open reading frame 85 increases expression ISO Bortezomib results in increased expression of C9ORF85 mRNA CTD PMID:20977926 NCBI chr 1:219,136,085...219,197,723
Ensembl chr 1:219,138,201...219,198,435 		JBrowse link
G C2h4orf3 similar to human chromosome 4 open reading frame 3 decreases expression ISO Bortezomib results in decreased expression of C4ORF3 mRNA CTD PMID:20977926 NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681 		JBrowse link
G C6h14orf132 similar to human chromosome 14 open reading frame 132 decreases expression ISO Bortezomib results in decreased expression of C14ORF132 mRNA CTD PMID:20977926 NCBI chr 6:124,365,466...124,398,449 JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314 		JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376 		JBrowse link
G Calr calreticulin multiple interactions
increases expression		 ISO [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]		 CTD PMID:30482226 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414 		JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508 		JBrowse link
G Car9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838 		JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237 		JBrowse link
G Casp12 caspase 12 increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775 PMID:16357177 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage		 ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein		 CTD PMID:15509775 PMID:16446371 PMID:18723477 NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379 		JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression		 ISO Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein		 CTD PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity		 ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein		 CTD PMID:16357177 PMID:18641367 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092 		JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage		 ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327 PMID:17510429 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502 		JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity		 ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein		 CTD PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More... NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage		 ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage		 ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib		 CTD PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More... NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of CAT protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]		 CTD PMID:35121005 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbl Cbl proto-oncogene multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176 		JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931 PMID:20977926 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875 		JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283 		JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647 PMID:21903591 NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526 		JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935 		JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975 		JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658 		JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression		 EXP
ISO		 Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA		 CTD PMID:18089816 PMID:20830808 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression		 ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein		 CTD PMID:19074855 PMID:20367638 PMID:25522274 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein] CTD PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495 		JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101 		JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830 		JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514 PMID:20977926 NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430 		JBrowse link
G Cd27 CD27 molecule increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592 		JBrowse link
G Cd38 CD38 molecule decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986 		JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313 		JBrowse link
G Cd69 Cd69 molecule increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542 		JBrowse link
G Cd79a CD79a molecule decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935 		JBrowse link
G Cd82 Cd82 molecule decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809 		JBrowse link
G Cd9 CD9 molecule increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222 		JBrowse link
G Cdc23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163 		JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186 		JBrowse link
G Cdc37 cell division cycle 37, HSP90 cochaperone increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809 		JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111 		JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
Ensembl chr 1:38,836,555...38,905,059 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity		 ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein		 CTD PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity		 ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein		 CTD PMID:14749476 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression		 ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein		 CTD PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 More... NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression		 ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein		 CTD PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 More... NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
decreases expression		 ISO
EXP		 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib results in decreased expression of CEBPB mRNA		 CTD PMID:20471514 PMID:20830808 PMID:30482226 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473 		JBrowse link
G Cenpc centromere protein C increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476 		JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392 		JBrowse link
G Cers2 ceramide synthase 2 multiple interactions ISO Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein] CTD PMID:34915026 NCBI chr 2:182,890,527...182,898,805
Ensembl chr 2:182,890,493...182,933,314 		JBrowse link
G Cers6 ceramide synthase 6 multiple interactions ISO Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] CTD PMID:34915026 NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression		 ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form		 CTD PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 More... NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526 		JBrowse link
G Chaf1a chromatin assembly factor 1 subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654 		JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502 		JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014 		JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111 		JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 8:95,960,067...95,966,312
Ensembl chr 8:95,959,826...95,966,955 		JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases expression
increases activity		 ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein		 CTD PMID:20471514 PMID:24085292 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065 		JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr15:29,252,208...29,256,482
Ensembl chr15:29,252,213...29,256,605 		JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691 		JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897 		JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr 6:23,616,280...23,697,625
NCBI chr 6:23,718,580...23,729,231
NCBI chr 6:23,597,729...23,601,000
Ensembl chr 6:23,616,281...23,677,874 		JBrowse link
G Cln6 CLN6, transmembrane ER protein decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360 		JBrowse link
G Clptm1 CLPTM1 regulator of GABA type A receptor forward trafficking decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092 		JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315 		JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:204,402,118...204,404,439 JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c increases response to substance ISO CPT1C gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of CREB1 protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein]		 CTD PMID:35121005 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816 		JBrowse link
G Crebbp CREB binding protein decreases expression ISO Bortezomib results in decreased expression of CREBBP mRNA CTD PMID:25913414 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888 		JBrowse link
G Crem cAMP responsive element modulator increases expression ISO Bortezomib results in increased expression of CREM mRNA CTD PMID:20977926 NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989 		JBrowse link
G Crip2 cysteine-rich protein 2 decreases expression ISO Bortezomib results in decreased expression of CRIP2 mRNA CTD PMID:20977926 NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065 		JBrowse link
G Cripto cripto, EGF-CFC family member increases expression ISO Bortezomib results in increased expression of CRIPTO mRNA CTD PMID:17895889 NCBI chr 8:110,924,774...110,938,545
Ensembl chr 8:110,925,024...110,930,308 		JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238 		JBrowse link
G Cryab crystallin, alpha B multiple interactions
increases expression		 ISO
EXP		 [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA		 CTD PMID:20830808 PMID:25522274 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157 		JBrowse link
G Cst7 cystatin F increases expression ISO Bortezomib results in increased expression of CST7 mRNA CTD PMID:20977926 NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557 		JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression ISO Bortezomib results in decreased expression of CTDSPL2 mRNA CTD PMID:20977926 NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227 		JBrowse link
G Cth cystathionine gamma-lyase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA CTD PMID:25522274 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases response to substance
increases expression		 ISO 2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] CTD PMID:18485479 PMID:19100720 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Ctsb cathepsin B multiple interactions
increases localization		 ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] CTD PMID:16446371 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500 		JBrowse link
G Ctsd cathepsin D increases expression ISO Bortezomib results in increased expression of CTSD mRNA CTD PMID:20977926 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Cul1 cullin 1 increases expression ISO Bortezomib results in increased expression of CUL1 mRNA CTD PMID:17895889 NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980 		JBrowse link
G Cul3 cullin 3 decreases expression ISO Bortezomib results in decreased expression of CUL3 mRNA CTD PMID:17659339 NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462 		JBrowse link
G Cwf19l1 CWF19 like cell cycle control factor 1 decreases expression ISO Bortezomib results in decreased expression of CWF19L1 mRNA CTD PMID:20977926 NCBI chr 1:242,997,720...243,020,989
Ensembl chr 1:242,997,726...243,020,961 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Bortezomib results in increased expression of CXCL1 mRNA CTD PMID:15509775 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215 		JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]		 CTD PMID:20830808 PMID:27194111 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075 		JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression		 ISO Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA		 CTD PMID:15509775 PMID:27194111 NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511 		JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Bortezomib results in decreased expression of CXCR4 mRNA CTD PMID:20977926 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883 		JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO Bortezomib results in increased expression of CYB5R1 mRNA CTD PMID:20977926 NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458 		JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression ISO Bortezomib results in decreased expression of CYBA mRNA CTD PMID:20977926 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721 		JBrowse link
G Cycs cytochrome c, somatic multiple interactions
affects localization		 ISO [Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein		 CTD PMID:12893773 PMID:16024631 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 affects metabolic processing ISO CYP2C19 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO Bortezomib results in increased expression of CYP2U1 mRNA CTD PMID:20977926 NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cytip cytohesin 1 interacting protein increases expression ISO Bortezomib results in increased expression of CYTIP mRNA CTD PMID:20977926 NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993 		JBrowse link
G Dap3 death associated protein 3 increases expression ISO Bortezomib results in increased expression of DAP3 mRNA CTD PMID:17659339 NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461 		JBrowse link
G Dapk2 death-associated protein kinase 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA CTD PMID:25522274 NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567 		JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression ISO Bortezomib results in decreased expression of DAZAP2 mRNA CTD PMID:20977926 NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265 		JBrowse link
G Dbn1 drebrin 1 increases expression ISO Bortezomib results in increased expression of DBN1 mRNA CTD PMID:20977926 NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984 		JBrowse link
G Dcaf11 DDB1 and CUL4 associated factor 11 decreases expression ISO Bortezomib results in decreased expression of DCAF11 mRNA CTD PMID:20977926 NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669 		JBrowse link
G Dcaf13 DDB1 and CUL4 associated factor 13 increases expression ISO Bortezomib results in increased expression of DCAF13 mRNA CTD PMID:20977926 NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142 		JBrowse link
G Dcps decapping enzyme, scavenger decreases expression ISO Bortezomib results in decreased expression of DCPS mRNA CTD PMID:20977926 NCBI chr 8:33,468,669...33,524,407
Ensembl chr 8:33,415,671...33,524,389 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
decreases response to substance		 ISO
EXP		 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 More... NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Ddx11 DEAD/H-box helicase 11 decreases expression ISO Bortezomib results in decreased expression of DDX11 mRNA CTD PMID:20977926 NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550 		JBrowse link
G Deaf1 DEAF1 transcription factor decreases expression ISO Bortezomib results in decreased expression of DEAF1 mRNA CTD PMID:20977926 NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541 		JBrowse link
G Dedd2 death effector domain containing 2 increases expression ISO Bortezomib results in increased expression of DEDD2 mRNA CTD PMID:17659339 NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714 		JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor decreases expression ISO Bortezomib results in decreased expression of DEF6 mRNA CTD PMID:20977926 NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961 		JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO Bortezomib results in increased expression of DENND4A mRNA CTD PMID:20977926 NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330 		JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO Bortezomib results in increased expression of DENND4B mRNA CTD PMID:15509775 NCBI chr 2:175,720,473...175,736,425
Ensembl chr 2:175,709,610...175,736,426 		JBrowse link
G Dennd4c DENN domain containing 4C increases expression ISO Bortezomib results in increased expression of DENND4C mRNA CTD PMID:20977926 NCBI chr 5:101,272,298...101,369,529
Ensembl chr 5:101,272,005...101,368,118 		JBrowse link
G Dgke diacylglycerol kinase epsilon decreases expression ISO Bortezomib results in decreased expression of DGKE mRNA CTD PMID:20977926 NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases localization
increases expression
multiple interactions		 ISO Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]		 CTD PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 More... NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387 		JBrowse link
G Dlgap5 DLG associated protein 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA CTD PMID:25522274 NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518 		JBrowse link
G Dnaaf5 dynein, axonemal, assembly factor 5 decreases expression ISO Bortezomib results in decreased expression of DNAAF5 mRNA CTD PMID:20977926 NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO Bortezomib results in increased expression of DNAJB1 mRNA CTD PMID:15509775 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dnajc14 DnaJ heat shock protein family (Hsp40) member C14 decreases expression ISO Bortezomib results in decreased expression of DNAJC14 mRNA CTD PMID:20977926 NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645 		JBrowse link
G Dnajc4 DnaJ heat shock protein family (Hsp40) member C4 decreases expression ISO Bortezomib results in decreased expression of DNAJC4 mRNA CTD PMID:20977926 NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387 		JBrowse link
G Dnm2 dynamin 2 decreases expression ISO Bortezomib results in decreased expression of DNM2 mRNA CTD PMID:20977926 NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157 		JBrowse link
G Dpy19l4 dpy-19 like 4 increases expression ISO Bortezomib results in increased expression of DPY19L4 mRNA CTD PMID:20977926 NCBI chr 5:24,351,289...24,410,932
Ensembl chr 5:24,353,900...24,410,912 		JBrowse link
G Dst dystonin increases expression ISO Bortezomib results in increased expression of DST mRNA CTD PMID:17659339 NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615 		JBrowse link
G Dusp15 dual specificity phosphatase 15 decreases expression ISO Bortezomib results in decreased expression of DUSP15 mRNA CTD PMID:20977926 NCBI chr 3:141,408,495...141,419,137
Ensembl chr 3:141,408,498...141,418,999 		JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Bortezomib results in decreased expression of DUSP4 mRNA CTD PMID:20977926 NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138 		JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA CTD PMID:25522274 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818 		JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression ISO Bortezomib results in increased expression of DYNC1I1 mRNA CTD PMID:20977926 NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149 		JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein CTD PMID:25522274 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold increases expression ISO Bortezomib results in increased expression of ECPAS mRNA CTD PMID:20977926 NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860 		JBrowse link
G Edaradd EDAR associated via death domain increases expression ISO Bortezomib results in increased expression of EDARADD mRNA CTD PMID:17895889 NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447 		JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA CTD PMID:25522274 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766 		JBrowse link
G Egr1 early growth response 1 increases expression ISO Bortezomib results in increased expression of EGR1 mRNA CTD PMID:20471514 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Egr2 early growth response 2 decreases expression ISO
EXP		 Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein		 CTD PMID:20830808 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562 		JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of EHMT2 mRNA CTD PMID:20977926 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547 		JBrowse link
G Eif1 eukaryotic translation initiation factor 1 increases expression ISO Bortezomib results in increased expression of EIF1 mRNA CTD PMID:20977926 NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A decreases phosphorylation ISO Bortezomib results in decreased phosphorylation of EIF2A protein CTD PMID:18641367 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation
multiple interactions
decreases response to substance		 ISO Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:16928686 PMID:20022965 PMID:22262760 PMID:22959925 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions
increases phosphorylation		 ISO Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] CTD PMID:16357177 PMID:20022965 PMID:21090173 PMID:22262760 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Eif2s3 eukaryotic translation initiation factor 2 subunit gamma decreases expression ISO Bortezomib results in decreased expression of EIF2S3 mRNA CTD PMID:20977926 NCBI chr  X:58,916,513...58,939,923
Ensembl chr  X:58,917,490...58,940,686 		JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:21345073 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984 		JBrowse link
G Eif5a eukaryotic translation initiation factor 5A decreases expression ISO Bortezomib results in decreased expression of EIF5A mRNA CTD PMID:20977926 NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656 		JBrowse link
G Elp5 elongator acetyltransferase complex subunit 5 decreases expression ISO Bortezomib results in decreased expression of ELP5 mRNA CTD PMID:20977926 NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923 		JBrowse link
G Eno2 enolase 2 increases expression ISO Bortezomib results in increased expression of ENO2 mRNA CTD PMID:20977926 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980 		JBrowse link
G Epha1 Eph receptor A1 decreases expression ISO Bortezomib results in decreased expression of EPHA1 mRNA CTD PMID:20977926 NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846 		JBrowse link
G Ephb2 Eph receptor B2 decreases expression ISO Bortezomib results in decreased expression of EPHB2 mRNA CTD PMID:20977926 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation		 ISO Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ercc3 ERCC excision repair 3, TFIIH core complex helicase subunit increases response to substance ISO ERCC3 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329 		JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases response to substance ISO ERCC4 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369 		JBrowse link
G Erlin2 ER lipid raft associated 2 decreases expression ISO Bortezomib results in decreased expression of ERLIN2 mRNA CTD PMID:20977926 NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
decreases response to substance		 ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein]
ERN1 results in decreased susceptibility to Bortezomib		 CTD PMID:16357177 PMID:22262760 PMID:25522274 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Esf1 ESF1 nucleolar pre-rRNA processing protein homolog increases expression ISO Bortezomib results in increased expression of ESF1 mRNA CTD PMID:20977926 NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:25752796 PMID:30818834 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:25752796 PMID:25913414 PMID:30818834 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Esrra estrogen related receptor, alpha decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]		 CTD PMID:20977926 PMID:30818834 NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268 		JBrowse link
G Esyt2 extended synaptotagmin 2 decreases expression ISO Bortezomib results in decreased expression of ESYT2 mRNA CTD PMID:20977926 NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590 		JBrowse link
G Etv4 ETS variant transcription factor 4 decreases expression ISO Bortezomib results in decreased expression of ETV4 mRNA CTD PMID:20977926 NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974 		JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression ISO Bortezomib results in decreased expression of F2RL1 mRNA CTD PMID:20977926 NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226 		JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions		 ISO Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein		 CTD PMID:23696885 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668 		JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Bortezomib results in decreased expression of FADS2 mRNA CTD PMID:20977926 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789 		JBrowse link
G Faf1 Fas associated factor 1 increases expression ISO Bortezomib results in increased expression of FAF1 mRNA CTD PMID:17895889 NCBI chr 5:124,426,032...124,790,014
Ensembl chr 5:124,426,062...124,789,977 		JBrowse link
G Fam118b family with sequence similarity 118, member B increases expression ISO Bortezomib results in increased expression of FAM118B mRNA CTD PMID:20977926 NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270 		JBrowse link
G Fam168a family with sequence similarity 168, member A increases expression ISO Bortezomib results in increased expression of FAM168A mRNA CTD PMID:20977926 NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220 		JBrowse link
G Fam20b FAM20B, glycosaminoglycan xylosylkinase decreases expression ISO Bortezomib results in decreased expression of FAM20B mRNA CTD PMID:20977926 NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915 		JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression ISO Bortezomib results in increased expression of FAM219A mRNA CTD PMID:20977926 NCBI chr 5:56,679,272...56,729,959
Ensembl chr 5:56,680,613...56,729,924 		JBrowse link
G Fam241b family with sequence similarity 241 member B increases expression ISO Bortezomib results in increased expression of FAM241B mRNA CTD PMID:20977926 NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084 		JBrowse link
G Fam43a family with sequence similarity 43, member A decreases expression ISO Bortezomib results in decreased expression of FAM43A mRNA CTD PMID:20977926 NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401 		JBrowse link
G Fam76a family with sequence similarity 76, member A increases expression ISO Bortezomib results in increased expression of FAM76A mRNA CTD PMID:20977926 NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574 		JBrowse link
G Fancd2 FA complementation group D2 decreases expression ISO Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein CTD PMID:19934314 PMID:21917757 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412 		JBrowse link
G Farsa phenylalanyl-tRNA synthetase subunit alpha decreases expression ISO Bortezomib results in decreased expression of FARSA mRNA CTD PMID:20977926 NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980 		JBrowse link
G Fas Fas cell surface death receptor multiple interactions
decreases expression
increases expression		 ISO [Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein		 CTD PMID:17351739 PMID:20471514 PMID:25913414 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Faslg Fas ligand multiple interactions
increases expression		 ISO [Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein		 CTD PMID:17351739 PMID:20471514 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fastk Fas-activated serine/threonine kinase decreases expression ISO Bortezomib results in decreased expression of FASTK mRNA CTD PMID:20977926 NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430 		JBrowse link
G Fbln5 fibulin 5 decreases expression ISO Bortezomib results in decreased expression of FBLN5 mRNA CTD PMID:20977926 NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755 		JBrowse link
G Fbxw7 F-box and WD repeat domain containing 7 decreases expression ISO Bortezomib results in decreased expression of FBXW7 mRNA CTD PMID:20977926 NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941 		JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA CTD PMID:25522274 NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454 		JBrowse link
G Fgfr1op2 FGFR1 oncogene partner 2 increases expression ISO Bortezomib results in increased expression of FGFR1OP2 mRNA CTD PMID:20977926 NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630 		JBrowse link
G Fkbp1a FKBP prolyl isomerase 1A decreases expression ISO Bortezomib results in decreased expression of FKBP1A mRNA CTD PMID:20977926 NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743 		JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 decreases expression ISO Bortezomib results in decreased expression of FKBP5 mRNA CTD PMID:20977926 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674 		JBrowse link
G Flcn folliculin increases expression ISO Bortezomib results in increased expression of FLCN mRNA CTD PMID:20977926 NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769 		JBrowse link
G Fmr1 fragile X messenger ribonucleoprotein 1 decreases expression ISO Bortezomib results in decreased expression of FMR1 mRNA CTD PMID:17659339 NCBI chr  X:147,240,239...147,278,057
Ensembl chr  X:147,240,301...147,278,050 		JBrowse link
G Folr1 folate receptor alpha decreases expression ISO Bortezomib results in decreased expression of FOLR1 mRNA CTD PMID:20977926 NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667 		JBrowse link
G Foxa1 forkhead box A1 multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA
Bortezomib results in decreased expression of FOXA1 mRNA		 CTD PMID:20471514 PMID:25913414 NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188 		JBrowse link
G Fry FRY microtubule binding protein increases expression ISO Bortezomib results in increased expression of FRY mRNA CTD PMID:20977926 NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116 		JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like increases expression ISO Bortezomib results in increased expression of FSD1L mRNA CTD PMID:20977926 NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928 		JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA CTD PMID:25522274 NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of G6PD mRNA CTD PMID:20977926 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO Bortezomib results in increased expression of GABARAPL1 mRNA CTD PMID:20977926 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of GADD45A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA		 CTD PMID:20830808 PMID:20977926 PMID:25522274 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions		 ISO Bortezomib results in increased expression of GADD45B mRNA
Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]		 CTD PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma increases expression ISO Bortezomib results in increased expression of GADD45G mRNA CTD PMID:17898295 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610 		JBrowse link
G Galnt4 polypeptide N-acetylgalactosaminyltransferase 4 increases expression ISO Bortezomib results in increased expression of GALNT4 mRNA CTD PMID:20977926 NCBI chr 7:33,925,229...33,927,770 JBrowse link
G Ganab glucosidase II alpha subunit decreases expression ISO Bortezomib results in decreased expression of GANAB mRNA CTD PMID:20977926 NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695 		JBrowse link
G Gas7 growth arrest specific 7 decreases expression ISO Bortezomib results in decreased expression of GAS7 mRNA CTD PMID:20977926 NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276 		JBrowse link
G Gbp2 guanylate binding protein 2 increases expression ISO Bortezomib results in increased expression of GBP2 mRNA CTD PMID:20977926 NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit increases expression
multiple interactions		 EXP Bortezomib results in increased expression of GCLC mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA]		 CTD PMID:35121005 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions		 EXP Bortezomib results in increased expression of GCLM mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA]		 CTD PMID:35121005 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 increases expression ISO Bortezomib results in increased expression of GCNT2 mRNA CTD PMID:20977926 NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions		 EXP
ISO		 Bortezomib results in increased expression of GDF15 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA		 CTD PMID:20830808 PMID:25522274 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions
increases expression		 EXP Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] CTD PMID:35121005 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Ghr growth hormone receptor increases expression ISO Bortezomib results in increased expression of GHR mRNA CTD PMID:17895889 NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735 		JBrowse link
G Git1 GIT ArfGAP 1 decreases expression ISO Bortezomib results in decreased expression of GIT1 mRNA CTD PMID:20977926 NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373 		JBrowse link
G Gkap1 G kinase anchoring protein 1 increases expression ISO Bortezomib results in increased expression of GKAP1 mRNA CTD PMID:20977926 NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679 		JBrowse link
G Gla galactosidase, alpha increases expression ISO Bortezomib results in increased expression of GLA mRNA CTD PMID:20977926 NCBI chr  X:97,769,227...97,780,646
Ensembl chr  X:97,768,996...97,780,664 		JBrowse link
G Gnai3 G protein subunit alpha i3 increases expression ISO Bortezomib results in increased expression of GNAI3 mRNA CTD PMID:20977926 NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742 		JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 increases expression ISO Bortezomib results in increased expression of GOSR2 mRNA CTD PMID:20977926 NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625 		JBrowse link
G Gpank1 G patch domain and ankyrin repeats 1 increases expression ISO Bortezomib results in increased expression of GPANK1 mRNA CTD PMID:20977926 NCBI chr20:3,697,641...3,700,814
Ensembl chr20:3,697,641...3,700,858 		JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression ISO Bortezomib results in increased expression of GPAT3 mRNA CTD PMID:20977926 NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490 		JBrowse link
G Gpatch2l G patch domain containing 2-like increases expression ISO Bortezomib results in increased expression of GPATCH2L mRNA CTD PMID:20977926 NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888 		JBrowse link
G Gphn gephyrin decreases expression ISO Bortezomib results in decreased expression of GPHN mRNA CTD PMID:20977926 NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612 		JBrowse link
G Gpr157 G protein-coupled receptor 157 decreases expression ISO Bortezomib results in decreased expression of GPR157 mRNA CTD PMID:20977926 NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432 		JBrowse link
G Gpsm3 G-protein signaling modulator 3 decreases expression ISO Bortezomib results in decreased expression of GPSM3 mRNA CTD PMID:20977926 NCBI chr20:4,157,123...4,158,984
Ensembl chr20:4,157,123...4,159,035 		JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form CTD PMID:16118318 NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] CTD PMID:16118318 PMID:24085292 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gspt1 G1 to S phase transition 1 decreases expression ISO Bortezomib results in decreased expression of GSPT1 mRNA CTD PMID:20977926 NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198 		JBrowse link
G Gsr glutathione-disulfide reductase increases expression ISO Bortezomib results in increased expression of GSR mRNA CTD PMID:20977926 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstcd glutathione S-transferase, C-terminal domain containing decreases expression ISO Bortezomib results in decreased expression of GSTCD mRNA CTD PMID:20977926 NCBI chr 2:221,499,732...221,591,888
Ensembl chr 2:221,499,083...221,591,857 		JBrowse link
G Gstm4 glutathione S-transferase mu 4 decreases expression ISO Bortezomib results in decreased expression of GSTM4 mRNA CTD PMID:20977926 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323 		JBrowse link
G Gtf3c2 general transcription factor IIIC subunit 2 decreases expression ISO Bortezomib results in decreased expression of GTF3C2 mRNA CTD PMID:20977926 NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490 		JBrowse link
G Gtpbp1 GTP binding protein 1 decreases expression ISO Bortezomib results in decreased expression of GTPBP1 mRNA CTD PMID:20977926 NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705 		JBrowse link
G Gzma granzyme A decreases expression ISO Bortezomib results in decreased expression of GZMA mRNA CTD PMID:20977926 NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493 		JBrowse link
G Gzmb granzyme B increases expression ISO Bortezomib results in increased expression of GZMB mRNA CTD PMID:20977926 NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
decreases phosphorylation
increases expression		 ISO
EXP		 [Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form]
Bortezomib results in decreased phosphorylation of H2AX protein
Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]		 CTD PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 		JBrowse link
G H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) decreases expression ISO Bortezomib results in decreased expression of H6PD mRNA CTD PMID:20977926 NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171 		JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases expression ISO Bortezomib results in increased expression of HADHA mRNA CTD PMID:20977926 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869 		JBrowse link
G Haus6 HAUS augmin like complex subunit 6 increases expression ISO Bortezomib results in increased expression of HAUS6 mRNA CTD PMID:20977926 NCBI chr 5:101,116,532...101,156,396
Ensembl chr 5:101,119,300...101,153,124 		JBrowse link
G Hdac10 histone deacetylase 10 decreases expression ISO Bortezomib results in decreased expression of HDAC10 mRNA CTD PMID:20977926 NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228 		JBrowse link
G Hdac4 histone deacetylase 4 decreases expression ISO Bortezomib results in decreased expression of HDAC4 mRNA CTD PMID:17659339 NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164 		JBrowse link
G Hdac6 histone deacetylase 6 decreases response to substance ISO HDAC6 results in decreased susceptibility to Bortezomib CTD PMID:16585204 NCBI chr  X:14,550,645...14,572,445
Ensembl chr  X:14,551,044...14,572,441 		JBrowse link
G Hectd2 HECT domain E3 ubiquitin protein ligase 2 increases expression ISO Bortezomib results in increased expression of HECTD2 mRNA CTD PMID:20977926 NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487 		JBrowse link
G Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA CTD PMID:25522274 NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720 		JBrowse link
G Hexd hexosaminidase D decreases expression ISO Bortezomib results in decreased expression of HEXD mRNA CTD PMID:20977926 NCBI chr10:106,479,781...106,498,799
Ensembl chr10:106,480,194...106,498,799 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bortezomib results in increased expression of HIF1A protein CTD PMID:16061869 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hikeshi heat shock protein nuclear import factor hikeshi multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA CTD PMID:25522274 NCBI chr 1:143,825,399...143,849,361
Ensembl chr 1:143,825,923...143,849,363 		JBrowse link
G Hist1h2ail1 histone cluster 1 H2a family member I like 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA CTD PMID:25522274 NCBI chr17:41,568,181...41,569,093
Ensembl chr17:41,568,471...41,569,109 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
increases response to substance		 ISO
EXP		 [arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
HMOX1 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein		 CTD PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 More... NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hmox2 heme oxygenase 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] CTD PMID:19417023 NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148 		JBrowse link
G Hnrnpll heterogeneous nuclear ribonucleoprotein L-like increases expression ISO Bortezomib results in increased expression of HNRNPLL mRNA CTD PMID:20977926 NCBI chr 6:14,969,953...15,000,574
Ensembl chr 6:14,970,057...14,999,745 		JBrowse link
G Hoxa11 homeobox A11 decreases expression ISO Bortezomib results in decreased expression of HOXA11 mRNA CTD PMID:20977926 NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232 		JBrowse link
G Hps3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 decreases expression ISO Bortezomib results in decreased expression of HPS3 mRNA CTD PMID:20977926 NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047 		JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22842577 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hsf1 heat shock transcription factor 1 increases expression
increases activity
multiple interactions		 ISO Bortezomib results in increased expression of HSF1 mRNA
Bortezomib results in increased activity of HSF1 protein
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]		 CTD PMID:17895889 PMID:23874968 PMID:24619424 PMID:31540997 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011 		JBrowse link
G Hsf2 heat shock transcription factor 2 increases expression
multiple interactions		 ISO Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein
HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]		 CTD PMID:24619424 NCBI chr20:36,819,864...36,847,490
Ensembl chr20:36,819,864...36,850,174 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases expression
decreases expression		 ISO
EXP		 Bortezomib results in increased expression of HSP90AA1 mRNA
Bortezomib results in decreased expression of HSP90AA1 mRNA		 CTD PMID:17895889 PMID:20471514 PMID:20830808 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression ISO Bortezomib results in increased expression of HSP90AB1 mRNA CTD PMID:17895889 NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions
decreases response to substance
increases expression		 ISO Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
HSPA1A protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA1A mRNA		 CTD PMID:17895889 PMID:23874968 NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression
affects response to substance
decreases response to substance		 ISO Bortezomib results in increased expression of HSPA1B mRNA
HSPA1B protein affects the susceptibility to Bortezomib
HSPA1B protein results in decreased susceptibility to Bortezomib		 CTD PMID:15509775 PMID:17895889 PMID:23874968 NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240 		JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression EXP Bortezomib results in increased expression of HSPA4L mRNA CTD PMID:20830808 NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
decreases response to substance		 ISO Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
Bortezomib results in increased expression of HSPA5 mRNA
HSPA5 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein		 CTD PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 More... NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 increases expression ISO Bortezomib results in increased expression of HSPA6 mRNA CTD PMID:15509775 PMID:17898295 PMID:20977926 NCBI chr13:83,273,176...83,274,317 JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression
decreases response to substance		 EXP
ISO		 Bortezomib results in increased expression of HSPB1 mRNA
HSPB1 protein results in decreased susceptibility to Bortezomib		 CTD PMID:14559800 PMID:20830808 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743 		JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 increases expression ISO Bortezomib results in increased expression of HSPH1 mRNA CTD PMID:17898295 NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224 		JBrowse link
G Htr2b 5-hydroxytryptamine receptor 2B decreases expression ISO Bortezomib results in decreased expression of HTR2B mRNA CTD PMID:20977926 NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108 		JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO Bortezomib affects the localization of HTRA2 protein CTD PMID:16024631 NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095 		JBrowse link
G Ibtk inhibitor of Bruton tyrosine kinase increases expression ISO Bortezomib results in increased expression of IBTK mRNA CTD PMID:20977926 NCBI chr 8:86,625,591...86,698,661
Ensembl chr 8:86,625,597...86,698,260 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein
Bortezomib results in decreased expression of ICAM1 mRNA		 CTD PMID:18223231 PMID:20471514 PMID:25913414 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Ide insulin degrading enzyme increases expression ISO Bortezomib results in increased expression of IDE mRNA CTD PMID:20977926 NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha decreases expression ISO Bortezomib results in decreased expression of IDH3A mRNA CTD PMID:30818834 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084 		JBrowse link
G Ifi44 interferon-induced protein 44 increases expression ISO Bortezomib results in increased expression of IFI44 mRNA CTD PMID:20977926 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844 		JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 decreases expression ISO Bortezomib results in decreased expression of IFITM1 mRNA CTD PMID:17659339 NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169 		JBrowse link
G Ifng interferon gamma multiple interactions ISO [Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] CTD PMID:30482226 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Ifrd2 interferon-related developmental regulator 2 decreases expression ISO Bortezomib results in decreased expression of IFRD2 mRNA CTD PMID:20977926 NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194 		JBrowse link
G Igf1r insulin-like growth factor 1 receptor increases response to substance ISO IGF1R gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777 		JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
decreases response to substance		 ISO Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased susceptibility to IGF2 protein		 CTD PMID:24055520 NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018 		JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
decreases expression		 ISO Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Bortezomib results in decreased expression of IKBKB mRNA		 CTD PMID:19417023 PMID:20471514 PMID:24085292 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250 		JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of IKZF1 mRNA CTD PMID:20977926 NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416 		JBrowse link
G Il10 interleukin 10 affects expression ISO Bortezomib affects the expression of IL10 protein CTD PMID:19922463 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il15 interleukin 15 increases expression ISO Bortezomib results in increased expression of IL15 mRNA CTD PMID:20977926 NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820 		JBrowse link
G Il18r1 interleukin 18 receptor 1 increases expression ISO Bortezomib results in increased expression of IL18R1 mRNA CTD PMID:17895889 NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715 		JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions		 EXP Bortezomib results in increased expression of IL1B mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]		 CTD PMID:35121005 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 increases expression ISO Bortezomib results in increased expression of IL1R1 mRNA CTD PMID:17895889 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il23a interleukin 23 subunit alpha increases expression ISO Bortezomib results in increased expression of IL23A mRNA CTD PMID:17895889 NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923 		JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
decreases expression
decreases secretion		 ISO
EXP		 [Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone]
Bortezomib results in increased expression of IL6 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]
Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]
Bortezomib results in decreased expression of IL6 mRNA
Bortezomib results in decreased secretion of IL6 protein		 CTD PMID:17895889 PMID:23063726 PMID:28134560 PMID:35121005 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Il7r interleukin 7 receptor increases expression
multiple interactions		 ISO Bortezomib results in increased expression of IL7R mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA		 CTD PMID:20471514 PMID:25522274 NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757 		JBrowse link
G Ino80b INO80 complex subunit B decreases expression ISO Bortezomib results in decreased expression of INO80B mRNA CTD PMID:20977926 NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO Bortezomib results in decreased expression of IRAK1 mRNA CTD PMID:20471514 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521 		JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 increases expression ISO Bortezomib results in increased expression of IRAK2 mRNA CTD PMID:20977926 NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602 		JBrowse link
G Irf4 interferon regulatory factor 4 multiple interactions
decreases expression		 ISO 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein] CTD PMID:37657595 NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070 		JBrowse link
G Irs1 insulin receptor substrate 1 decreases degradation ISO Bortezomib results in decreased degradation of IRS1 protein CTD PMID:16227402 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122 		JBrowse link
G Isca1 iron-sulfur cluster assembly 1 increases expression ISO Bortezomib results in increased expression of ISCA1 mRNA CTD PMID:20977926 NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955 		JBrowse link
G Itga6 integrin subunit alpha 6 decreases expression ISO Bortezomib results in decreased expression of ITGA6 mRNA CTD PMID:20977926 NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428 		JBrowse link
G Itgal integrin subunit alpha L decreases expression ISO Bortezomib results in decreased expression of ITGAL mRNA CTD PMID:20977926 NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732 		JBrowse link
G Itgav integrin subunit alpha V multiple interactions
increases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA
Bortezomib results in increased expression of ITGAV mRNA		 CTD PMID:20471514 PMID:25913414 NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639 		JBrowse link
G Itgb6 integrin subunit beta 6 increases expression ISO Bortezomib results in increased expression of ITGB6 mRNA CTD PMID:20977926 NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671 		JBrowse link
G Jak1 Janus kinase 1 decreases expression ISO Bortezomib results in decreased expression of JAK1 mRNA CTD PMID:20977926 NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression
increases expression
increases phosphorylation
multiple interactions		 ISO
EXP		 Bortezomib results in decreased expression of JUN mRNA
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form
Bortezomib results in increased phosphorylation of JUN protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]		 CTD PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 More... NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of JUNB protein
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein]		 CTD PMID:37657595 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Bortezomib results in decreased expression of JUND mRNA CTD PMID:20977926 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799 		JBrowse link
G Kat2b lysine acetyltransferase 2B decreases expression ISO Bortezomib results in decreased expression of KAT2B mRNA CTD PMID:20471514 NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064 		JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression ISO Bortezomib results in decreased expression of KAT6B mRNA CTD PMID:20977926 NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316 		JBrowse link
G Katnal1 katanin catalytic subunit A1 like 1 increases expression ISO Bortezomib results in increased expression of KATNAL1 mRNA CTD PMID:20977926 NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553 		JBrowse link
G Kcmf1 potassium channel modulatory factor 1 increases expression ISO Bortezomib results in increased expression of KCMF1 mRNA CTD PMID:20977926 NCBI chr 4:104,888,452...104,950,234
Ensembl chr 4:104,889,847...104,950,234 		JBrowse link
G Kctd10 potassium channel tetramerization domain containing 10 increases expression ISO Bortezomib results in increased expression of KCTD10 mRNA CTD PMID:20977926 NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783 		JBrowse link
G Kdelr1 KDEL endoplasmic reticulum protein retention receptor 1 decreases expression ISO Bortezomib results in decreased expression of KDELR1 mRNA CTD PMID:20977926 NCBI chr 1:96,347,258...96,358,145
Ensembl chr 1:96,347,150...96,358,157 		JBrowse link
G Kdm4b lysine demethylase 4B decreases expression ISO Bortezomib results in decreased expression of KDM4B mRNA CTD PMID:20977926 NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543 		JBrowse link
G Kdm5c lysine demethylase 5C decreases expression ISO Bortezomib results in decreased expression of KDM5C mRNA CTD PMID:20977926 NCBI chr  X:21,345,459...21,387,045
Ensembl chr  X:21,345,481...21,381,870 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein CTD PMID:16985072 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Kif22 kinesin family member 22 decreases expression ISO Bortezomib results in decreased expression of KIF22 mRNA CTD PMID:20977926 NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401 		JBrowse link
G Kif9 kinesin family member 9 decreases expression ISO Bortezomib results in decreased expression of KIF9 mRNA CTD PMID:20977926 NCBI chr 8:110,459,467...110,504,492
Ensembl chr 8:110,459,383...110,505,252 		JBrowse link
G Kifc1 kinesin family member C1 decreases expression ISO Bortezomib results in decreased expression of KIFC1 mRNA CTD PMID:20977926 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105 		JBrowse link
G Klf6 KLF transcription factor 6 increases expression ISO Bortezomib results in increased expression of KLF6 mRNA CTD PMID:20977926 NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570 		JBrowse link
G Klhdc7b kelch domain containing 7B increases expression ISO Bortezomib results in increased expression of KLHDC7B mRNA CTD PMID:20977926 NCBI chr 7:120,452,081...120,455,737
Ensembl chr 7:120,453,932...120,455,737 		JBrowse link
G Klhl20 kelch-like family member 20 increases expression ISO Bortezomib results in increased expression of KLHL20 mRNA CTD PMID:20977926 NCBI chr13:73,363,451...73,408,293
Ensembl chr13:73,363,455...73,408,337 		JBrowse link
G Klrk1 killer cell lectin like receptor K1 decreases expression ISO Bortezomib results in decreased expression of KLRK1 mRNA CTD PMID:20977926 NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459 		JBrowse link
G Kmt2a lysine methyltransferase 2A multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181 		JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression ISO Bortezomib results in increased expression of KPNA2 mRNA CTD PMID:20977926 NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150 		JBrowse link
G Kri1 KRI1 homolog increases expression ISO Bortezomib results in increased expression of KRI1 mRNA CTD PMID:20977926 NCBI chr 8:19,817,005...19,831,516
Ensembl chr 8:19,817,017...19,831,392 		JBrowse link
G Krit1 KRIT1, ankyrin repeat containing increases expression ISO Bortezomib results in increased expression of KRIT1 mRNA CTD PMID:20977926 NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359 		JBrowse link
G Ktn1 kinectin 1 increases expression ISO Bortezomib results in increased expression of KTN1 mRNA CTD PMID:20977926 NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578 		JBrowse link
G Lgals2 galectin 2 decreases expression ISO Bortezomib results in decreased expression of LGALS2 mRNA CTD PMID:17659339 NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802 		JBrowse link
G Lgals8 galectin 8 increases expression ISO Bortezomib results in increased expression of LGALS8 mRNA CTD PMID:20977926 NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764 		JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA CTD PMID:25522274 NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899 		JBrowse link
G Lig4 DNA ligase 4 increases expression ISO Bortezomib results in increased expression of LIG4 mRNA CTD PMID:20977926 NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040 		JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression ISO Bortezomib results in increased expression of LIMA1 mRNA CTD PMID:20977926 NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473 		JBrowse link
G Limd1 LIM domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMD1 mRNA CTD PMID:20977926 NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714 		JBrowse link
G Lims1 LIM zinc finger domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMS1 mRNA CTD PMID:20977926 NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500 		JBrowse link
G Lmna lamin A/C increases cleavage ISO Bortezomib results in increased cleavage of LMNA protein CTD PMID:20110775 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423 		JBrowse link
G Lrfn4 leucine rich repeat and fibronectin type III domain containing 4 decreases expression ISO Bortezomib results in decreased expression of LRFN4 mRNA CTD PMID:20977926 NCBI chr 1:201,888,569...201,891,861
Ensembl chr 1:201,888,569...201,891,861 		JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression ISO Bortezomib results in decreased expression of LRRC41 mRNA CTD PMID:20977926 NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449 		JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 increases expression ISO Bortezomib results in increased expression of LRRFIP1 mRNA CTD PMID:20977926 NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250 		JBrowse link
G Lsm4 LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated decreases expression ISO Bortezomib results in decreased expression of LSM4 mRNA CTD PMID:20977926 NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926 		JBrowse link
G Lst1 leukocyte specific transcript 1 decreases expression ISO Bortezomib results in decreased expression of LST1 mRNA CTD PMID:20977926 NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997 		JBrowse link
G Luc7l LUC7-like increases expression ISO Bortezomib results in increased expression of LUC7L mRNA CTD PMID:20977926 NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112 		JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386 		JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868 		JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] CTD PMID:31645432 NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249 		JBrowse link
G Mafg MAF bZIP transcription factor G increases expression ISO Bortezomib results in increased expression of MAFG mRNA CTD PMID:20977926 NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein CTD PMID:12893773 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147 		JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAP2K2 mRNA CTD PMID:20977926 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243 		JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein CTD PMID:15039284 NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993 		JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO Bortezomib results in decreased expression of MAP2K6 mRNA CTD PMID:20977926 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293 		JBrowse link
G Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 increases expression ISO Bortezomib results in increased expression of MAP4K3 mRNA CTD PMID:20977926 NCBI chr 6:14,276,623...14,446,321
Ensembl chr 6:14,277,121...14,446,334 		JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO Bortezomib results in increased expression of MAP4K4 mRNA CTD PMID:20977926 NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases expression
increases phosphorylation
decreases activity		 ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]
Bortezomib results in decreased activity of MAPK1 protein		 CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk10 mitogen activated protein kinase 10 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] CTD PMID:15173093 NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201 		JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] CTD PMID:12893773 PMID:18790767 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases expression
increases phosphorylation
decreases activity		 ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]
Bortezomib results in decreased activity of MAPK3 protein		 CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation		 ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] CTD PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions		 ISO Bortezomib results in increased phosphorylation of MAPK9 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]		 CTD PMID:16985072 PMID:18559525 PMID:18718063 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapkap1 MAPK associated protein 1 decreases expression ISO Bortezomib results in decreased expression of MAPKAP1 mRNA CTD PMID:20977926 NCBI chr 3:17,715,813...17,918,387
Ensembl chr 3:17,715,834...17,918,384 		JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAPKAPK2 mRNA CTD PMID:20977926 NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457 		JBrowse link
G Mark2 microtubule affinity regulating kinase 2 decreases expression ISO Bortezomib results in decreased expression of MARK2 mRNA CTD PMID:20977926 NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652 		JBrowse link
G Maz MYC associated zinc finger protein decreases expression ISO Bortezomib results in decreased expression of MAZ mRNA CTD PMID:20977926 NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408 		JBrowse link
G Mbd1 methyl-CpG binding domain protein 1 decreases expression ISO Bortezomib results in decreased expression of MBD1 mRNA CTD PMID:20977926 NCBI chr18:67,869,870...67,884,501
Ensembl chr18:67,869,992...67,886,554 		JBrowse link
G Mbd4 methyl-CpG binding domain 4 DNA glycosylase increases expression ISO Bortezomib results in increased expression of MBD4 mRNA CTD PMID:20977926 NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982 		JBrowse link
G Mbl2 mannose binding lectin 2 increases response to substance ISO MBL2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:228,016,439...228,024,736 JBrowse link
G Mbnl1 muscleblind-like splicing regulator 1 decreases expression ISO Bortezomib results in decreased expression of MBNL1 mRNA CTD PMID:20977926 NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368 		JBrowse link
G Mbp myelin basic protein decreases expression ISO Bortezomib results in decreased expression of MBP mRNA CTD PMID:20977926 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases expression
decreases response to substance
increases cleavage		 ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]
Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein]
MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein		 CTD PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 More... NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO Bortezomib results in decreased expression of MCM7 mRNA CTD PMID:17659339 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063 		JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 decreases expression ISO Bortezomib results in decreased expression of MDC1 mRNA CTD PMID:20977926 NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240 		JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases cleavage
affects expression		 ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]
Bortezomib affects the expression of MDM2 protein		 CTD PMID:12393500 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915 		JBrowse link
G Me1 malic enzyme 1 increases expression ISO Bortezomib results in increased expression of ME1 mRNA CTD PMID:20977926 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304 		JBrowse link
G Mettl21a methyltransferase 21A, HSPA lysine increases expression ISO Bortezomib results in increased expression of METTL21A mRNA CTD PMID:20977926 NCBI chr 9:65,934,253...65,999,964
Ensembl chr 9:65,978,051...65,987,550 		JBrowse link
G Mettl27 methyltransferase like 27 decreases expression ISO Bortezomib results in decreased expression of METTL27 mRNA CTD PMID:20977926 NCBI chr12:21,757,545...21,766,698
Ensembl chr12:21,757,329...21,766,685 		JBrowse link
G Mex3d mex-3 RNA binding family member D decreases expression ISO Bortezomib results in decreased expression of MEX3D mRNA CTD PMID:20977926 NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096 		JBrowse link
G Mfn1 mitofusin 1 decreases expression ISO Bortezomib results in decreased expression of MFN1 mRNA CTD PMID:20977926 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640 		JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression ISO Bortezomib results in decreased expression of MFNG mRNA CTD PMID:20977926 NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653 		JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] CTD PMID:24193513 NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756 		JBrowse link
G Mir21 microRNA 21 increases expression ISO Bortezomib results in increased expression of MIR21 mRNA CTD PMID:20977926 NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of MKI67 protein
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]		 CTD PMID:19372569 PMID:30482226 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mllt11 MLLT11, transcription factor 7 cofactor increases expression ISO Bortezomib results in increased expression of MLLT11 mRNA CTD PMID:20977926 NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein] CTD PMID:20696233 PMID:24333736 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mob3a MOB kinase activator 3A decreases expression ISO Bortezomib results in decreased expression of MOB3A mRNA CTD PMID:17659339 NCBI chr 7:9,010,490...9,027,888
Ensembl chr 7:9,010,587...9,027,879 		JBrowse link
G Morc2 MORC family CW-type zinc finger 2 increases expression ISO Bortezomib results in increased expression of MORC2 mRNA CTD PMID:20977926 NCBI chr14:78,529,603...78,571,375
Ensembl chr14:78,527,009...78,571,343 		JBrowse link
G Mpz myelin protein zero decreases expression EXP
ISO		 Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein CTD PMID:20830808 NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679 		JBrowse link
G Mrpl19 mitochondrial ribosomal protein L19 increases expression ISO Bortezomib results in increased expression of MRPL19 mRNA CTD PMID:20977926 NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053 		JBrowse link
G Mrpl30 mitochondrial ribosomal protein L30 decreases expression ISO Bortezomib results in decreased expression of MRPL30 mRNA CTD PMID:20977926 NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257 		JBrowse link
G Mrps12 mitochondrial ribosomal protein S12 decreases expression ISO Bortezomib results in decreased expression of MRPS12 mRNA CTD PMID:20977926 NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780 		JBrowse link
G Mrps5 mitochondrial ribosomal protein S5 decreases expression ISO Bortezomib results in decreased expression of MRPS5 mRNA CTD PMID:20977926 NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291 		JBrowse link
G Msh6 mutS homolog 6 decreases expression ISO Bortezomib results in decreased expression of MSH6 mRNA CTD PMID:17659339 NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956 		JBrowse link
G Mtmr6 myotubularin related protein 6 increases expression ISO Bortezomib results in increased expression of MTMR6 mRNA CTD PMID:20977926 NCBI chr15:34,419,931...34,457,863
Ensembl chr15:34,419,903...34,457,861 		JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Bortezomib results in decreased expression of MUC1 mRNA CTD PMID:20977926 NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733 		JBrowse link
G Mutyh mutY DNA glycosylase decreases expression ISO Bortezomib results in decreased expression of MUTYH mRNA CTD PMID:17659339 NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
increases expression
decreases expression		 ISO [Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]
Bortezomib results in increased expression of MYC protein
Bortezomib results in decreased expression of MYC protein		 CTD PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor decreases expression ISO Bortezomib results in decreased expression of MYD88 mRNA CTD PMID:20471514 NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415 		JBrowse link
G Myl12a myosin light chain 12A increases expression ISO Bortezomib results in increased expression of MYL12A mRNA CTD PMID:20977926 NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580 		JBrowse link
G Myo5a myosin VA increases response to substance ISO MYO5A gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918 		JBrowse link
G Naa80 N(alpha)-acetyltransferase 80, NatH catalytic subunit decreases expression ISO Bortezomib results in decreased expression of NAA80 mRNA CTD PMID:17659339 NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563 		JBrowse link
G Nab2 Ngfi-A binding protein 2 decreases expression ISO Bortezomib results in decreased expression of NAB2 mRNA CTD PMID:20977926 NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989 		JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression ISO Bortezomib results in increased expression of NABP1 mRNA CTD PMID:20977926 NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107 		JBrowse link
G Nadk NAD kinase decreases expression ISO Bortezomib results in decreased expression of NADK mRNA CTD PMID:20977926 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322 		JBrowse link
G Nadk2 NAD kinase 2, mitochondrial increases expression ISO Bortezomib results in increased expression of NADK2 mRNA CTD PMID:20977926 NCBI chr 2:58,117,674...58,159,815
Ensembl chr 2:58,117,674...58,159,808 		JBrowse link
G Naf1 nuclear assembly factor 1 ribonucleoprotein increases expression ISO Bortezomib results in increased expression of NAF1 mRNA CTD PMID:20977926 NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293 		JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 affects expression ISO Bortezomib affects the expression of NAIP mRNA CTD PMID:25913414 NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542 		JBrowse link
G Nap1l2 nucleosome assembly protein 1-like 2 increases expression ISO Bortezomib results in increased expression of NAP1L2 mRNA CTD PMID:20977926 NCBI chr  X:68,174,051...68,176,449
Ensembl chr  X:68,173,987...68,176,666 		JBrowse link
G Ncf4 neutrophil cytosolic factor 4 decreases expression ISO Bortezomib results in decreased expression of NCF4 mRNA CTD PMID:20977926 NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389 		JBrowse link
G Nckap1 NCK-associated protein 1 increases expression ISO Bortezomib results in increased expression of NCKAP1 mRNA CTD PMID:20977926 NCBI chr 3:65,417,450...65,491,769
Ensembl chr 3:65,417,453...65,492,217 		JBrowse link
G Ncoa3 nuclear receptor coactivator 3 increases expression ISO Bortezomib results in increased expression of NCOA3 mRNA CTD PMID:20977926 NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594 		JBrowse link
G Ncr1 natural cytotoxicity triggering receptor 1 decreases expression ISO Bortezomib results in decreased expression of NCR1 protein CTD PMID:19229052 NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558 		JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO Bortezomib results in increased expression of NDRG1 mRNA CTD PMID:20977926 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880 		JBrowse link
G Ndrg3 NDRG family member 3 decreases expression ISO Bortezomib results in decreased expression of NDRG3 mRNA CTD PMID:20977926 NCBI chr 3:145,587,505...145,650,896
Ensembl chr 3:145,548,041...145,650,873 		JBrowse link
G Nedd1 NEDD1 gamma-tubulin ring complex targeting factor increases expression ISO Bortezomib results in increased expression of NEDD1 mRNA CTD PMID:20977926 NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486 		JBrowse link
G Neto2 neuropilin and tolloid like 2 decreases expression ISO Bortezomib results in decreased expression of NETO2 mRNA CTD PMID:20977926 NCBI chr19:21,344,299...21,415,524
Ensembl chr19:21,344,289...21,417,023 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 increases expression
multiple interactions
increases activity		 ISO
EXP		 [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein
Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]
Bortezomib results in increased activity of NFE2L2 protein		 CTD PMID:20806931 PMID:30818834 PMID:35121005 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfia nuclear factor I/A decreases expression ISO Bortezomib results in decreased expression of NFIA mRNA CTD PMID:20977926 NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
increases expression
decreases expression		 ISO
EXP		 [Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]
Bortezomib results in increased expression of NFKB1 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA]
Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein		 CTD PMID:12893773 PMID:16230421 PMID:17164350 PMID:17626072 PMID:18223231 More... NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 decreases cleavage
decreases expression		 ISO Bortezomib results in decreased cleavage of NFKB2 protein
Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein		 CTD PMID:17626072 PMID:18223231 PMID:25913414 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
increases phosphorylation
increases stability
increases degradation
increases expression
decreases degradation		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]
Bortezomib results in increased stability of NFKBIA protein
Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form
Bortezomib results in decreased degradation of NFKBIA protein		 CTD PMID:15039284 PMID:15543232 PMID:17895889 PMID:18089816 PMID:18223231 More... NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nfkbib NFKB inhibitor beta increases stability
increases expression		 ISO Bortezomib results in increased stability of NFKBIB protein
Bortezomib results in increased expression of NFKBIB mRNA		 CTD PMID:15543232 PMID:20977926 PMID:25913414 NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862 		JBrowse link
G Nfkbie NFKB inhibitor epsilon multiple interactions
increases stability		 ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA]
Bortezomib results in increased stability of NFKBIE protein		 CTD PMID:15543232 PMID:20471514 NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437 		JBrowse link
G Nfyc nuclear transcription factor Y subunit gamma decreases expression ISO Bortezomib results in decreased expression of NFYC mRNA CTD PMID:20977926 NCBI chr 5:134,336,802...134,405,372
Ensembl chr 5:134,336,808...134,405,377 		JBrowse link
G Nipsnap1 nipsnap homolog 1 decreases expression ISO Bortezomib results in decreased expression of NIPSNAP1 mRNA CTD PMID:20977926 NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098 		JBrowse link
G Nlrp12 NLR family, pyrin domain containing 12 multiple interactions
increases expression		 ISO Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA]
Bortezomib results in increased expression of NLRP12 mRNA		 CTD PMID:20471514 NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934 		JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 decreases expression
increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in decreased expression of NLRP3 mRNA
Bortezomib results in increased expression of NLRP3 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA]		 CTD PMID:17659339 PMID:35121005 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811 		JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
multiple interactions		 ISO Bortezomib results in increased expression of NOS1 protein
Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]		 CTD PMID:30482226 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945 		JBrowse link
G Notch2 notch receptor 2 decreases expression ISO Bortezomib results in decreased expression of NOTCH2 mRNA CTD PMID:20977926 NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088 		JBrowse link
G Npm1 nucleophosmin 1 multiple interactions
affects response to substance
increases response to substance		 ISO Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib]
NPM1 protein affects the susceptibility to Bortezomib		 CTD PMID:23877794 NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645 		JBrowse link
G Nptx1 neuronal pentraxin 1 decreases expression ISO Bortezomib results in decreased expression of NPTX1 mRNA CTD PMID:20977926 NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of NQO1 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA]		 CTD PMID:20977926 PMID:35121005 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone dehydrogenase 2 increases expression ISO Bortezomib results in increased expression of NQO2 mRNA CTD PMID:20977926 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320 		JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases expression ISO Bortezomib results in decreased expression of NR1H3 mRNA CTD PMID:20977926 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722 		JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO Bortezomib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] CTD PMID:25257666 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] CTD PMID:30818834 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Nrip3 nuclear receptor interacting protein 3 increases expression EXP Bortezomib results in increased expression of NRIP3 mRNA CTD PMID:20830808 NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600 		JBrowse link
G Ns5atp4 NS5A transactivated protein 4 decreases expression ISO Bortezomib results in decreased expression of C1ORF43 mRNA CTD PMID:20977926 NCBI chr 2:175,494,406...175,507,281
Ensembl chr 2:175,494,304...175,510,663 		JBrowse link
G Nt5c2 5'-nucleotidase, cytosolic II increases expression ISO Bortezomib results in increased expression of NT5C2 mRNA CTD PMID:20977926 NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913 		JBrowse link
G Nt5e 5' nucleotidase, ecto decreases expression ISO Bortezomib results in decreased expression of NT5E mRNA CTD PMID:20977926 NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881 		JBrowse link
G Nub1 negative regulator of ubiquitin-like proteins 1 increases expression ISO Bortezomib results in increased expression of NUB1 mRNA CTD PMID:20977926 NCBI chr 4:10,442,917...10,473,689
Ensembl chr 4:10,442,917...10,473,694 		JBrowse link
G Nucks1 nuclear casein kinase and cyclin-dependent kinase substrate 1 decreases expression ISO Bortezomib results in decreased expression of NUCKS1 mRNA CTD PMID:20977926 NCBI chr13:43,345,091...43,374,316
Ensembl chr13:43,345,115...43,370,229 		JBrowse link
G Numb NUMB, endocytic adaptor protein increases expression ISO Bortezomib results in increased expression of NUMB mRNA CTD PMID:20977926 NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354 		JBrowse link
G Numbl NUMB-like, endocytic adaptor protein increases expression ISO Bortezomib results in increased expression of NUMBL mRNA CTD PMID:20977926 NCBI chr 1:82,549,814...82,573,788
Ensembl chr 1:82,550,054...82,573,776 		JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator multiple interactions
increases expression		 ISO NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of NUPR1 mRNA		 CTD PMID:20022965 NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281 		JBrowse link
G Nxpe3 neurexophilin and PC-esterase domain family, member 3 increases expression ISO Bortezomib results in increased expression of NXPE3 mRNA CTD PMID:20977926 NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694 		JBrowse link
G Obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF decreases expression ISO Bortezomib results in decreased expression of OBSCN mRNA CTD PMID:20977926 NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723 		JBrowse link
G Ogdh oxoglutarate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of OGDH mRNA CTD PMID:20977926 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479 		JBrowse link
G Ogfr opioid growth factor receptor decreases expression ISO Bortezomib results in decreased expression of OGFR mRNA CTD PMID:20977926 NCBI chr 3:167,703,173...167,709,459
Ensembl chr 3:167,702,695...167,709,473 		JBrowse link
G Ogt O-linked N-acetylglucosamine (GlcNAc) transferase decreases expression ISO Bortezomib results in decreased expression of OGT mRNA CTD PMID:20977926 NCBI chr  X:66,771,278...66,816,148
Ensembl chr  X:66,771,349...66,816,146 		JBrowse link
G Orai2 ORAI calcium release-activated calcium modulator 2 decreases expression ISO Bortezomib results in decreased expression of ORAI2 mRNA CTD PMID:20977926 NCBI chr12:20,500,308...20,520,428
Ensembl chr12:20,497,317...20,520,428 		JBrowse link
G Os9 OS9, endoplasmic reticulum lectin increases expression ISO Bortezomib results in increased expression of OS9 mRNA CTD PMID:20977926 NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745 		JBrowse link
G Osbpl2 oxysterol binding protein-like 2 increases expression ISO Bortezomib results in increased expression of OSBPL2 mRNA CTD PMID:20977926 NCBI chr 3:167,210,945...167,256,219
Ensembl chr 3:167,210,832...167,256,219 		JBrowse link
G Osgin1 oxidative stress induced growth inhibitor 1 increases expression ISO
EXP		 Bortezomib results in increased expression of OSGIN1 mRNA CTD PMID:20830808 PMID:20977926 NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516 		JBrowse link
G Pacsin1 protein kinase C and casein kinase substrate in neurons 1 increases expression ISO Bortezomib results in increased expression of PACSIN1 mRNA CTD PMID:20977926 NCBI chr20:5,718,134...5,768,064
Ensembl chr20:5,719,857...5,765,313 		JBrowse link
G Palld palladin, cytoskeletal associated protein increases expression ISO Bortezomib results in increased expression of PALLD mRNA CTD PMID:20977926 NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337 		JBrowse link
G Panx2 pannexin 2 increases expression ISO Bortezomib results in increased expression of PANX2 mRNA CTD PMID:20977926 NCBI chr 7:120,139,259...120,153,056
Ensembl chr 7:120,139,294...120,152,361 		JBrowse link
G Papola poly (A) polymerase alpha decreases expression ISO Bortezomib results in decreased expression of PAPOLA mRNA CTD PMID:20977926 NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases expression		 ISO [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with Vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]]; Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; Bortezomib results in increased cleavage of and results in increased activity of PARP1 protein; gambogic acid promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]
Bortezomib results in increased expression of PARP1 protein		 CTD PMID:12893773 PMID:12902978 PMID:15039284 PMID:16617327 PMID:16904634 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Parp6 poly (ADP-ribose) polymerase family, member 6 decreases expression ISO Bortezomib results in decreased expression of PARP6 mRNA CTD PMID:20977926 NCBI chr 8:60,016,594...60,049,108
Ensembl chr 8:60,016,877...60,049,108 		JBrowse link
G Patz1 POZ (BTB) and AT hook containing zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of PATZ1 mRNA CTD PMID:20977926 NCBI chr14:78,154,590...78,173,032
Ensembl chr14:78,152,516...78,173,032 		JBrowse link
G Pawr pro-apoptotic WT1 regulator multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA CTD PMID:25522274 NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028 		JBrowse link
G Pbx3 PBX homeobox 3 decreases expression ISO Bortezomib results in decreased expression of PBX3 mRNA CTD PMID:20977926 NCBI chr 3:17,488,691...17,682,412
Ensembl chr 3:17,488,693...17,682,791 		JBrowse link
G Pcgf3 polycomb group ring finger 3 increases expression ISO Bortezomib results in increased expression of PCGF3 mRNA CTD PMID:20977926 NCBI chr14:1,237,594...1,291,717
Ensembl chr14:1,233,947...1,291,793 		JBrowse link
G Pcnx4 pecanex 4 increases expression ISO Bortezomib results in increased expression of PCNX4 mRNA CTD PMID:20977926 NCBI chr 6:91,125,063...91,170,423
Ensembl chr 6:91,125,063...91,170,439 		JBrowse link
G Pcyt1a phosphate cytidylyltransferase 1A, choline increases expression
multiple interactions		 ISO Bortezomib results in increased expression of PCYT1A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA		 CTD PMID:20977926 PMID:25522274 NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357 		JBrowse link
G Pdcl phosducin like increases expression ISO Bortezomib results in increased expression of PDCL mRNA CTD PMID:20977926 NCBI chr 3:21,110,165...21,119,763
Ensembl chr 3:21,110,167...21,119,715 		JBrowse link
G Pde7a phosphodiesterase 7A decreases expression ISO Bortezomib results in decreased expression of PDE7A mRNA CTD PMID:20977926 NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:101,718,444...101,806,681 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of PDGFRB protein CTD PMID:16985072 NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843 		JBrowse link
G Pdk2 pyruvate dehydrogenase kinase 2 decreases expression ISO Bortezomib results in decreased expression of PDK2 mRNA CTD PMID:20977926 NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085 		JBrowse link
G Pfdn4 prefoldin subunit 4 increases expression ISO Bortezomib results in increased expression of PFDN4 mRNA CTD PMID:20977926 NCBI chr 3:159,303,173...159,311,221
Ensembl chr 3:159,303,071...159,311,219 		JBrowse link
G Pgr progesterone receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of PGR protein; Bortezomib inhibits the reaction [Promegestone results in increased activity of PGR protein] CTD PMID:25752796 PMID:30818834 NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344 		JBrowse link
G Phc3 polyhomeotic homolog 3 increases expression ISO Bortezomib results in increased expression of PHC3 mRNA CTD PMID:20977926 NCBI chr 2:112,408,709...112,483,719
Ensembl chr 2:112,408,531...112,476,540 		JBrowse link
G Phf1 PHD finger protein 1 increases expression ISO Bortezomib results in increased expression of PHF1 mRNA CTD PMID:20977926 NCBI chr20:5,017,765...5,022,872
Ensembl chr20:5,017,893...5,022,871 		JBrowse link
G Phkb phosphorylase kinase regulatory subunit beta increases expression ISO Bortezomib results in increased expression of PHKB mRNA CTD PMID:20977926 NCBI chr19:21,013,719...21,210,671
Ensembl chr19:21,025,733...21,210,633 		JBrowse link
G Phlda1 pleckstrin homology-like domain, family A, member 1 increases expression ISO Bortezomib results in increased expression of PHLDA1 mRNA CTD PMID:20977926 NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861 		JBrowse link
G Phtf1 putative homeodomain transcription factor 1 increases expression ISO Bortezomib results in increased expression of PHTF1 mRNA CTD PMID:20977926 NCBI chr 2:191,470,849...191,537,399
Ensembl chr 2:191,473,130...191,512,078 		JBrowse link
G Pi4kb phosphatidylinositol 4-kinase beta decreases expression ISO Bortezomib results in decreased expression of PI4KB mRNA CTD PMID:20977926 NCBI chr 2:182,540,377...182,572,684
Ensembl chr 2:182,540,567...182,588,488 		JBrowse link
G Pip4p1 phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 decreases expression ISO Bortezomib results in decreased expression of PIP4P1 mRNA CTD PMID:20977926 NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702 		JBrowse link
G Pip5k1a phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha decreases expression ISO Bortezomib results in decreased expression of PIP5K1A mRNA CTD PMID:20977926 NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598 		JBrowse link
G Pir pirin increases expression ISO Bortezomib results in increased expression of PIR mRNA CTD PMID:20977926 NCBI chr  X:30,108,536...30,219,269
Ensembl chr  X:30,108,538...30,219,218 		JBrowse link
G Pkia cAMP-dependent protein kinase inhibitor alpha increases expression ISO Bortezomib results in increased expression of PKIA mRNA CTD PMID:20977926 NCBI chr 2:94,398,869...94,473,638
Ensembl chr 2:94,398,869...94,414,282 		JBrowse link
G Plaa phospholipase A2, activating protein increases expression ISO Bortezomib results in increased expression of PLAA mRNA CTD PMID:20977926 NCBI chr 5:109,428,600...109,460,373
Ensembl chr 5:109,428,265...109,460,282 		JBrowse link
G Plekhm2 pleckstrin homology and RUN domain containing M2 decreases expression ISO Bortezomib results in decreased expression of PLEKHM2 mRNA CTD PMID:20977926 NCBI chr 5:153,939,582...153,978,625
Ensembl chr 5:153,940,262...153,978,689 		JBrowse link
G Pm20d2 peptidase M20 domain containing 2 increases expression ISO Bortezomib results in increased expression of PM20D2 mRNA CTD PMID:20977926 NCBI chr 5:47,566,059...47,586,334
Ensembl chr 5:47,566,072...47,586,212 		JBrowse link
G Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 multiple interactions
increases response to substance
increases expression
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of PMAIP1 mRNA; [Bortezomib co-treated with arsenic trioxide] results in increased expression of PMAIP1 protein; [Bortezomib co-treated with vorinostat] results in increased expression of PMAIP1 protein; [nutlin 3 co-treated with Bortezomib] results in increased expression of PMAIP1 protein; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with arsenic trioxide] results in increased activity of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]
PMAIP1 protein results in increased susceptibility to Bortezomib; PMAIP1 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of PMAIP1 mRNA; Bortezomib results in increased expression of PMAIP1 protein
Bortezomib results in decreased expression of PMAIP1 mRNA		 CTD PMID:16024631 PMID:16166592 PMID:16928686 PMID:17898295 PMID:18534018 More... NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429 		JBrowse link
G Pml PML nuclear body scaffold multiple interactions ISO Bortezomib inhibits the reaction [Arsenic results in increased degradation of PML protein] CTD PMID:36880596 NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971 		JBrowse link
G Pnisr PNN interacting serine and arginine rich protein increases expression ISO Bortezomib results in increased expression of PNISR mRNA CTD PMID:20977926 NCBI chr 5:35,395,965...35,422,852
Ensembl chr 5:35,395,965...35,422,844 		JBrowse link
G Pnmt phenylethanolamine-N-methyltransferase decreases expression ISO Bortezomib results in decreased expression of PNMT mRNA CTD PMID:20977926 NCBI chr10:83,383,019...83,386,557
Ensembl chr10:83,384,923...83,386,556 		JBrowse link
G Pno1 partner of NOB1 homolog increases expression ISO Bortezomib results in increased expression of PNO1 mRNA CTD PMID:20977926 NCBI chr14:91,609,711...91,618,280
Ensembl chr14:91,609,233...91,618,324 		JBrowse link
G Poc1b POC1 centriolar protein B increases expression ISO Bortezomib results in increased expression of POC1B mRNA CTD PMID:20977926 NCBI chr 7:33,924,112...34,025,908
Ensembl chr 7:33,924,189...34,025,903 		JBrowse link
G Polm DNA polymerase mu decreases expression ISO Bortezomib results in decreased expression of POLM mRNA CTD PMID:20977926 NCBI chr14:80,707,075...80,716,677
Ensembl chr14:80,706,345...80,717,086 		JBrowse link
G Polr2a RNA polymerase II subunit A multiple interactions ISO Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein]; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased phosphorylation of POLR2A protein] CTD PMID:15039284 NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455 		JBrowse link
G Polr3e RNA polymerase III subunit E increases expression ISO Bortezomib results in increased expression of POLR3E mRNA CTD PMID:20977926 NCBI chr 1:175,466,091...175,494,679
Ensembl chr 1:175,466,127...175,494,667 		JBrowse link
G Polr3h RNA polymerase III subunit H decreases expression ISO Bortezomib results in decreased expression of POLR3H mRNA CTD PMID:20977926 NCBI chr 7:113,429,434...113,439,743
Ensembl chr 7:113,429,451...113,439,778 		JBrowse link
G Ppard peroxisome proliferator-activated receptor delta increases response to substance ISO PPARD gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha multiple interactions ISO Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein] CTD PMID:30818834 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Ppm1a protein phosphatase, Mg2+/Mn2+ dependent, 1A increases expression ISO Bortezomib results in increased expression of PPM1A mRNA CTD PMID:20977926 NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697 		JBrowse link
G Ppm1f protein phosphatase, Mg2+/Mn2+ dependent, 1F increases expression ISO Bortezomib results in increased expression of PPM1F mRNA CTD PMID:20977926 NCBI chr11:84,064,422...84,094,410
Ensembl chr11:84,064,420...84,094,340 		JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO Bortezomib results in increased expression of PPP1R15A mRNA; Bortezomib results in increased expression of PPP1R15A protein CTD PMID:15509775 PMID:20022965 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171 		JBrowse link
G Ppp2r2a protein phosphatase 2, regulatory subunit B, alpha increases expression ISO Bortezomib results in increased expression of PPP2R2A mRNA CTD PMID:20977926 NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924 		JBrowse link
G Ppp2r5d protein phosphatase 2, regulatory subunit B', delta decreases expression ISO Bortezomib results in decreased expression of PPP2R5D mRNA CTD PMID:20977926 NCBI chr 9:14,270,364...14,300,396
Ensembl chr 9:14,268,745...14,300,400 		JBrowse link
G Ppp3r1 protein phosphatase 3, regulatory subunit B, alpha decreases expression ISO Bortezomib results in decreased expression of PPP3R1 mRNA CTD PMID:20977926 NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907 		JBrowse link
G Ppp5c protein phosphatase 5, catalytic subunit decreases expression ISO Bortezomib results in decreased expression of PPP5C mRNA CTD PMID:20977926 NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456 		JBrowse link
G Prdm2 PR/SET domain 2 decreases expression ISO Bortezomib results in decreased expression of PRDM2 mRNA CTD PMID:20977926 NCBI chr 5:155,421,066...155,531,884
Ensembl chr 5:155,422,134...155,531,825 		JBrowse link
G Prf1 perforin 1 decreases expression ISO Bortezomib results in decreased expression of PRF1 mRNA CTD PMID:20977926 NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions ISO Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of PRKAA1 protein] CTD PMID:37481222 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978 		JBrowse link
G Prkaa2 protein kinase AMP-activated catalytic subunit alpha 2 multiple interactions ISO Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of PRKAA2 protein] CTD PMID:37481222 NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543 		JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased cleavage of and results in increased activity of PRKCD protein; Bortezomib promotes the reaction [NSC606985 results in increased activity of and results in increased cleavage of PRKCD protein] CTD PMID:17495969 PMID:19662097 NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352 		JBrowse link
G Prkdc protein kinase, DNA-activated, catalytic subunit multiple interactions
increases cleavage
decreases expression		 ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of PRKDC protein]
Bortezomib results in decreased expression of PRKDC mRNA		 CTD PMID:12393500 PMID:20977926 NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952 		JBrowse link
G Prnp prion protein increases expression ISO Bortezomib results in increased expression of PRNP mRNA CTD PMID:20977926 NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937 		JBrowse link
G Prpf6 pre-mRNA processing factor 6 decreases expression ISO Bortezomib results in decreased expression of PRPF6 mRNA CTD PMID:20977926 NCBI chr 3:168,706,952...168,771,191
Ensembl chr 3:168,704,299...168,774,991 		JBrowse link
G Prr7 proline rich 7 (synaptic) decreases expression ISO Bortezomib results in decreased expression of PRR7 mRNA CTD PMID:20977926 NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536 		JBrowse link
G Psap prosaposin increases expression ISO Bortezomib results in increased expression of PSAP mRNA CTD PMID:20977926 NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498 		JBrowse link
G Psen1 presenilin 1 decreases expression ISO Bortezomib results in decreased expression of PSEN1 mRNA CTD PMID:20977926 NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650 		JBrowse link
G Psmb5 proteasome 20S subunit beta 5 affects binding
affects response to substance
increases expression
decreases response to substance		 ISO
EXP		 Bortezomib binds to PSMB5 protein
PSMB5 protein affects the susceptibility to Bortezomib
Bortezomib results in increased expression of PSMB5 mRNA
PSMB5 gene mutant form results in decreased susceptibility to Bortezomib		 CTD PMID:20213465 PMID:22216088 NCBI chr15:28,072,772...28,077,367
Ensembl chr15:28,072,781...28,077,440 		JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 increases expression ISO Bortezomib results in increased expression of PSMC4 mRNA CTD PMID:20977926 NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494 		JBrowse link
G Psmd12 proteasome 26S subunit, non-ATPase 12 increases expression ISO Bortezomib results in increased expression of PSMD12 mRNA CTD PMID:20977926 NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287 		JBrowse link
G Psmd13 proteasome 26S subunit, non-ATPase 13 increases expression ISO Bortezomib results in increased expression of PSMD13 mRNA CTD PMID:20977926 NCBI chr 1:195,964,617...195,976,895
Ensembl chr 1:195,964,138...195,976,905 		JBrowse link
G Psmd7 proteasome 26S subunit, non-ATPase 7 increases expression ISO Bortezomib results in increased expression of PSMD7 mRNA CTD PMID:20977926 NCBI chr19:35,494,317...35,501,605
Ensembl chr19:35,494,316...35,501,588 		JBrowse link
G Psmf1 proteasome inhibitor subunit 1 decreases expression ISO Bortezomib results in decreased expression of PSMF1 mRNA CTD PMID:20977926 NCBI chr 3:140,235,371...140,260,546
Ensembl chr 3:140,235,373...140,260,546 		JBrowse link
G Ptbp1 polypyrimidine tract binding protein 1 decreases expression ISO Bortezomib results in decreased expression of PTBP1 mRNA CTD PMID:20977926 NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions		 ISO Bortezomib results in increased expression of PTGS2 mRNA; Bortezomib results in increased expression of PTGS2 protein
Bortezomib promotes the reaction [capillarisin results in decreased expression of PTGS2 protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]		 CTD PMID:21215737 PMID:24085292 PMID:24333736 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Pthlh parathyroid hormone-like hormone decreases expression ISO Bortezomib results in decreased expression of PTHLH mRNA CTD PMID:18089816 NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847 		JBrowse link
G Ptp4a3 protein tyrosine phosphatase 4A3 decreases expression ISO Bortezomib results in decreased expression of PTP4A3 mRNA CTD PMID:20977926 NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:105,628,029...105,660,919 		JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 decreases expression ISO Bortezomib results in decreased expression of PTPN11 mRNA CTD PMID:20977926 NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925 		JBrowse link
G Ptpn6 protein tyrosine phosphatase, non-receptor type 6 decreases expression ISO Bortezomib results in decreased expression of PTPN6 mRNA CTD PMID:17659339 NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984 		JBrowse link
G Ptx3 pentraxin 3 decreases expression ISO Bortezomib results in decreased expression of PTX3 mRNA CTD PMID:20471514 NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323 		JBrowse link
G R3hdm4 R3H domain containing 4 decreases expression ISO Bortezomib results in decreased expression of R3HDM4 mRNA CTD PMID:20977926 NCBI chr 7:9,790,401...9,797,512
Ensembl chr 7:9,790,322...9,797,512 		JBrowse link
G Rab5a RAB5A, member RAS oncogene family decreases expression ISO Bortezomib results in decreased expression of RAB5A mRNA CTD PMID:20977926 NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873 		JBrowse link
G Rab8b RAB8B, member RAS oncogene family decreases expression ISO Bortezomib results in decreased expression of RAB8B mRNA CTD PMID:20977926 NCBI chr 8:67,458,921...67,536,466
Ensembl chr 8:67,458,923...67,536,384 		JBrowse link
G Rac2 Rac family small GTPase 2 decreases expression ISO Bortezomib results in decreased expression of RAC2 mRNA CTD PMID:20977926 NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720 		JBrowse link
G Rad51 RAD51 recombinase decreases expression ISO Bortezomib results in decreased expression of RAD51 mRNA CTD PMID:21917757 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions
decreases expression		 ISO [Bortezomib co-treated with Butyrates] results in decreased expression of RAF1 protein; [Bortezomib co-treated with panobinostat] results in decreased expression of RAF1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of RAF1 protein
Bortezomib results in decreased expression of RAF1 protein		 CTD PMID:12893773 PMID:18445700 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rala RAS like proto-oncogene A increases expression ISO Bortezomib results in increased expression of RALA mRNA CTD PMID:20977926 NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063 		JBrowse link
G Rapgef1 Rap guanine nucleotide exchange factor 1 decreases expression ISO Bortezomib results in decreased expression of RAPGEF1 mRNA CTD PMID:20977926 NCBI chr 3:12,898,349...13,016,234
Ensembl chr 3:12,898,266...13,013,984 		JBrowse link
G Raph1 Ras association (RalGDS/AF-6) and pleckstrin homology domains 1 increases expression ISO Bortezomib results in increased expression of RAPH1 mRNA CTD PMID:20977926 NCBI chr 9:61,907,476...61,990,170
Ensembl chr 9:61,907,758...61,961,209 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
increases response to substance		 ISO [Bortezomib co-treated with Butyrates] results in increased degradation of RB1 protein; [Bortezomib co-treated with vorinostat] results in increased degradation of RB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] CTD PMID:12893773 PMID:25522274 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rb1cc1 RB1-inducible coiled-coil 1 increases expression ISO Bortezomib results in increased expression of RB1CC1 mRNA CTD PMID:20977926 NCBI chr 5:13,161,648...13,225,560
Ensembl chr 5:13,161,648...13,225,560 		JBrowse link
G Rcan3 RCAN family member 3 decreases expression ISO Bortezomib results in decreased expression of RCAN3 mRNA CTD PMID:20977926 NCBI chr 5:147,650,935...147,671,881
Ensembl chr 5:147,655,085...147,671,937 		JBrowse link
G Rdh11 retinol dehydrogenase 11 increases expression ISO Bortezomib results in increased expression of RDH11 mRNA CTD PMID:20977926 NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252 		JBrowse link
G Rdh13 retinol dehydrogenase 13 increases expression ISO Bortezomib results in increased expression of RDH13 mRNA CTD PMID:20977926 NCBI chr 1:69,373,014...69,401,454
Ensembl chr 1:69,373,113...69,400,908 		JBrowse link
G Recql4 RecQ like helicase 4 increases expression ISO Bortezomib results in increased expression of RECQL4 mRNA CTD PMID:20977926 NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases expression
decreases activity		 ISO [Bortezomib co-treated with Arsenic Trioxide] results in decreased activity of RELA protein; [Bortezomib co-treated with Doxorubicin] results in decreased phosphorylation of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of and results in decreased activity of RELA protein; [Bortezomib co-treated with trichostatin A] results in decreased expression of RELA protein; [Bortezomib co-treated with Vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [Resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [romidepsin results in increased acetylation of RELA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]]
Bortezomib results in decreased expression of RELA mRNA; Bortezomib results in decreased expression of RELA protein
Bortezomib results in decreased activity of RELA protein		 CTD PMID:12893773 PMID:16230421 PMID:16904634 PMID:17164350 PMID:17626072 More... NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rffl ring finger and FYVE-like domain containing E3 ubiquitin protein ligase increases expression ISO Bortezomib results in increased expression of RFFL mRNA CTD PMID:20977926 NCBI chr10:67,740,711...67,803,669
Ensembl chr10:67,740,712...67,824,434 		JBrowse link
G Rhobtb2 Rho-related BTB domain containing 2 increases response to substance ISO RHOBTB2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr15:44,868,251...44,888,436
Ensembl chr15:44,870,376...44,888,651 		JBrowse link
G Rhot2 ras homolog family member T2 decreases expression ISO Bortezomib results in decreased expression of RHOT2 mRNA CTD PMID:20977926 NCBI chr10:14,858,954...14,864,751
Ensembl chr10:14,858,956...14,864,751 		JBrowse link
G Ripk1 receptor interacting serine/threonine kinase 1 decreases expression
increases expression		 ISO Bortezomib results in decreased expression of RIPK1 mRNA
Bortezomib results in increased expression of RIPK1 protein		 CTD PMID:20471514 PMID:26769846 NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824 		JBrowse link
G Ripk3 receptor-interacting serine-threonine kinase 3 increases expression ISO Bortezomib results in increased expression of RIPK3 protein CTD PMID:26769846 NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121 		JBrowse link
G Rit1 Ras-like without CAAX 1 increases expression ISO Bortezomib results in increased expression of RIT1 mRNA CTD PMID:20977926 NCBI chr 2:174,180,742...174,195,455
Ensembl chr 2:174,180,848...174,195,455 		JBrowse link
G Rnd3 Rho family GTPase 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA CTD PMID:25522274 NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327 		JBrowse link
G Rnf11 ring finger protein 11 increases expression ISO Bortezomib results in increased expression of RNF11 mRNA CTD PMID:20977926 NCBI chr 5:124,212,433...124,243,125
Ensembl chr 5:124,212,445...124,234,750 		JBrowse link
G Rnf138 ring finger protein 138 increases expression ISO Bortezomib results in increased expression of RNF138 mRNA CTD PMID:20977926 NCBI chr18:12,291,557...12,315,931
Ensembl chr18:12,291,590...12,315,930 		JBrowse link
G Rnf14 ring finger protein 14 increases expression ISO Bortezomib results in increased expression of RNF14 mRNA CTD PMID:20977926 NCBI chr18:30,131,627...30,155,686
Ensembl chr18:30,131,691...30,155,685 		JBrowse link
G Rnf2 ring finger protein 2 increases expression ISO Bortezomib results in increased expression of RNF2 mRNA CTD PMID:20977926 NCBI chr13:63,553,964...63,584,047
Ensembl chr13:63,554,862...63,583,099 		JBrowse link
G Rpa3 replication protein A3 decreases expression ISO Bortezomib results in decreased expression of RPA3 mRNA CTD PMID:17659339 NCBI chr 4:36,304,649...36,307,755
Ensembl chr 4:36,304,651...36,307,709 		JBrowse link
G Rpap3 RNA polymerase II associated protein 3 increases expression ISO Bortezomib results in increased expression of RPAP3 mRNA CTD PMID:20977926 NCBI chr 7:128,810,820...128,840,006
Ensembl chr 7:128,810,827...128,839,950 		JBrowse link
G Rpl26 ribosomal protein L26 increases expression ISO Bortezomib results in increased expression of RPL26 mRNA CTD PMID:20977926 NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966 		JBrowse link
G Rps11 ribosomal protein S11 increases expression ISO Bortezomib results in increased expression of RPS11 mRNA CTD PMID:20977926 NCBI chr 1:95,605,690...95,607,798
Ensembl chr 1:95,605,692...95,607,874 		JBrowse link
G Rps19 ribosomal protein S19 increases expression ISO Bortezomib results in increased expression of RPS19 mRNA CTD PMID:15509775 NCBI chr 1:80,480,718...80,486,511
Ensembl chr 1:80,480,951...80,486,508 		JBrowse link
G Rps6 ribosomal protein S6 increases expression ISO Bortezomib results in increased expression of RPS6 protein modified form CTD PMID:29384525 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 increases expression ISO Bortezomib results in increased expression of RPS6KB1 mRNA CTD PMID:20977926 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Rps6kc1 ribosomal protein S6 kinase C1 increases expression ISO Bortezomib results in increased expression of RPS6KC1 mRNA CTD PMID:20977926 NCBI chr13:102,346,160...102,491,000
Ensembl chr13:102,346,160...102,490,303 		JBrowse link
G Rrm2b ribonucleotide reductase regulatory TP53 inducible subunit M2B increases expression ISO Bortezomib results in increased expression of RRM2B mRNA CTD PMID:20977926 NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633 		JBrowse link
G Rsu1 Ras suppressor protein 1 increases expression ISO Bortezomib results in increased expression of RSU1 mRNA CTD PMID:20977926 NCBI chr17:76,128,774...76,377,515
Ensembl chr17:76,188,812...76,377,454 		JBrowse link
G RT1-Da RT1 class II, locus Da decreases expression ISO Bortezomib results in decreased expression of HLA-DRA mRNA CTD PMID:20977926 NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455 		JBrowse link
G RT1-DMb RT1 class II, locus DMb decreases expression ISO Bortezomib results in decreased expression of HLA-DMB mRNA CTD PMID:20977926 NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340 		JBrowse link
G RT1-DOa RT1 class II, locus DOa decreases expression ISO Bortezomib results in decreased expression of HLA-DOA mRNA CTD PMID:20977926 NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577 		JBrowse link
G RT1-Hb-ps1 RT1 class II, locus Hb, pseudogene 1 decreases expression ISO Bortezomib results in decreased expression of HLA-DPB1 mRNA CTD PMID:20977926 NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618 		JBrowse link
G Safb scaffold attachment factor B decreases expression ISO Bortezomib results in decreased expression of SAFB mRNA CTD PMID:20977926 NCBI chr 9:1,417,449...1,438,408
Ensembl chr 9:1,417,525...1,438,644 		JBrowse link
G Sall4 spalt-like transcription factor 4 multiple interactions ISO Bortezomib inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein] CTD PMID:30067223 NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822 		JBrowse link
G Samd10 sterile alpha motif domain containing 10 decreases expression ISO Bortezomib results in decreased expression of SAMD10 mRNA CTD PMID:20977926 NCBI chr 3:168,700,280...168,704,427
Ensembl chr 3:168,700,284...168,705,248 		JBrowse link
G Scarna17 small Cajal body-specific RNA 17 increases expression ISO Bortezomib results in increased expression of SCARNA17 mRNA CTD PMID:20977926 NCBI chr18:68,344,475...68,344,553
Ensembl chr18:68,344,475...68,344,553 		JBrowse link
G Scd stearoyl-CoA desaturase decreases expression ISO Bortezomib results in decreased expression of SCD mRNA CTD PMID:20977926 NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562 		JBrowse link
G Schip1 schwannomin interacting protein 1 decreases expression ISO Bortezomib results in decreased expression of SCHIP1 mRNA CTD PMID:20977926 NCBI chr 2:152,127,171...152,888,587
Ensembl chr 2:152,126,953...152,888,585 		JBrowse link
G Scpep1 serine carboxypeptidase 1 increases expression ISO Bortezomib results in increased expression of SCPEP1 mRNA CTD PMID:20977926 NCBI chr10:73,703,275...73,732,892
Ensembl chr10:73,703,278...73,732,850 		JBrowse link
G Sdhc succinate dehydrogenase complex subunit C decreases expression ISO Bortezomib results in decreased expression of SDHC mRNA CTD PMID:20977926 NCBI chr13:83,544,652...83,565,560
Ensembl chr13:83,544,652...83,566,253 		JBrowse link
G Selenok selenoprotein K increases expression ISO Bortezomib results in increased expression of SELENOK mRNA CTD PMID:20977926 NCBI chr16:5,152,066...5,160,648
Ensembl chr16:5,152,066...5,159,188 		JBrowse link
G Senp3 SUMO specific peptidase 3 decreases expression ISO Bortezomib results in decreased expression of SENP3 mRNA CTD PMID:20977926 NCBI chr10:54,390,698...54,399,590
Ensembl chr10:54,390,694...54,399,593 		JBrowse link
G Serpine1 serpin family E member 1 increases expression EXP Bortezomib results in increased expression of SERPINE1 mRNA CTD PMID:20830808 NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657 		JBrowse link
G Setd1b SET domain containing 1B, histone lysine methyltransferase increases expression ISO Bortezomib results in increased expression of SETD1B mRNA CTD PMID:20977926 NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934 		JBrowse link
G Sfn stratifin increases expression
multiple interactions		 ISO Bortezomib results in increased expression of SFN mRNA
[irinotecan co-treated with Bortezomib] results in decreased expression of SFN protein		 CTD PMID:16373703 PMID:20977926 NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314 		JBrowse link
G Sft2d3 SFT2 domain containing 3 decreases expression ISO Bortezomib results in decreased expression of SFT2D3 mRNA CTD PMID:20977926 NCBI chr18:23,537,105...23,539,305
Ensembl chr18:23,537,105...23,539,305 		JBrowse link
G Sgk1 serum/glucocorticoid regulated kinase 1 increases expression ISO Bortezomib results in increased expression of SGK1 mRNA CTD PMID:20977926 NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283 		JBrowse link
G Sgms1 sphingomyelin synthase 1 increases expression ISO Bortezomib results in increased expression of SGMS1 mRNA CTD PMID:20977926 NCBI chr 1:229,996,673...230,259,591
Ensembl chr 1:229,998,119...230,259,603 		JBrowse link
G Sgpp1 sphingosine-1-phosphate phosphatase 1 increases expression ISO Bortezomib results in increased expression of SGPP1 mRNA CTD PMID:20977926 NCBI chr 6:94,425,339...94,446,534
Ensembl chr 6:94,425,339...94,446,534 		JBrowse link
G Sgsh N-sulfoglucosamine sulfohydrolase increases expression ISO Bortezomib results in increased expression of SGSH mRNA CTD PMID:20977926 NCBI chr10:104,596,810...104,613,510
Ensembl chr10:104,598,112...104,613,486 		JBrowse link
G Sh2d3c SH2 domain containing 3C decreases expression ISO Bortezomib results in decreased expression of SH2D3C mRNA CTD PMID:20977926 NCBI chr 3:16,010,622...16,046,491
Ensembl chr 3:16,010,625...16,046,484 		JBrowse link
G Sh3glb2 SH3 domain-containing GRB2-like endophilin B2 decreases expression ISO Bortezomib results in decreased expression of SH3GLB2 mRNA CTD PMID:20977926 NCBI chr 3:13,616,936...13,631,785
Ensembl chr 3:13,616,938...13,631,757 		JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions
decreases expression		 ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of SHC1 mRNA
Bortezomib results in decreased expression of SHC1 mRNA		 CTD PMID:20471514 PMID:25913414 NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536 		JBrowse link
G Sigmar1 sigma non-opioid intracellular receptor 1 decreases expression ISO Bortezomib results in decreased expression of SIGMAR1 mRNA CTD PMID:20977926 NCBI chr 5:56,904,155...56,907,012
Ensembl chr 5:56,904,159...56,907,017 		JBrowse link
G Sirt1 sirtuin 1 decreases expression
multiple interactions		 EXP Bortezomib results in decreased expression of SIRT1 protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein]		 CTD PMID:35121005 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Siva1 SIVA1, apoptosis-inducing factor decreases expression ISO Bortezomib results in decreased expression of SIVA1 mRNA CTD PMID:17659339 NCBI chr 6:131,705,323...131,709,697
Ensembl chr 6:131,705,323...131,709,690 		JBrowse link
G Skp2 S-phase kinase associated protein 2 decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of SKP2 protein
Cisplatin promotes the reaction [Bortezomib results in decreased expression of SKP2 protein]		 CTD PMID:18850583 PMID:19636294 NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338 		JBrowse link
G Slc10a7 solute carrier family 10, member 7 increases expression ISO Bortezomib results in increased expression of SLC10A7 mRNA CTD PMID:20977926 NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464 		JBrowse link
G Slc25a11 solute carrier family 25 member 11 decreases expression ISO Bortezomib results in decreased expression of SLC25A11 mRNA CTD PMID:20977926 NCBI chr10:55,357,590...55,360,441
Ensembl chr10:55,357,597...55,360,410 		JBrowse link
G Slc26a11 solute carrier family 26 member 11 increases expression ISO Bortezomib results in increased expression of SLC26A11 mRNA CTD PMID:20977926 NCBI chr10:104,613,498...104,635,873
Ensembl chr10:104,613,564...104,635,970 		JBrowse link
G Slc2a3 solute carrier family 2 member 3 increases expression ISO Bortezomib results in increased expression of SLC2A3 mRNA CTD PMID:20977926 NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472 		JBrowse link
G Slc31a1 solute carrier family 31 member 1 multiple interactions
decreases degradation		 ISO [Bortezomib inhibits the reaction [Cisplatin results in decreased expression of SLC31A1 protein]] which results in increased uptake of Cisplatin; [Bortezomib results in decreased degradation of SLC31A1 protein] which results in increased uptake of Platinum; Bortezomib inhibits the reaction [Cisplatin results in decreased expression of SLC31A1 protein] CTD PMID:19147760 PMID:24209693 NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228 		JBrowse link
G Slc35c2 solute carrier family 35 member C2 decreases expression ISO Bortezomib results in decreased expression of SLC35C2 mRNA CTD PMID:20977926 NCBI chr 3:154,012,262...154,023,549
Ensembl chr 3:154,012,416...154,023,488 		JBrowse link
G Slc35g1 solute carrier family 35, member G1 decreases expression ISO Bortezomib results in decreased expression of SLC35G1 mRNA CTD PMID:20977926 NCBI chr 1:236,163,593...236,172,115
Ensembl chr 1:236,163,175...236,170,262 		JBrowse link
G Slc38a6 solute carrier family 38, member 6 increases expression ISO Bortezomib results in increased expression of SLC38A6 mRNA CTD PMID:20977926 NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:91,987,672...92,049,935 		JBrowse link
G Slc43a3 solute carrier family 43, member 3 decreases expression ISO Bortezomib results in decreased expression of SLC43A3 mRNA CTD PMID:20977926 NCBI chr 3:70,008,160...70,030,324
Ensembl chr 3:70,009,313...70,029,749 		JBrowse link
G Slc7a5 solute carrier family 7 member 5 decreases expression ISO Bortezomib results in decreased expression of SLC7A5 mRNA CTD PMID:20977926 NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823 		JBrowse link
G Smc1a structural maintenance of chromosomes 1A decreases expression ISO Bortezomib results in decreased expression of SMC1A mRNA CTD PMID:20977926 NCBI chr  X:21,103,323...21,148,053
Ensembl chr  X:21,103,282...21,148,056 		JBrowse link
G Smc3 structural maintenance of chromosomes 3 increases expression ISO Bortezomib results in increased expression of SMC3 mRNA CTD PMID:20977926 NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522 		JBrowse link
G Smc6 structural maintenance of chromosomes 6 increases expression ISO Bortezomib results in increased expression of SMC6 mRNA CTD PMID:20977926 NCBI chr 6:33,978,730...34,033,201
Ensembl chr 6:33,978,716...34,031,746 		JBrowse link
G Smim11 small integral membrane protein 11 decreases expression ISO Bortezomib results in decreased expression of SMIM11 mRNA CTD PMID:20977926 NCBI chr11:31,533,257...31,543,002
Ensembl chr11:31,532,764...31,543,002 		JBrowse link
G Smurf2 SMAD specific E3 ubiquitin protein ligase 2 increases expression ISO Bortezomib results in increased expression of SMURF2 mRNA CTD PMID:20977926 NCBI chr10:91,761,798...91,862,485
Ensembl chr10:91,761,807...91,862,488 		JBrowse link
G Snca synuclein alpha increases expression ISO Bortezomib results in increased expression of SNCA mRNA CTD PMID:17895889 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262 		JBrowse link
G Snrnp48 small nuclear ribonucleoprotein U11/U12 subunit 48 increases expression ISO Bortezomib results in increased expression of SNRNP48 mRNA CTD PMID:20977926 NCBI chr17:26,596,266...26,616,058
Ensembl chr17:26,596,275...26,616,040 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 increases expression ISO Bortezomib results in increased expression of SOCS3 mRNA CTD PMID:20977926 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787 		JBrowse link
G Socs5 suppressor of cytokine signaling 5 increases expression ISO Bortezomib results in increased expression of SOCS5 mRNA CTD PMID:20977926 NCBI chr 6:7,481,039...7,512,644
Ensembl chr 6:7,481,095...7,514,834 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases response to substance		 ISO [Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of SOD2 mRNA
SOD2 gene SNP results in increased susceptibility to Bortezomib		 CTD PMID:20864405 PMID:23063726 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sox10 SRY-box transcription factor 10 decreases expression EXP Bortezomib results in decreased expression of SOX10 mRNA CTD PMID:20830808 NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544 		JBrowse link
G Sox8 SRY-box transcription factor 8 increases response to substance ISO SOX8 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818 		JBrowse link
G Sphk1 sphingosine kinase 1 decreases expression ISO Bortezomib results in decreased expression of SPHK1 protein CTD PMID:21195056 NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240 		JBrowse link
G Spn sialophorin decreases expression ISO Bortezomib results in decreased expression of SPN mRNA CTD PMID:20977926 NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628 		JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression ISO Bortezomib results in decreased expression of SPP1 mRNA CTD PMID:20471514 PMID:25913414 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162 		JBrowse link
G Spsb3 splA/ryanodine receptor domain and SOCS box containing 3 increases expression ISO Bortezomib results in increased expression of SPSB3 mRNA CTD PMID:20977926 NCBI chr10:13,907,175...13,912,841
Ensembl chr10:13,907,253...13,912,841 		JBrowse link
G Sptbn1 spectrin, beta, non-erythrocytic 1 increases expression ISO Bortezomib results in increased expression of SPTBN1 mRNA CTD PMID:20977926 NCBI chr14:103,841,713...104,016,900
Ensembl chr14:103,842,684...104,008,507 		JBrowse link
G Spty2d1 SPT2 chromatin protein domain containing 1 increases expression ISO Bortezomib results in increased expression of SPTY2D1 mRNA CTD PMID:20977926 NCBI chr 1:97,531,495...97,549,616
Ensembl chr 1:97,531,508...97,549,581 		JBrowse link
G Sqstm1 sequestosome 1 increases expression
decreases expression		 ISO
EXP		 Bortezomib results in increased expression of SQSTM1 mRNA
Bortezomib results in decreased expression of SQSTM1 protein		 CTD PMID:20830808 PMID:20977926 PMID:37481222 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srrt serrate, RNA effector molecule decreases expression ISO Bortezomib results in decreased expression of SRRT mRNA CTD PMID:20977926 NCBI chr12:19,392,578...19,406,098
Ensembl chr12:19,392,625...19,406,095 		JBrowse link
G Srsf1 serine and arginine rich splicing factor 1 decreases expression ISO Bortezomib results in decreased expression of SRSF1 mRNA CTD PMID:20977926 NCBI chr10:72,838,926...72,859,066
Ensembl chr10:72,839,274...72,845,336 		JBrowse link
G Ssrp1 structure specific recognition protein 1 decreases expression ISO Bortezomib results in decreased expression of SSRP1 mRNA CTD PMID:20977926 NCBI chr 3:70,124,371...70,134,481
Ensembl chr 3:70,118,655...70,134,482 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
increases expression		 ISO
EXP		 [alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein; [resveratrol co-treated with Bortezomib] results in decreased phosphorylation of STAT3 protein; Bortezomib promotes the reaction [Capsaicin results in decreased phosphorylation of and results in decreased activity of STAT3 protein]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of STAT3 protein]; Bortezomib results in increased expression of and results in increased phosphorylation of STAT3 protein
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA]		 CTD PMID:15039284 PMID:17164350 PMID:17505005 PMID:19383353 PMID:24627483 More... NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Stim2 stromal interaction molecule 2 decreases expression ISO Bortezomib results in decreased expression of STIM2 mRNA CTD PMID:20977926 NCBI chr14:56,878,428...57,004,405
Ensembl chr14:56,878,645...57,004,179 		JBrowse link
G Stip1 stress-induced phosphoprotein 1 decreases expression
increases expression		 ISO Bortezomib results in decreased expression of STIP1 mRNA
Bortezomib results in increased expression of STIP1 mRNA		 CTD PMID:17895889 PMID:20977926 NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476 		JBrowse link
G Stk11 serine/threonine kinase 11 multiple interactions ISO Bortezomib inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of and results in decreased phosphorylation of STK11 protein]; Bortezomib inhibits the reaction [geldanamycin results in decreased expression of and results in decreased phosphorylation of STK11 protein] CTD PMID:37481222 NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315 		JBrowse link
G Stk4 serine/threonine kinase 4 multiple interactions
increases response to substance		 ISO Bortezomib results in increased activity of and results in increased localization of STK4 protein; leptomycin B promotes the reaction [Bortezomib results in increased activity of STK4 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]
STK4 protein results in increased susceptibility to Bortezomib; STK4 results in increased susceptibility to Bortezomib		 CTD PMID:16778179 NCBI chr 3:152,745,958...152,827,747
Ensembl chr 3:152,745,681...152,827,744 		JBrowse link
G Sts steroid sulfatase multiple interactions
decreases expression		 ISO Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased expression of STS mRNA		 CTD PMID:20977926 PMID:24055520 NCBI chr  X:42,225,131...42,233,403
Ensembl chr  X:42,225,372...42,233,402 		JBrowse link
G Stx12 syntaxin 12 increases expression ISO Bortezomib results in increased expression of STX12 mRNA CTD PMID:20977926 NCBI chr 5:145,062,978...145,092,423
Ensembl chr 5:145,063,587...145,092,377 		JBrowse link
G Styk1 serine/threonine/tyrosine kinase 1 increases expression ISO Bortezomib results in increased expression of STYK1 mRNA CTD PMID:20977926 NCBI chr 4:165,047,613...165,097,890
Ensembl chr 4:165,048,440...165,096,440 		JBrowse link
G Suds3 SDS3 homolog, SIN3A corepressor complex component increases expression ISO Bortezomib results in increased expression of SUDS3 mRNA CTD PMID:20977926 NCBI chr12:39,477,181...39,499,633
Ensembl chr12:39,477,568...39,499,628 		JBrowse link
G Sumo1 small ubiquitin-like modifier 1 increases expression ISO Bortezomib results in increased expression of SUMO1 mRNA CTD PMID:20977926 NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761 		JBrowse link
G Susd4 sushi domain containing 4 decreases expression ISO Bortezomib results in decreased expression of SUSD4 mRNA CTD PMID:20977926 NCBI chr13:94,455,180...94,577,773
Ensembl chr13:94,455,165...94,577,750 		JBrowse link
G Suv39h1 SUV39H1 histone lysine methyltransferase decreases expression ISO Bortezomib results in decreased expression of SUV39H1 mRNA CTD PMID:17659339 NCBI chr  X:14,421,028...14,433,993
Ensembl chr  X:14,421,109...14,433,982 		JBrowse link
G Suv39h1-ps1 SUV39H1 histone lysine methyltransferase, pseudogene 1 decreases expression ISO Bortezomib results in decreased expression of SUV39H1 mRNA CTD PMID:17659339 NCBI chr  X:141,792,589...141,795,257 JBrowse link
G Svopl SVOP like decreases expression ISO Bortezomib results in decreased expression of SVOPL mRNA CTD PMID:20977926 NCBI chr 4:66,697,550...66,751,699
Ensembl chr 4:66,698,177...66,758,978 		JBrowse link
G Syngr2 synaptogyrin 2 decreases expression ISO Bortezomib results in decreased expression of SYNGR2 mRNA CTD PMID:20977926 NCBI chr10:103,029,903...103,034,473
Ensembl chr10:103,029,917...103,034,473 		JBrowse link
G Tagln2 transgelin 2 decreases expression ISO Bortezomib results in decreased expression of TAGLN2 mRNA CTD PMID:20977926 NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972 		JBrowse link
G Tank TRAF family member-associated NFKB activator increases expression ISO Bortezomib results in increased expression of TANK mRNA CTD PMID:20977926 NCBI chr 3:46,114,230...46,190,270
Ensembl chr 3:46,114,274...46,190,264 		JBrowse link
G Tasor2 transcription activation suppressor family member 2 decreases expression ISO Bortezomib results in decreased expression of TASOR2 mRNA CTD PMID:20977926 NCBI chr17:66,583,554...66,650,127
Ensembl chr17:66,594,908...66,649,135 		JBrowse link
G Tbc1d9 TBC1 domain family member 9 increases expression ISO Bortezomib results in increased expression of TBC1D9 mRNA CTD PMID:20977926 NCBI chr19:24,842,166...24,951,383
Ensembl chr19:24,842,205...24,943,129 		JBrowse link
G Tbcd tubulin folding cofactor D decreases expression ISO Bortezomib results in decreased expression of TBCD mRNA CTD PMID:20977926 NCBI chr10:106,717,340...106,874,126
Ensembl chr10:106,717,367...106,874,122 		JBrowse link
G Tbl1x transducin (beta)-like 1 X-linked increases expression ISO Bortezomib results in increased expression of TBL1X mRNA CTD PMID:20977926 NCBI chr  X:41,574,558...41,731,117
Ensembl chr  X:41,576,047...41,731,101 		JBrowse link
G Tceal1 transcription elongation factor A like 1 increases expression ISO Bortezomib results in increased expression of TCEAL1 mRNA CTD PMID:17895889 NCBI chr  X:100,058,485...100,060,439
Ensembl chr  X:100,058,132...100,060,551 		JBrowse link
G Tcf19 transcription factor 19 decreases expression ISO Bortezomib results in decreased expression of TCF19 mRNA CTD PMID:17659339 NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271 		JBrowse link
G Tcf4 transcription factor 4 increases expression ISO Bortezomib results in increased expression of TCF4 mRNA CTD PMID:17895889 NCBI chr18:62,941,739...63,288,126
Ensembl chr18:62,943,782...63,284,425 		JBrowse link
G Tcf7 transcription factor 7 decreases expression ISO Bortezomib results in decreased expression of TCF7 mRNA CTD PMID:20977926 NCBI chr10:36,423,443...36,454,350
Ensembl chr10:36,423,445...36,453,535 		JBrowse link
G Tcf7l2 transcription factor 7 like 2 increases expression ISO Bortezomib results in increased expression of TCF7L2 mRNA CTD PMID:17895889 NCBI chr 1:254,785,956...254,978,967
Ensembl chr 1:254,786,091...254,978,967 		JBrowse link
G Tfdp1 transcription factor Dp-1 decreases expression ISO Bortezomib results in decreased expression of TFDP1 mRNA CTD PMID:20977926 NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817 		JBrowse link
G Them6 thioesterase superfamily member 6 decreases expression ISO Bortezomib results in decreased expression of THEM6 mRNA CTD PMID:20977926 NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746 		JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; Bortezomib binds to and results in decreased activity of THRA protein CTD PMID:25522274 PMID:25752796 NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936 		JBrowse link
G Thy1 Thy-1 cell surface antigen decreases expression ISO Bortezomib results in decreased expression of THY1 mRNA CTD PMID:20977926 NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659 		JBrowse link
G Ticam2 TIR domain containing adaptor molecule 2 multiple interactions
increases expression		 ISO Bortezomib promotes the reaction [arsenic trioxide results in increased expression of TICAM2 mRNA]
Bortezomib results in increased expression of TICAM2 mRNA		 CTD PMID:20471514 NCBI chr18:39,289,902...39,311,462
Ensembl chr18:39,294,453...39,311,462 		JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions
increases expression		 ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of TLR2 mRNA]
Bortezomib results in increased expression of TLR2 mRNA		 CTD PMID:20471514 NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630 		JBrowse link
G Tlr4 toll-like receptor 4 increases expression
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of TLR4 mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein]		 CTD PMID:17895889 PMID:35121005 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tm2d2 TM2 domain containing 2 increases expression ISO Bortezomib results in increased expression of TM2D2 mRNA CTD PMID:20977926 NCBI chr16:67,016,683...67,022,206
Ensembl chr16:67,012,675...67,022,226 		JBrowse link
G Tm2d3 TM2 domain containing 3 increases expression ISO Bortezomib results in increased expression of TM2D3 mRNA CTD PMID:20977926 NCBI chr 1:119,267,194...119,277,094
Ensembl chr 1:119,264,576...119,277,099 		JBrowse link
G Tmem230 transmembrane protein 230 decreases expression ISO Bortezomib results in decreased expression of TMEM230 mRNA CTD PMID:20977926 NCBI chr 3:119,473,109...119,497,617
Ensembl chr 3:119,480,735...119,497,614 		JBrowse link
G Tmem254 transmembrane protein 254 decreases expression ISO Bortezomib results in decreased expression of TMEM254 mRNA CTD PMID:20977926 NCBI chr16:1,503,931...1,507,819
Ensembl chr16:1,503,933...1,507,895 		JBrowse link
G Tmem263 transmembrane protein 263 increases expression ISO Bortezomib results in increased expression of TMEM263 mRNA CTD PMID:20977926 NCBI chr 7:18,610,151...18,628,311
Ensembl chr 7:18,610,149...18,628,534 		JBrowse link
G Tmem41b transmembrane protein 41B increases expression ISO Bortezomib results in increased expression of TMEM41B mRNA CTD PMID:20977926 NCBI chr 1:164,012,585...164,026,967
Ensembl chr 1:164,012,592...164,026,933 		JBrowse link
G Tmem92 transmembrane protein 92 decreases expression ISO Bortezomib results in decreased expression of TMEM92 mRNA CTD PMID:20977926 NCBI chr10:79,749,242...79,760,807 JBrowse link
G Tmpo thymopoietin decreases expression ISO Bortezomib results in decreased expression of TMPO mRNA CTD PMID:20977926 NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression		 ISO
EXP		 [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of TNF protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [TNF protein affects the localization of RELA protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of RELA protein]]
Bortezomib results in increased expression of TNF mRNA
Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]
Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Bortezomib inhibits the reaction [TNF protein results in increased activity of UPP1 protein]; Bortezomib inhibits the reaction [TNF protein results in increased expression of UPP1 mRNA]		 CTD PMID:16230421 PMID:16397116 PMID:19261616 PMID:20471514 PMID:28134560 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip3 TNF alpha induced protein 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA CTD PMID:25522274 NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282 		JBrowse link
G Tnfaip8l1 TNF alpha induced protein 8 like 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA CTD PMID:25522274 NCBI chr 9:988,587...999,342
Ensembl chr 9:988,594...1,002,254 		JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b affects expression
increases localization
increases expression
decreases expression
multiple interactions		 ISO Bortezomib affects the expression of TNFRSF10A mRNA; Bortezomib affects the expression of TNFRSF10A protein
Bortezomib results in increased localization of TNFRSF10A protein
Bortezomib results in increased expression of TNFRSF10A protein
Bortezomib results in decreased expression of TNFRSF10A protein
[Bortezomib co-treated with arsenic trioxide] results in increased expression of TNFRSF10A protein; [Bortezomib results in increased localization of TNFRSF10A protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; Brefeldin A inhibits the reaction [Bortezomib results in increased localization of TNFRSF10A protein]		 CTD PMID:12902978 PMID:17326159 PMID:17327374 PMID:17510429 PMID:17620439 More... NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467 		JBrowse link
G Tnfrsf9 TNF receptor superfamily member 9 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA CTD PMID:25522274 NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000 		JBrowse link
G Tnfsf10 TNF superfamily member 10 multiple interactions
decreases expression		 ISO [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of TNFSF10 mRNA; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib results in increased localization of TNFRSF10A protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; [Bortezomib results in increased localization of TNFRSF10B protein] promotes the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of XIAP protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]; Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein; Brefeldin A affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of XIAP protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in decreased expression of TNFSF10 mRNA; Bortezomib results in decreased expression of TNFSF10 protein		 CTD PMID:12902978 PMID:15930312 PMID:17172406 PMID:17326159 PMID:17510429 More... NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tnks tankyrase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA CTD PMID:25522274 NCBI chr16:57,223,174...57,370,740
Ensembl chr16:57,225,094...57,366,260 		JBrowse link
G Top2b DNA topoisomerase II beta multiple interactions EXP Bortezomib inhibits the reaction [4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione results in increased degradation of and results in decreased expression of TOP2B protein]; Bortezomib inhibits the reaction [Razoxane results in increased degradation of and results in decreased expression of TOP2B protein] CTD PMID:17875725 NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085 		JBrowse link
G Tor1aip1 torsin 1A interacting protein 1 decreases expression ISO Bortezomib results in decreased expression of TOR1AIP1 mRNA CTD PMID:20977926 NCBI chr13:68,196,681...68,226,121
Ensembl chr13:68,196,681...68,225,862 		JBrowse link
G Tp53 tumor protein p53 increases expression
affects activity
increases activity
multiple interactions
increases stability		 ISO Bortezomib results in increased expression of TP53 protein
Bortezomib affects the activity of TP53 protein
Bortezomib results in increased activity of TP53 protein
[SCIO-469 co-treated with Bortezomib] results in increased expression of TRP53 protein
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [irinotecan co-treated with Bortezomib] results in increased ubiquitination of TP53 protein; [vorinostat co-treated with Bortezomib] results in increased expression of TP53 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]; Bortezomib results in increased phosphorylation of and results in increased localization of TP53 protein; Caffeine inhibits the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased expression of TP53 protein]; TP53 protein affects the susceptibility to [irinotecan co-treated with Bortezomib]
Bortezomib results in increased stability of TP53 protein		 CTD PMID:12393500 PMID:15173093 PMID:15543232 PMID:16373703 PMID:16617327 More... NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tp53bp1 tumor protein p53 binding protein 1 multiple interactions ISO TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] CTD PMID:25522274 NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822 		JBrowse link
G Tpi1 triosephosphate isomerase 1 increases expression ISO Bortezomib results in increased expression of TPI1 mRNA CTD PMID:20977926 NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541 		JBrowse link
G Tpm1 tropomyosin 1 increases expression ISO Bortezomib results in increased expression of TPM1 mRNA CTD PMID:20977926 NCBI chr 8:67,635,479...67,662,330
Ensembl chr 8:67,635,479...67,662,802 		JBrowse link
G Tra2a transformer 2 alpha decreases expression ISO Bortezomib results in decreased expression of TRA2A mRNA CTD PMID:20977926 NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712 		JBrowse link
G Trafd1 TRAF type zinc finger domain containing 1 increases expression ISO Bortezomib results in increased expression of TRAFD1 mRNA CTD PMID:20977926 NCBI chr12:35,165,606...35,179,525
Ensembl chr12:35,165,606...35,179,525 		JBrowse link
G Trib3 tribbles pseudokinase 3 multiple interactions
increases expression		 ISO 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of TRIB3 protein]		 CTD PMID:25522274 PMID:30482226 NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497 		JBrowse link
G Trim65 tripartite motif-containing 65 decreases expression ISO Bortezomib results in decreased expression of TRIM65 mRNA CTD PMID:20977926 NCBI chr10:101,357,937...101,364,036
Ensembl chr10:101,357,937...101,364,971 		JBrowse link
G Triml2 tripartite motif family-like 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA CTD PMID:25522274 NCBI chr16:48,944,712...48,960,949
Ensembl chr16:48,944,838...48,955,453 		JBrowse link
G Trio trio Rho guanine nucleotide exchange factor decreases expression ISO Bortezomib results in decreased expression of TRIO mRNA CTD PMID:20977926 NCBI chr 2:78,505,069...78,801,384
Ensembl chr 2:78,505,070...78,803,135 		JBrowse link
G Trrap transformation/transcription domain-associated protein decreases expression ISO Bortezomib results in decreased expression of TRRAP mRNA CTD PMID:20977926 NCBI chr12:9,738,006...9,827,708
Ensembl chr12:9,738,006...9,827,674 		JBrowse link
G Tsen15 tRNA splicing endonuclease subunit 15 decreases expression ISO Bortezomib results in decreased expression of TSEN15 mRNA CTD PMID:20977926 NCBI chr13:64,490,216...64,505,591
Ensembl chr13:64,490,218...64,505,617 		JBrowse link
G Ttc39a tetratricopeptide repeat domain 39A increases expression ISO Bortezomib results in increased expression of TTC39A mRNA CTD PMID:20977926 NCBI chr 5:124,165,102...124,204,740
Ensembl chr 5:124,151,760...124,204,973 		JBrowse link
G Ttc7a tetratricopeptide repeat domain 7A decreases expression ISO Bortezomib results in decreased expression of TTC7A mRNA CTD PMID:20977926 NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892 		JBrowse link
G Ttl tubulin tyrosine ligase decreases expression ISO Bortezomib results in decreased expression of TTL mRNA CTD PMID:20977926 NCBI chr 3:116,298,813...116,328,538
Ensembl chr 3:116,298,797...116,328,538 		JBrowse link
G Ttpal alpha tocopherol transfer protein like decreases expression ISO Bortezomib results in decreased expression of TTPAL mRNA CTD PMID:20977926 NCBI chr 3:152,278,246...152,296,550
Ensembl chr 3:152,278,303...152,296,513 		JBrowse link
G Tubb2a tubulin, beta 2A class IIa increases expression ISO Bortezomib results in increased expression of TUBB2A mRNA CTD PMID:20977926 NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714 		JBrowse link
G Tubd1 tubulin, delta 1 increases expression ISO Bortezomib results in increased expression of TUBD1 mRNA CTD PMID:20977926 NCBI chr10:71,367,936...71,391,387
Ensembl chr10:71,368,133...71,391,266 		JBrowse link
G Txn2 thioredoxin 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of TXN2 mRNA] CTD PMID:19417023 NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359 		JBrowse link
G Txndc9 thioredoxin domain containing 9 increases expression ISO Bortezomib results in increased expression of TXNDC9 mRNA CTD PMID:20977926 NCBI chr 9:40,211,818...40,221,953
Ensembl chr 9:40,211,412...40,384,279
Ensembl chr 9:40,211,412...40,384,279 		JBrowse link
G Txnrd2 thioredoxin reductase 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of TXNRD2 mRNA] CTD PMID:19417023 NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156 		JBrowse link
G U2af2 U2 small nuclear RNA auxiliary factor 2 decreases expression ISO Bortezomib results in decreased expression of U2AF2 mRNA CTD PMID:20977926 NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492 		JBrowse link
G Ubr3 ubiquitin protein ligase E3 component n-recognin 3 increases expression ISO Bortezomib results in increased expression of UBR3 mRNA CTD PMID:20977926 NCBI chr 3:54,649,803...54,806,779
Ensembl chr 3:54,649,992...54,806,247 		JBrowse link
G Ubxn4 UBX domain protein 4 increases expression ISO Bortezomib results in increased expression of UBXN4 mRNA CTD PMID:20977926 NCBI chr13:39,740,064...39,772,493
Ensembl chr13:39,740,107...39,772,491 		JBrowse link
G Ufd1 ubiquitin recognition factor in ER associated degradation 1 increases expression ISO Bortezomib results in increased expression of UFD1 mRNA CTD PMID:20977926 NCBI chr11:82,161,618...82,185,107
Ensembl chr11:82,161,619...82,185,087 		JBrowse link
G Unc93b1 unc-93 homolog B1, TLR signaling regulator decreases expression ISO Bortezomib results in decreased expression of UNC93B1 mRNA CTD PMID:20977926 NCBI chr 1:201,167,388...201,178,343
Ensembl chr 1:201,152,693...201,178,338 		JBrowse link
G Unkl unk like zinc finger increases expression ISO Bortezomib results in increased expression of UNKL mRNA CTD PMID:20977926 NCBI chr10:14,206,125...14,252,226
Ensembl chr10:14,206,189...14,252,225 		JBrowse link
G Upp1 uridine phosphorylase 1 multiple interactions
decreases activity		 ISO Bortezomib inhibits the reaction [TNF protein results in increased activity of UPP1 protein]; Bortezomib inhibits the reaction [TNF protein results in increased expression of UPP1 mRNA]
Bortezomib results in decreased activity of UPP1 protein		 CTD PMID:16397116 NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462 		JBrowse link
G Uqcrb ubiquinol-cytochrome c reductase binding protein increases expression ISO Bortezomib results in increased expression of UQCRB mRNA CTD PMID:20977926 NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150 		JBrowse link
G Usp45 ubiquitin specific peptidase 45 increases expression ISO Bortezomib results in increased expression of USP45 mRNA CTD PMID:20977926 NCBI chr 5:35,318,621...35,392,090
Ensembl chr 5:35,318,635...35,389,420 		JBrowse link
G Usp5 ubiquitin specific peptidase 5 increases expression ISO Bortezomib results in increased expression of USP5 protein CTD PMID:30552955 NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711 		JBrowse link
G Usp53 ubiquitin specific peptidase 53 increases expression ISO Bortezomib results in increased expression of USP53 mRNA CTD PMID:20977926 NCBI chr 2:211,059,512...211,120,942
Ensembl chr 2:211,059,520...211,120,943 		JBrowse link
G Vasp vasodilator-stimulated phosphoprotein decreases expression ISO Bortezomib results in decreased expression of VASP mRNA CTD PMID:20977926 NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061 		JBrowse link
G Vcp valosin-containing protein increases expression ISO Bortezomib results in increased expression of VCP mRNA CTD PMID:20977926 NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 decreases expression ISO Bortezomib results in decreased expression of VDAC1 mRNA CTD PMID:20977926 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
multiple interactions		 ISO Bortezomib results in decreased expression of VEGFA protein
[Curcumin co-treated with Bortezomib] results in decreased expression of VEGFA protein; Bortezomib promotes the reaction [docetaxel results in decreased expression of VEGFA protein]; CGC 11093 promotes the reaction [Bortezomib results in decreased expression of VEGFA protein]; docetaxel promotes the reaction [Bortezomib results in decreased expression of VEGFA protein]		 CTD PMID:14749476 PMID:18559525 PMID:19372569 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vegfb vascular endothelial growth factor B decreases expression
increases expression		 ISO Bortezomib results in decreased expression of VEGFB mRNA
Bortezomib results in increased expression of VEGFB mRNA		 CTD PMID:17659339 PMID:17895889 NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944 		JBrowse link
G Vezt vezatin, adherens junctions transmembrane protein increases expression ISO Bortezomib results in increased expression of VEZT mRNA CTD PMID:20977926 NCBI chr 7:28,512,214...28,597,429
Ensembl chr 7:28,534,249...28,597,356 		JBrowse link
G Wbp4 WW domain binding protein 4 increases expression ISO Bortezomib results in increased expression of WBP4 mRNA CTD PMID:20977926 NCBI chr15:54,862,700...54,890,668
Ensembl chr15:54,862,843...54,890,647 		JBrowse link
G Wdr44 WD repeat domain 44 increases expression ISO Bortezomib results in increased expression of WDR44 mRNA CTD PMID:20977926 NCBI chr  X:114,481,890...114,587,307
Ensembl chr  X:114,482,006...114,587,224 		JBrowse link
G Wdr48 WD repeat domain 48 increases expression ISO Bortezomib results in increased expression of WDR48 mRNA CTD PMID:20977926 NCBI chr 8:119,622,053...119,655,264
Ensembl chr 8:119,622,048...119,655,264 		JBrowse link
G Wdr74 WD repeat domain 74 increases expression ISO Bortezomib results in increased expression of WDR74 mRNA CTD PMID:20977926 NCBI chr 1:205,631,769...205,636,558
Ensembl chr 1:205,631,824...205,636,563 		JBrowse link
G Wdr82 WD repeat domain 82 increases expression ISO Bortezomib results in increased expression of WDR82 mRNA CTD PMID:20977926 NCBI chr 8:106,814,569...106,834,535
Ensembl chr 8:106,814,569...106,834,438 		JBrowse link
G Wee1 WEE1 G2 checkpoint kinase increases ubiquitination ISO Bortezomib results in increased ubiquitination of WEE1 protein CTD PMID:20367638 NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688 		JBrowse link
G Wt1 WT1 transcription factor decreases expression ISO Bortezomib results in decreased expression of WT1 mRNA; Bortezomib results in decreased expression of WT1 protein CTD PMID:17629554 PMID:20471514 PMID:20977926 PMID:25913414 NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643 		JBrowse link
G Xaf1 XIAP associated factor 1 decreases expression ISO Bortezomib results in decreased expression of XAF1 mRNA CTD PMID:20977926 NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770 		JBrowse link
G Xbp1 X-box binding protein 1 multiple interactions
increases expression
increases activity		 ISO [ricolinostat co-treated with Bortezomib] results in increased expression of XBP1 protein alternative form; Bortezomib inhibits the reaction [Brefeldin A results in increased activity of XBP1 protein]
Bortezomib results in increased expression of XBP1 protein alternative form
Bortezomib results in increased activity of XBP1 protein		 CTD PMID:18723477 PMID:22262760 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
G Xcl1 X-C motif chemokine ligand 1 decreases expression ISO Bortezomib results in decreased expression of XCL1 mRNA CTD PMID:20977926 NCBI chr13:77,248,687...77,252,343
Ensembl chr13:77,248,717...77,252,329 		JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions
increases expression
increases cleavage
affects expression
decreases expression		 ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XIAP protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of XIAP protein; [Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein; [Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein; [romidepsin co-treated with Bortezomib] results in decreased expression of XIAP protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of XIAP protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of XIAP protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of XIAP protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of XIAP protein]
Bortezomib results in increased expression of XIAP mRNA; Bortezomib results in increased expression of XIAP protein
Bortezomib affects the expression of XIAP protein
Bortezomib results in decreased expression of XIAP protein		 CTD PMID:15173093 PMID:15543232 PMID:17326159 PMID:17626072 PMID:18223231 More... NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700 		JBrowse link
G Xpnpep3 X-prolyl aminopeptidase 3 decreases expression ISO Bortezomib results in decreased expression of XPNPEP3 mRNA CTD PMID:20977926 NCBI chr 7:112,926,154...112,978,793
Ensembl chr 7:112,926,248...112,974,878 		JBrowse link
G Xpo5 exportin 5 decreases expression ISO Bortezomib results in decreased expression of XPO5 mRNA CTD PMID:20977926 NCBI chr 9:14,740,182...14,778,171
Ensembl chr 9:14,740,182...14,778,171 		JBrowse link
G Xrcc3 X-ray repair cross complementing 3 decreases expression ISO Bortezomib results in decreased expression of XRCC3 mRNA CTD PMID:20977926 NCBI chr 6:130,863,405...130,873,765
Ensembl chr 6:130,863,959...130,872,444 		JBrowse link
G Xxylt1 xyloside xylosyltransferase 1 decreases expression ISO Bortezomib results in decreased expression of XXYLT1 mRNA CTD PMID:20977926 NCBI chr11:69,658,481...69,790,938
Ensembl chr11:69,658,460...69,790,730 		JBrowse link
G Yes1 YES proto-oncogene 1, Src family tyrosine kinase increases expression ISO Bortezomib results in increased expression of YES1 mRNA CTD PMID:20977926 NCBI chr 9:113,200,256...113,275,942
Ensembl chr 9:113,200,256...113,299,837 		JBrowse link
G Ypel5 yippee-like 5 increases expression ISO Bortezomib results in increased expression of YPEL5 mRNA CTD PMID:20977926 NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691 		JBrowse link
G Ywhae tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon decreases expression ISO Bortezomib results in decreased expression of YWHAE mRNA CTD PMID:20977926 NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589 		JBrowse link
G Ywhaz tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta increases expression ISO Bortezomib results in increased expression of YWHAZ mRNA CTD PMID:20977926 NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668 		JBrowse link
G Zbtb3 zinc finger and BTB domain containing 3 increases expression ISO Bortezomib results in increased expression of ZBTB3 mRNA CTD PMID:20977926 NCBI chr 1:205,693,906...205,703,277
Ensembl chr 1:205,686,620...205,704,515 		JBrowse link
G Zcchc2 zinc finger CCHC-type containing 2 increases expression ISO Bortezomib results in increased expression of ZCCHC2 mRNA CTD PMID:20977926 NCBI chr13:22,118,677...22,193,626
Ensembl chr13:22,119,568...22,166,373 		JBrowse link
G Zfand2a zinc finger AN1-type containing 2A increases expression
decreases response to substance
multiple interactions		 ISO
EXP		 Bortezomib results in increased expression of ZFAND2A mRNA; Bortezomib results in increased expression of ZFAND2A protein
ZFAND2A protein results in decreased susceptibility to Bortezomib
Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of PARP1 protein]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein]; HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of PARP1 protein]		 CTD PMID:20830808 PMID:20977926 PMID:24619424 PMID:31540997 NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677 		JBrowse link
G Zfp335 zinc finger protein 335 decreases expression ISO Bortezomib results in decreased expression of ZNF335 mRNA CTD PMID:20977926 NCBI chr 3:153,618,587...153,648,213
Ensembl chr 3:153,627,467...153,647,054 		JBrowse link
G Zfp580 zinc finger protein 580 decreases expression ISO Bortezomib results in decreased expression of ZNF580 mRNA CTD PMID:20977926 NCBI chr 1:68,787,118...68,789,286
Ensembl chr 1:68,787,118...68,789,286 		JBrowse link
G Zfp612 zinc finger protein 612 increases expression ISO Bortezomib results in increased expression of ZNF23 mRNA CTD PMID:20977926 NCBI chr19:38,053,953...38,071,196
Ensembl chr19:38,053,967...38,067,455 		JBrowse link
G Zfp768 zinc finger protein 768 decreases expression ISO Bortezomib results in decreased expression of ZNF768 mRNA CTD PMID:20977926 NCBI chr 1:181,966,314...181,968,950
Ensembl chr 1:181,966,316...181,969,147 		JBrowse link
G Zfp787 zinc finger protein 787 increases expression ISO Bortezomib results in increased expression of ZNF787 mRNA CTD PMID:20977926 NCBI chr 1:67,745,702...67,771,132
Ensembl chr 1:67,758,757...67,771,132 		JBrowse link
G Zfpm1 zinc finger protein, multitype 1 decreases expression ISO Bortezomib results in decreased expression of ZFPM1 mRNA CTD PMID:20977926 NCBI chr19:50,334,352...50,391,029
Ensembl chr19:50,334,682...50,390,591 		JBrowse link
G Zfx zinc finger protein X-linked increases expression ISO Bortezomib results in increased expression of ZFX mRNA CTD PMID:20977926 NCBI chr  X:58,804,690...58,853,155
Ensembl chr  X:58,804,691...58,853,265 		JBrowse link
G Zgpat zinc finger CCCH-type and G-patch domain containing increases expression ISO Bortezomib results in increased expression of ZGPAT mRNA CTD PMID:20977926 NCBI chr 3:168,473,836...168,490,380
Ensembl chr 3:168,473,981...168,490,380 		JBrowse link
G Zmynd11 zinc finger, MYND-type containing 11 decreases expression ISO Bortezomib results in decreased expression of ZMYND11 mRNA CTD PMID:20977926 NCBI chr17:60,542,669...60,631,913
Ensembl chr17:60,543,077...60,631,902 		JBrowse link
G Zmynd8 zinc finger, MYND-type containing 8 decreases expression ISO Bortezomib results in decreased expression of ZMYND8 mRNA CTD PMID:20977926 NCBI chr 3:154,528,917...154,629,532
Ensembl chr 3:154,529,043...154,628,463 		JBrowse link
G Znrf2 zinc and ring finger 2 increases expression ISO Bortezomib results in increased expression of ZNRF2 mRNA CTD PMID:20977926 NCBI chr 4:83,950,406...84,032,676
Ensembl chr 4:83,949,309...84,027,818 		JBrowse link
Calpeptin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions
decreases cleavage		 ISO calpeptin inhibits the reaction [Arsenic Trioxide results in increased cleavage of BAX protein]; calpeptin inhibits the reaction [sodium arsenite results in increased cleavage of BAX protein]
calpeptin results in decreased cleavage of BAX protein		 CTD PMID:15131059 PMID:34861471 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Capn1 calpain 1 multiple interactions ISO
EXP		 calpeptin inhibits the reaction [CAPN1 protein results in increased degradation of MFN2 protein]; calpeptin inhibits the reaction [Paraquat results in increased activity of CAPN1 protein]
calpeptin inhibits the reaction [Acrylamide results in increased expression of CAPN1 protein]		 CTD PMID:24509835 PMID:25416777 PMID:30096436 NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177 		JBrowse link
G Capn2 calpain 2 multiple interactions EXP calpeptin inhibits the reaction [Acrylamide results in increased expression of CAPN2 protein] CTD PMID:29524570 PMID:30096436 NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO
EXP		 calpeptin inhibits the reaction [[lactacystin results in increased activity of CASP3 protein] which results in increased cleavage of SPTAN1 protein]; calpeptin inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein]
calpeptin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]
calpeptin inhibits the reaction [Paraquat results in increased cleavage of CASP3 protein]; calpeptin inhibits the reaction [Propofol results in increased cleavage of CASP3 protein]		 CTD PMID:21683092 PMID:25947082 PMID:29111403 PMID:35525317 PMID:36640868 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO calpeptin inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein] CTD PMID:29111403 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Ccne2 cyclin E2 decreases expression ISO calpeptin results in decreased expression of CCNE2 protein CTD PMID:22432027 NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632 		JBrowse link
G Cdk5 cyclin-dependent kinase 5 multiple interactions EXP calpeptin inhibits the reaction [Acrylamide results in increased expression of CDK5 protein] CTD PMID:30096436 NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112 		JBrowse link
G Cdk5r1 cyclin-dependent kinase 5 regulatory subunit 1 multiple interactions ISO calpeptin inhibits the reaction [arsenite metabolite results in increased cleavage of CDK5R1 protein]; calpeptin inhibits the reaction [Calcium results in increased cleavage of CDK5R1 protein] CTD PMID:18242949 NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO calpeptin results in increased expression of CDKN1A protein CTD PMID:22432027 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B decreases expression ISO calpeptin results in decreased expression of CDKN1B protein modified form CTD PMID:22432027 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Dnm1l dynamin 1-like multiple interactions ISO calpeptin affects the reaction [Acetaminophen affects the phosphorylation of DNM1L protein]; calpeptin inhibits the reaction [Acetaminophen results in increased expression of and results in increased cleavage of DNM1L protein] CTD PMID:35713544 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO calpeptin inhibits the reaction [Acetaminophen results in increased activity of GPT protein] CTD PMID:35713544 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsdme gasdermin E multiple interactions ISO calpeptin inhibits the reaction [Cisplatin results in increased cleavage of GSDME protein] CTD PMID:35525317 NCBI chr 4:79,258,799...79,321,129
Ensembl chr 4:79,257,804...79,320,806 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO calpeptin inhibits the reaction [dehydroeburicoic acid affects the localization of MAP1LC3B protein]; calpeptin inhibits the reaction [dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]] CTD PMID:19848398 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions EXP calpeptin inhibits the reaction [Acrylamide results in decreased expression of MAP2 protein]; calpeptin inhibits the reaction [Acrylamide results in increased expression of MAP2 protein] CTD PMID:29524570 PMID:30096436 NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions EXP calpeptin inhibits the reaction [Acrylamide results in increased expression of MAPT protein] CTD PMID:30096436 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Mfn2 mitofusin 2 multiple interactions ISO
EXP		 calpeptin inhibits the reaction [Acetaminophen results in decreased expression of and results in increased cleavage of MFN2 protein]; calpeptin inhibits the reaction [CAPN1 protein results in increased degradation of MFN2 protein]
calpeptin inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of MFN2 protein]		 CTD PMID:25416777 PMID:35713544 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Nefl neurofilament light chain multiple interactions EXP calpeptin inhibits the reaction [Calcium results in increased degradation of NEFL protein] CTD PMID:11071371 NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions EXP
ISO		 calpeptin inhibits the reaction [Paraquat results in increased cleavage of PARP1 protein]
calpeptin inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein]		 CTD PMID:25947082 PMID:29111403 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 decreases phosphorylation
multiple interactions		 ISO calpeptin results in decreased phosphorylation of PTPN11 protein
LM11A-31 inhibits the reaction [calpeptin results in decreased phosphorylation of PTPN11 protein]		 CTD PMID:25277379 NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925 		JBrowse link
G Rhoa ras homolog family member A increases activity
multiple interactions		 ISO calpeptin results in increased activity of RHOA protein
LM11A-31 inhibits the reaction [calpeptin results in increased activity of RHOA protein]		 CTD PMID:25277379 NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746 		JBrowse link
G Snca synuclein alpha multiple interactions ISO calpeptin inhibits the reaction [Paraquat results in increased expression of SNCA protein alternative form] CTD PMID:24509835 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262 		JBrowse link
G Sptan1 spectrin, alpha, non-erythrocytic 1 multiple interactions ISO calpeptin inhibits the reaction [dehydroeburicoic acid results in increased degradation of SPTAN1 protein]
calpeptin inhibits the reaction [[lactacystin results in increased activity of CASP3 protein] which results in increased cleavage of SPTAN1 protein]; calpeptin inhibits the reaction [lactacystin results in increased cleavage of SPTAN1 protein]		 CTD PMID:19848398 PMID:21683092 NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046 		JBrowse link
G Tp73 tumor protein p73 multiple interactions ISO calpeptin inhibits the reaction [Cisplatin results in decreased expression of TP73 protein modified form] CTD PMID:21516125 NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128 		JBrowse link
G Tubb5 tubulin, beta 5 class I multiple interactions EXP calpeptin inhibits the reaction [Acrylamide results in increased expression of TUBB protein]; calpeptin inhibits the reaction [Acrylamide results in increased expression of TUBB5 protein] CTD PMID:29524570 PMID:30096436 NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940 		JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases degradation ISO calpeptin results in decreased degradation of XIAP protein CTD PMID:16223472 NCBI chr  X:120,890,537...120,938,413
Ensembl chr  X:120,897,907...120,934,700 		JBrowse link
eluxadoline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Oprd1 opioid receptor, delta 1 affects response to substance ISO OPRD1 protein affects the susceptibility to eluxadoline CTD PMID:25261794 NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960 		JBrowse link
lidocaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 increases expression EXP Lidocaine results in increased expression of ABCA1 mRNA CTD PMID:35283115 NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170 		JBrowse link
G Abca8 ATP binding cassette subfamily A member 8 decreases expression EXP Lidocaine results in decreased expression of ABCA8 mRNA CTD PMID:35283115 NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 increases expression EXP Lidocaine results in increased expression of ABCB4 mRNA CTD PMID:35283115 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Actb actin, beta increases expression EXP Lidocaine results in increased expression of RASA4 mRNA CTD PMID:35283115 NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877 		JBrowse link
G Actn3 actinin alpha 3 increases expression EXP Lidocaine results in increased expression of ACTN3 mRNA CTD PMID:35283115 NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012 		JBrowse link
G Adamts13 ADAM metallopeptidase with thrombospondin type 1 motif, 13 increases expression EXP Lidocaine results in increased expression of ADAMTS13 mRNA CTD PMID:35283115 NCBI chr 3:10,299,264...10,338,464
Ensembl chr 3:10,300,028...10,346,687 		JBrowse link
G Adamts15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 decreases expression EXP Lidocaine results in decreased expression of ADAMTS15 mRNA CTD PMID:35283115 NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249 		JBrowse link
G Adgra2 adhesion G protein-coupled receptor A2 decreases expression EXP Lidocaine results in decreased expression of ADGRA2 mRNA CTD PMID:35283115 NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483 		JBrowse link
G Agpat2 1-acylglycerol-3-phosphate O-acyltransferase 2 increases expression EXP Lidocaine results in increased expression of AGPAT2 mRNA CTD PMID:35283115 NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371 		JBrowse link
G Akap5 A-kinase anchoring protein 5 decreases expression EXP Lidocaine results in decreased expression of AKAP5 mRNA CTD PMID:35283115 NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578 		JBrowse link
G Akt1s1 AKT1 substrate 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; dorsomorphin inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]; MK-8722 promotes the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] CTD PMID:37914286 NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677 		JBrowse link
G Aldh3b1 aldehyde dehydrogenase 3 family, member B1 increases expression EXP Lidocaine results in increased expression of ALDH3B1 mRNA CTD PMID:35283115 NCBI chr 1:201,145,309...201,162,675
Ensembl chr 1:201,145,309...201,163,921 		JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases expression EXP Lidocaine results in increased expression of ALOX12 mRNA CTD PMID:35283115 NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542 		JBrowse link
G Alpk1 alpha-kinase 1 increases expression EXP Lidocaine results in increased expression of ALPK1 mRNA CTD PMID:35283115 NCBI chr 2:216,126,939...216,247,180
Ensembl chr 2:216,128,825...216,247,157 		JBrowse link
G Amdhd2 amidohydrolase domain containing 2 increases expression EXP Lidocaine results in increased expression of AMDHD2 mRNA CTD PMID:35283115 NCBI chr10:13,187,579...13,196,148
Ensembl chr10:13,187,578...13,196,095 		JBrowse link
G Amelx amelogenin, X-linked increases expression EXP Lidocaine results in increased expression of AMELX mRNA CTD PMID:35283115 NCBI chr  X:25,076,362...25,087,660
Ensembl chr  X:25,076,362...25,087,660 		JBrowse link
G Ampd1 adenosine monophosphate deaminase 1 increases expression EXP Lidocaine results in increased expression of AMPD1 mRNA CTD PMID:35283115 NCBI chr 2:190,598,707...190,619,938
Ensembl chr 2:190,598,700...190,619,938 		JBrowse link
G Angpt2 angiopoietin 2 decreases expression EXP Lidocaine results in decreased expression of ANGPT2 mRNA CTD PMID:35283115 NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804 		JBrowse link
G Angpt4 angiopoietin 4 increases expression EXP Lidocaine results in increased expression of ANGPT4 mRNA CTD PMID:35283115 NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:140,420,389...140,453,583 		JBrowse link
G Angptl2 angiopoietin-like 2 increases expression EXP Lidocaine results in increased expression of ANGPTL2 mRNA CTD PMID:35283115 NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178 		JBrowse link
G Ankrd33b ankyrin repeat domain 33B increases expression EXP Lidocaine results in increased expression of ANKRD33B mRNA CTD PMID:35283115 NCBI chr 2:82,277,604...82,359,420
Ensembl chr 2:82,283,108...82,358,872 		JBrowse link
G Anp32a acidic nuclear phosphoprotein 32 family member A increases expression EXP Lidocaine results in increased expression of ANP32A mRNA CTD PMID:35283115 NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443 		JBrowse link
G Anxa6 annexin A6 increases expression EXP Lidocaine results in increased expression of ANXA6 mRNA; Lidocaine results in increased expression of ANXA6 protein CTD PMID:27018092 NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433 		JBrowse link
G Aoc3 amine oxidase, copper containing 3 decreases expression EXP Lidocaine results in decreased expression of AOC3 mRNA CTD PMID:35283115 NCBI chr10:86,272,757...86,280,702 JBrowse link
G Apobec1 apolipoprotein B mRNA editing enzyme catalytic subunit 1 increases expression EXP Lidocaine results in increased expression of APOBEC1 mRNA CTD PMID:35283115 NCBI chr 4:155,800,030...155,828,515
Ensembl chr 4:155,800,887...155,827,390 		JBrowse link
G Apold1 apolipoprotein L domain containing 1 increases expression EXP Lidocaine results in increased expression of APOLD1 mRNA CTD PMID:35283115 NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706 		JBrowse link
G Aqp4 aquaporin 4 decreases expression EXP Lidocaine results in decreased expression of AQP4 mRNA CTD PMID:35283115 NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856 		JBrowse link
G Arhgap11a Rho GTPase activating protein 11A increases expression EXP Lidocaine results in increased expression of ARHGAP11A mRNA CTD PMID:35283115 NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559 		JBrowse link
G Arhgap30 Rho GTPase activating protein 30 decreases expression EXP Lidocaine results in decreased expression of ARHGAP30 mRNA CTD PMID:35283115 NCBI chr13:83,822,290...83,843,634
Ensembl chr13:83,822,283...83,854,885 		JBrowse link
G Arhgap45 Rho GTPase activating protein 45 increases expression EXP Lidocaine results in increased expression of ARHGAP45 mRNA CTD PMID:35283115 NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268 		JBrowse link
G Arhgef3 Rho guanine nucleotide exchange factor 3 decreases expression EXP Lidocaine results in decreased expression of ARHGEF3 mRNA CTD PMID:35283115 NCBI chr16:2,301,573...2,581,951
Ensembl chr16:2,300,138...2,581,945 		JBrowse link
G Arl11 ADP-ribosylation factor like GTPase 11 increases expression EXP Lidocaine results in increased expression of ARL11 mRNA CTD PMID:35283115 NCBI chr15:35,483,330...35,485,579
Ensembl chr15:35,480,018...35,496,596 		JBrowse link
G Aspg asparaginase increases expression EXP Lidocaine results in increased expression of ASPG mRNA CTD PMID:35283115 NCBI chr 6:131,176,727...131,196,268
Ensembl chr 6:131,176,874...131,196,268 		JBrowse link
G Aspm assembly factor for spindle microtubules increases expression EXP Lidocaine results in increased expression of ASPM mRNA CTD PMID:35283115 NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755 		JBrowse link
G Aspn asporin decreases expression EXP Lidocaine results in decreased expression of ASPN mRNA CTD PMID:35283115 NCBI chr17:15,079,910...15,104,369
Ensembl chr17:15,080,639...15,104,041 		JBrowse link
G Atad2 ATPase family, AAA domain containing 2 increases expression EXP Lidocaine results in increased expression of ATAD2 mRNA CTD PMID:35283115 NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738 		JBrowse link
G Atad5 ATPase family, AAA domain containing 5 increases expression EXP Lidocaine results in increased expression of ATAD5 mRNA CTD PMID:35283115 NCBI chr10:65,070,682...65,118,489
Ensembl chr10:65,070,689...65,117,845 		JBrowse link
G Atp2c1 ATPase secretory pathway Ca2+ transporting 1 increases expression EXP Lidocaine results in increased expression of ATP2C1 mRNA CTD PMID:35283115 NCBI chr 8:106,034,777...106,155,854
Ensembl chr 8:106,034,636...106,156,006 		JBrowse link
G Atp6v0d2 ATPase H+ transporting V0 subunit D2 increases expression EXP Lidocaine results in increased expression of ATP6V0D2 mRNA CTD PMID:35283115 NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354 		JBrowse link
G Atp8b4 ATPase phospholipid transporting 8B4 (putative) increases expression EXP Lidocaine results in increased expression of ATP8B4 mRNA CTD PMID:35283115 NCBI chr 3:113,554,979...113,757,635
Ensembl chr 3:113,556,192...113,757,225 		JBrowse link
G Aunip aurora kinase A and ninein interacting protein increases expression EXP Lidocaine results in increased expression of AUNIP mRNA CTD PMID:35283115 NCBI chr 5:146,722,329...146,734,924
Ensembl chr 5:146,722,337...146,736,501 		JBrowse link
G Baat bile acid CoA:amino acid N-acyltransferase increases expression EXP Lidocaine results in increased expression of BAAT mRNA CTD PMID:35283115 NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685 		JBrowse link
G Bcl2l2 Bcl2-like 2 decreases expression EXP Lidocaine results in decreased expression of BCL2L2 mRNA CTD PMID:35283115 NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624 		JBrowse link
G Best2 bestrophin 2 increases expression EXP Lidocaine results in increased expression of BEST2 mRNA CTD PMID:35283115 NCBI chr19:23,142,324...23,148,351
Ensembl chr19:23,141,602...23,148,339 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression EXP Lidocaine results in increased expression of BIRC5 mRNA CTD PMID:35283115 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase increases expression EXP Lidocaine results in increased expression of BLK mRNA CTD PMID:35283115 NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031 		JBrowse link
G Blnk B-cell linker increases expression EXP Lidocaine results in increased expression of BLNK mRNA CTD PMID:35283115 NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113 		JBrowse link
G Blvrb biliverdin reductase B decreases expression EXP Lidocaine results in decreased expression of BLVRB protein CTD PMID:27018092 NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375 		JBrowse link
G Bmf Bcl2 modifying factor increases expression EXP Lidocaine results in increased expression of BMF mRNA CTD PMID:35283115 NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145 		JBrowse link
G Bpifa5 BPI fold containing family A, member 5 decreases expression EXP Lidocaine results in decreased expression of BPIFA5 mRNA CTD PMID:35283115 NCBI chr 3:142,646,103...142,652,884
Ensembl chr 3:142,646,103...142,652,883 		JBrowse link
G Bpifb2 BPI fold containing family B, member 2 decreases expression EXP Lidocaine results in decreased expression of BPIFB2 mRNA CTD PMID:35283115 NCBI chr 3:142,356,990...142,377,053
Ensembl chr 3:142,358,051...142,377,044 		JBrowse link
G Bsn bassoon (presynaptic cytomatrix protein) decreases expression EXP Lidocaine results in decreased expression of BSN mRNA CTD PMID:35283115 NCBI chr 8:108,784,849...108,875,819
Ensembl chr 8:108,788,542...108,875,819 		JBrowse link
G Btc betacellulin increases expression EXP Lidocaine results in increased expression of BTC mRNA CTD PMID:35283115 NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049 		JBrowse link
G Btnl5 butyrophilin-like 5 increases expression EXP Lidocaine results in increased expression of BTNL5 mRNA CTD PMID:35283115 NCBI chr20:4,366,780...4,376,385
Ensembl chr20:4,365,793...4,376,385 		JBrowse link
G Bub1 BUB1 mitotic checkpoint serine/threonine kinase increases expression EXP Lidocaine results in increased expression of BUB1 mRNA CTD PMID:35283115 NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650 		JBrowse link
G Bub1b BUB1 mitotic checkpoint serine/threonine kinase B increases expression EXP Lidocaine results in increased expression of BUB1B mRNA CTD PMID:35283115 NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547 		JBrowse link
G C1qc complement C1q C chain increases expression EXP Lidocaine results in increased expression of C1QC mRNA CTD PMID:35283115 NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017 		JBrowse link
G C9h6orf132 similar to human chromosome 6 open reading frame 132 increases expression EXP Lidocaine results in increased expression of C9H6ORF132 mRNA CTD PMID:35283115 NCBI chr 9:13,524,822...13,561,756
Ensembl chr 9:13,525,395...13,561,585 		JBrowse link
G Calca calcitonin-related polypeptide alpha increases secretion
increases expression
multiple interactions		 ISO
EXP		 Lidocaine results in increased secretion of CALCA protein
Lidocaine results in increased expression of CALCA mRNA
Lidocaine inhibits the reaction [Potassium results in increased secretion of CALCA protein]
capsazepine inhibits the reaction [Lidocaine results in increased secretion of CALCA protein]; TRPV1 protein affects the reaction [Lidocaine results in increased secretion of CALCA protein]		 CTD PMID:18172555 PMID:18178321 PMID:35283115 NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105 		JBrowse link
G Calhm2 calcium homeostasis modulator family member 2 increases expression EXP Lidocaine results in increased expression of CALHM2 mRNA CTD PMID:35283115 NCBI chr 1:246,022,324...246,028,050
Ensembl chr 1:246,022,324...246,028,218 		JBrowse link
G Capg capping actin protein, gelsolin like increases expression EXP Lidocaine results in increased expression of CAPG mRNA CTD PMID:35283115 NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856 		JBrowse link
G Casp3 caspase 3 decreases expression
increases activity
decreases activity		 ISO
EXP		 Lidocaine results in decreased expression of CASP3 protein
Lidocaine results in increased activity of CASP3 protein
Lidocaine results in decreased activity of CASP3 protein		 CTD PMID:15099683 PMID:17585225 PMID:20194319 PMID:21047305 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp9 caspase 9 decreases expression
multiple interactions
increases expression		 ISO
EXP		 Lidocaine results in decreased expression of CASP9 protein
cordycepin inhibits the reaction [Lidocaine results in increased expression of CASP9 mRNA]; cordycepin inhibits the reaction [Lidocaine results in increased expression of CASP9 protein]
Lidocaine results in increased expression of CASP9 mRNA; Lidocaine results in increased expression of CASP9 protein		 CTD PMID:20194319 PMID:29382532 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccdc172 coiled-coil domain containing 172 decreases expression EXP Lidocaine results in decreased expression of CCDC172 mRNA CTD PMID:35283115 NCBI chr 1:257,629,188...257,682,373
Ensembl chr 1:257,629,208...257,675,247 		JBrowse link
G Ccdc42 coiled-coil domain containing 42 decreases expression EXP Lidocaine results in decreased expression of CCDC42 mRNA CTD PMID:35283115 NCBI chr10:53,289,956...53,300,135
Ensembl chr10:53,289,956...53,300,135 		JBrowse link
G Ccdc69 coiled-coil domain containing 69 increases expression EXP Lidocaine results in increased expression of CCDC69 mRNA CTD PMID:35283115 NCBI chr10:39,173,282...39,200,358
Ensembl chr10:39,173,282...39,199,878 		JBrowse link
G Ccdc71l coiled-coil domain containing 71-like decreases expression EXP Lidocaine results in decreased expression of CCDC71L mRNA CTD PMID:35283115 NCBI chr 6:48,960,020...48,964,112
Ensembl chr 6:48,960,191...48,960,841
Ensembl chr 6:48,960,191...48,960,841 		JBrowse link
G Ccl19 C-C motif chemokine ligand 19 decreases expression EXP Lidocaine results in decreased expression of CCL19 mRNA CTD PMID:35283115 NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO Lidocaine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Lidocaine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] CTD PMID:14570645 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccl20 C-C motif chemokine ligand 20 decreases expression EXP Lidocaine results in decreased expression of CCL20 mRNA CTD PMID:35283115 NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression EXP Lidocaine results in increased expression of CCL3 mRNA CTD PMID:35283115 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938 		JBrowse link
G Ccl4 C-C motif chemokine ligand 4 increases expression EXP Lidocaine results in increased expression of CCL4 mRNA CTD PMID:35283115 NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231 		JBrowse link
G Ccl9 C-C motif chemokine ligand 9 increases expression EXP Lidocaine results in increased expression of CCL6 mRNA CTD PMID:35283115 NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369 		JBrowse link
G Ccna1 cyclin A1 affects expression ISO Lidocaine affects the expression of CCNA1 mRNA CTD PMID:18931217 NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157 		JBrowse link
G Ccna2 cyclin A2 affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of CCNA2 mRNA
Lidocaine results in increased expression of CCNA2 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Ccnb1 cyclin B1 affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of CCNB1 mRNA
Lidocaine results in increased expression of CCNB1 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnb2 cyclin B2 affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of CCNB2 mRNA
Lidocaine results in increased expression of CCNB2 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874 		JBrowse link
G Ccnc cyclin C affects expression ISO Lidocaine affects the expression of CCNC mRNA CTD PMID:18931217 NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584 		JBrowse link
G Ccnd1 cyclin D1 affects expression ISO Lidocaine affects the expression of CCND1 mRNA CTD PMID:18931217 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 affects expression ISO Lidocaine affects the expression of CCNE1 mRNA CTD PMID:18931217 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Ccnf cyclin F affects expression ISO Lidocaine affects the expression of CCNF mRNA CTD PMID:18931217 NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101 		JBrowse link
G Ccr1 C-C motif chemokine receptor 1 decreases expression EXP Lidocaine results in decreased expression of CCR1 mRNA CTD PMID:35283115 NCBI chr 8:123,556,286...123,561,841 JBrowse link
G Cd200r1 CD200 receptor 1 increases expression EXP Lidocaine results in increased expression of CD200R1 mRNA CTD PMID:35283115 NCBI chr11:55,886,937...55,921,217
Ensembl chr11:55,887,717...55,921,285 		JBrowse link
G Cd276 Cd276 molecule increases expression EXP Lidocaine results in increased expression of CD276 mRNA CTD PMID:35283115 NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380 		JBrowse link
G Cd34 CD34 molecule increases expression EXP Lidocaine results in increased expression of CD34 mRNA CTD PMID:35283115 NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832 		JBrowse link
G Cd48 Cd48 molecule increases expression EXP Lidocaine results in increased expression of CD48 mRNA CTD PMID:35283115 NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142 		JBrowse link
G Cd68 Cd68 molecule increases expression EXP Lidocaine results in increased expression of CD68 mRNA CTD PMID:35283115 NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697 		JBrowse link
G Cd72 Cd72 molecule increases expression EXP Lidocaine results in increased expression of CD72 mRNA CTD PMID:35283115 NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725 		JBrowse link
G Cd84 CD84 molecule increases expression EXP Lidocaine results in increased expression of CD84 mRNA CTD PMID:35283115 NCBI chr13:84,327,580...84,367,153
Ensembl chr13:84,327,553...84,362,076 		JBrowse link
G Cd86 CD86 molecule increases expression EXP Lidocaine results in increased expression of CD86 mRNA CTD PMID:35283115 NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818 		JBrowse link
G Cdc20 cell division cycle 20 increases expression EXP Lidocaine results in increased expression of CDC20 mRNA CTD PMID:35283115 NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512 		JBrowse link
G Cdc25c cell division cycle 25C increases expression EXP Lidocaine results in increased expression of CDC25C mRNA CTD PMID:35283115 NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185 		JBrowse link
G Cdc45 cell division cycle 45 increases expression EXP Lidocaine results in increased expression of CDC45 mRNA CTD PMID:35283115 NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619 		JBrowse link
G Cdc6 cell division cycle 6 increases expression EXP Lidocaine results in increased expression of CDC6 mRNA CTD PMID:35283115 NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011 		JBrowse link
G Cdca3 cell division cycle associated 3 increases expression EXP Lidocaine results in increased expression of CDCA3 mRNA CTD PMID:35283115 NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799 		JBrowse link
G Cdca7 cell division cycle associated 7 increases expression EXP Lidocaine results in increased expression of CDCA7 mRNA CTD PMID:35283115 NCBI chr 3:57,322,718...57,333,353
Ensembl chr 3:57,322,708...57,333,353 		JBrowse link
G Cdca7l cell division cycle associated 7 like increases expression EXP Lidocaine results in increased expression of CDCA7L mRNA CTD PMID:35283115 NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888 		JBrowse link
G Cdca8 cell division cycle associated 8 increases expression EXP Lidocaine results in increased expression of CDCA8 mRNA CTD PMID:35283115 NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629 		JBrowse link
G Cdhr3 cadherin-related family member 3 decreases expression EXP Lidocaine results in decreased expression of CDHR3 mRNA CTD PMID:35283115 NCBI chr 6:49,641,833...49,702,016
Ensembl chr 6:49,641,813...49,702,017 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases expression EXP Lidocaine results in increased expression of CDK1 mRNA CTD PMID:35283115 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk2 cyclin dependent kinase 2 affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of CDK2 mRNA
Lidocaine results in increased expression of CDK2 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 affects expression ISO Lidocaine affects the expression of CDK4 mRNA CTD PMID:18931217 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 increases expression EXP Lidocaine results in increased expression of CDK6 mRNA CTD PMID:35283115 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkl4 cyclin-dependent kinase-like 4 decreases expression EXP Lidocaine results in decreased expression of CDKL4 mRNA CTD PMID:35283115 NCBI chr 6:14,449,822...14,492,568
Ensembl chr 6:14,450,681...14,492,046 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of CDKN1A mRNA
Lidocaine results in increased expression of CDKN1A mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B affects expression ISO Lidocaine affects the expression of CDKN1B mRNA CTD PMID:18931217 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdkn2a cyclin-dependent kinase inhibitor 2A affects expression ISO Lidocaine affects the expression of CDKN2A mRNA CTD PMID:18931217 NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149 		JBrowse link
G Cdkn2c cyclin-dependent kinase inhibitor 2C increases expression EXP Lidocaine results in increased expression of CDKN2C mRNA CTD PMID:35283115 NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278 		JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 increases expression EXP Lidocaine results in increased expression of CDT1 mRNA CTD PMID:35283115 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659 		JBrowse link
G Ceacam4 CEA cell adhesion molecule 4 increases expression EXP Lidocaine results in increased expression of CEACAM4 mRNA CTD PMID:35283115 NCBI chr 1:80,376,667...80,382,943
Ensembl chr 1:80,376,648...80,382,915 		JBrowse link
G Cenpa centromere protein A increases expression EXP Lidocaine results in increased expression of CENPA mRNA CTD PMID:35283115 NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675 		JBrowse link
G Cenpe centromere protein E increases expression EXP Lidocaine results in increased expression of CENPE mRNA CTD PMID:35283115 NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669 		JBrowse link
G Cenph centromere protein H increases expression EXP Lidocaine results in increased expression of CENPH mRNA CTD PMID:35283115 NCBI chr 2:31,896,675...31,910,179
Ensembl chr 2:31,894,667...31,910,154 		JBrowse link
G Cenpm centromere protein M increases expression EXP Lidocaine results in increased expression of CENPM mRNA CTD PMID:35283115 NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258 		JBrowse link
G Cenpo centromere protein O increases expression EXP Lidocaine results in increased expression of CENPO mRNA CTD PMID:35283115 NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314 		JBrowse link
G Cenpt centromere protein T increases expression EXP Lidocaine results in increased expression of CENPT mRNA CTD PMID:35283115 NCBI chr19:33,734,684...33,741,159
Ensembl chr19:33,734,685...33,741,142 		JBrowse link
G Cenpu centromere protein U increases expression EXP Lidocaine results in increased expression of CENPU mRNA CTD PMID:35283115 NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823 		JBrowse link
G Cenpw centromere protein W increases expression EXP Lidocaine results in increased expression of CENPW mRNA CTD PMID:35283115 NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464 		JBrowse link
G Cep55 centrosomal protein 55 increases expression EXP Lidocaine results in increased expression of CEP55 mRNA CTD PMID:35283115 NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394 		JBrowse link
G Cep72 centrosomal protein 72 increases expression EXP Lidocaine results in increased expression of CEP72 mRNA CTD PMID:35283115 NCBI chr 1:29,225,312...29,255,294
Ensembl chr 1:29,225,361...29,255,271 		JBrowse link
G Ces1d carboxylesterase 1D increases hydrolysis EXP CES1D protein results in increased hydrolysis of Lidocaine CTD PMID:12019189 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035 		JBrowse link
G Cesl1 carboxylesterase-like 1 decreases expression EXP Lidocaine results in decreased expression of CESL1 mRNA CTD PMID:35283115 NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608 		JBrowse link
G Cfd complement factor D increases expression EXP Lidocaine results in increased expression of CFD mRNA CTD PMID:35283115 NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053 		JBrowse link
G Cgas cyclic GMP-AMP synthase increases expression EXP Lidocaine results in increased expression of CGAS mRNA CTD PMID:35283115 NCBI chr 8:79,292,282...79,306,998
Ensembl chr 8:79,294,511...79,305,496 		JBrowse link
G Chaf1b chromatin assembly factor 1 subunit B increases expression EXP Lidocaine results in increased expression of CHAF1B mRNA CTD PMID:35283115 NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070 		JBrowse link
G Chodl chondrolectin decreases expression EXP Lidocaine results in decreased expression of CHODL mRNA CTD PMID:35283115 NCBI chr11:17,654,137...17,676,450
Ensembl chr11:17,654,206...17,676,441 		JBrowse link
G Chtf18 chromosome transmission fidelity factor 18 increases expression EXP Lidocaine results in increased expression of CHTF18 mRNA CTD PMID:35283115 NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050 		JBrowse link
G Cip2a cellular inhibitor of PP2A increases expression EXP Lidocaine results in increased expression of CIP2A mRNA CTD PMID:35283115 NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938 		JBrowse link
G Ckap2 cytoskeleton associated protein 2 increases expression EXP Lidocaine results in increased expression of CKAP2 mRNA CTD PMID:35283115 NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913 		JBrowse link
G Cks1l CDC28 protein kinase regulatory subunit 1-like increases expression EXP Lidocaine results in increased expression of CKS1L mRNA CTD PMID:35283115 NCBI chr 5:106,982,443...106,983,182
Ensembl chr 5:106,982,882...106,983,121 		JBrowse link
G Cks2 CDC28 protein kinase regulatory subunit 2 increases expression EXP Lidocaine results in increased expression of CKS2 mRNA CTD PMID:35283115 NCBI chr17:13,570,611...13,575,770 JBrowse link
G Clca4l chloride channel calcium activated 4-like increases expression EXP Lidocaine results in increased expression of CLCA4L mRNA CTD PMID:35283115 NCBI chr 2:233,826,133...233,846,137
Ensembl chr 2:233,826,133...233,846,716 		JBrowse link
G Clcf1 cardiotrophin-like cytokine factor 1 increases expression EXP Lidocaine results in increased expression of CLCF1 mRNA CTD PMID:35283115 NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605 		JBrowse link
G Cldn14 claudin 14 increases expression EXP Lidocaine results in increased expression of CLDN14 mRNA CTD PMID:35283115 NCBI chr11:33,232,281...33,329,440
Ensembl chr11:33,232,220...33,329,171 		JBrowse link
G Cldn23 claudin 23 increases expression EXP Lidocaine results in increased expression of CLDN23 mRNA CTD PMID:35283115 NCBI chr16:56,413,677...56,415,401
Ensembl chr16:56,413,381...56,415,523 		JBrowse link
G Clec12a C-type lectin domain family 12, member A increases expression EXP Lidocaine results in increased expression of CLEC12A mRNA CTD PMID:35283115 NCBI chr 4:162,798,125...162,816,757
Ensembl chr 4:162,798,125...162,816,753 		JBrowse link
G Clec2d C-type lectin domain family 2, member D increases expression EXP Lidocaine results in increased expression of CLEC2D mRNA CTD PMID:35283115 NCBI chr 4:162,216,052...162,239,530
Ensembl chr 4:162,216,572...162,239,527 		JBrowse link
G Clec4e C-type lectin domain family 4, member E decreases expression EXP Lidocaine results in decreased expression of CLEC4E mRNA CTD PMID:35283115 NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767 		JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression EXP Lidocaine results in increased expression of CLEC7A mRNA CTD PMID:35283115 NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897 		JBrowse link
G Cmtm3 CKLF-like MARVEL transmembrane domain containing 3 increases expression EXP Lidocaine results in increased expression of CMTM3 mRNA CTD PMID:35283115 NCBI chr19:622,563...630,721
Ensembl chr19:604,458...629,790 		JBrowse link
G Cndp1 carnosine dipeptidase 1 increases expression EXP Lidocaine results in increased expression of CNDP1 mRNA CTD PMID:35283115 NCBI chr18:77,984,886...78,030,837
Ensembl chr18:77,984,907...78,007,765 		JBrowse link
G Cnga2 cyclic nucleotide gated channel subunit alpha 2 increases expression EXP Lidocaine results in increased expression of CNGA2 mRNA CTD PMID:35283115 NCBI chr  X:149,696,999...149,715,051
Ensembl chr  X:149,696,997...149,715,051 		JBrowse link
G Cnr2 cannabinoid receptor 2 increases expression EXP Lidocaine results in increased expression of CNR2 mRNA CTD PMID:35283115 NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548 		JBrowse link
G Cntn5 contactin 5 decreases expression EXP Lidocaine results in decreased expression of CNTN5 mRNA CTD PMID:35283115 NCBI chr 8:6,735,715...7,967,727
Ensembl chr 8:6,738,239...7,967,957 		JBrowse link
G Cntnap1 contactin associated protein 1 decreases expression EXP Lidocaine results in decreased expression of CNTNAP1 mRNA CTD PMID:35283115 NCBI chr10:86,109,850...86,125,612
Ensembl chr10:86,111,643...86,125,611 		JBrowse link
G Cntnap3 contactin associated protein family member 3 increases expression EXP Lidocaine results in increased expression of CNTNAP3 mRNA CTD PMID:35283115 NCBI chr17:267,379...455,478
Ensembl chr17:267,508...454,102 		JBrowse link
G Cp ceruloplasmin decreases expression EXP Lidocaine results in decreased expression of CP mRNA CTD PMID:35283115 NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075 		JBrowse link
G Crh corticotropin releasing hormone increases expression EXP Lidocaine results in increased expression of CRH mRNA CTD PMID:35283115 NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919 		JBrowse link
G Crispld1 cysteine-rich secretory protein LCCL domain containing 1 decreases expression EXP Lidocaine results in decreased expression of CRISPLD1 mRNA CTD PMID:35283115 NCBI chr 5:1,267,347...1,314,926
Ensembl chr 5:1,274,647...1,314,926 		JBrowse link
G Crtap cartilage associated protein increases expression EXP Lidocaine results in increased expression of CRTAP mRNA CTD PMID:35283115 NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631 		JBrowse link
G Csf2ra colony stimulating factor 2 receptor subunit alpha increases expression EXP Lidocaine results in increased expression of CSF2RA mRNA CTD PMID:35283115 NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128 		JBrowse link
G Csrp3 cysteine and glycine rich protein 3 increases expression EXP Lidocaine results in increased expression of CSRP3 mRNA CTD PMID:35283115 NCBI chr 1:98,528,067...98,546,647
Ensembl chr 1:98,528,068...98,546,653 		JBrowse link
G Ctsc cathepsin C increases expression EXP Lidocaine results in increased expression of CTSC mRNA CTD PMID:35283115 NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387 		JBrowse link
G Ctsz cathepsin Z increases expression EXP Lidocaine results in increased expression of CTSZ mRNA CTD PMID:35283115 NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645 		JBrowse link
G Cux1 cut-like homeobox 1 increases expression EXP Lidocaine results in increased expression of CUX1 mRNA CTD PMID:35283115 NCBI chr12:20,107,062...20,425,868
Ensembl chr12:20,107,311...20,425,866 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 decreases expression EXP Lidocaine results in decreased expression of CXCL1 mRNA CTD PMID:35283115 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215 		JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression EXP Lidocaine results in decreased expression of CXCL12 mRNA CTD PMID:35283115 NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168 		JBrowse link
G Cxcl13 C-X-C motif chemokine ligand 13 decreases expression EXP Lidocaine results in decreased expression of CXCL13 mRNA CTD PMID:35283115 NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933 		JBrowse link
G Cxcl16 C-X-C motif chemokine ligand 16 increases expression EXP Lidocaine results in increased expression of CXCL16 mRNA CTD PMID:35283115 NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592 		JBrowse link
G Cybb cytochrome b-245 beta chain increases expression EXP Lidocaine results in increased expression of CYBB mRNA CTD PMID:35283115 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Lidocaine CTD PMID:15447735 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp2ac1 cytochrome P450, family 2, subfamily ac, polypeptide 1 decreases expression EXP Lidocaine results in decreased expression of CYP2AC1 mRNA CTD PMID:35283115 NCBI chr 9:20,035,823...20,058,570
Ensembl chr 9:20,033,780...20,058,837 		JBrowse link
G Cyp2d1 cytochrome P450, family 2, subfamily d, polypeptide 1 increases expression EXP Lidocaine results in increased expression of CYP2D1 mRNA CTD PMID:35283115 NCBI chr 7:113,908,950...113,913,420
Ensembl chr 7:113,908,947...113,922,084 		JBrowse link
G Cyp2d5 cytochrome P450, family 2, subfamily d, polypeptide 5 increases expression EXP Lidocaine results in increased expression of CYP2D5 mRNA CTD PMID:35283115 NCBI chr 7:113,899,905...113,904,458
Ensembl chr 7:113,899,890...113,904,495 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 multiple interactions
increases metabolic processing
decreases methylation
affects metabolic processing
decreases ethylation		 ISO Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]
CYP3A4 protein results in decreased methylation of Lidocaine
CYP3A4 protein affects the metabolism of Lidocaine
CYP3A4 protein results in decreased ethylation of Lidocaine		 CTD PMID:9298257 PMID:15383492 PMID:15447735 PMID:15887009 PMID:18846481 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 decreases methylation ISO CYP3A5 protein results in decreased methylation of Lidocaine CTD PMID:15383492 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Cytip cytohesin 1 interacting protein increases expression EXP Lidocaine results in increased expression of CYTIP mRNA CTD PMID:35283115 NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993 		JBrowse link
G Dapl1 death associated protein-like 1 increases expression EXP Lidocaine results in increased expression of DAPL1 mRNA CTD PMID:35283115 NCBI chr 3:43,960,993...43,980,940
Ensembl chr 3:43,960,810...43,980,940 		JBrowse link
G Dbf4 DBF4-CDC7 kinase regulatory subunit increases expression EXP Lidocaine results in increased expression of DBF4 mRNA CTD PMID:35283115 NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066 		JBrowse link
G Dcn decorin decreases expression EXP Lidocaine results in decreased expression of DCN mRNA CTD PMID:35283115 NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270 		JBrowse link
G Ddah2 DDAH family member 2, ADMA-independent decreases expression
increases expression		 EXP Lidocaine results in decreased expression of DDAH2 protein
Lidocaine results in increased expression of DDAH2 mRNA		 CTD PMID:27018092 NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511 		JBrowse link
G Ddias DNA damage-induced apoptosis suppressor increases expression EXP Lidocaine results in increased expression of DDIAS mRNA CTD PMID:35283115 NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462 		JBrowse link
G Ddx60 DEXD/H-box helicase 60 increases expression EXP Lidocaine results in increased expression of DDX60 mRNA CTD PMID:35283115 NCBI chr16:28,077,000...28,197,903
Ensembl chr16:28,076,999...28,179,526 		JBrowse link
G Dennd2d DENN domain containing 2D increases expression EXP Lidocaine results in increased expression of DENND2D mRNA CTD PMID:35283115 NCBI chr 2:193,973,231...193,992,275
Ensembl chr 2:193,973,231...193,992,270 		JBrowse link
G Deptor DEP domain containing MTOR-interacting protein multiple interactions EXP bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; dorsomorphin inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]; MK-8722 promotes the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] CTD PMID:37914286 NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773 		JBrowse link
G Diaph3 diaphanous-related formin 3 increases expression EXP Lidocaine results in increased expression of DIAPH3 mRNA CTD PMID:35283115 NCBI chr15:62,543,375...63,013,060
Ensembl chr15:62,543,375...63,012,975 		JBrowse link
G Dio3 iodothyronine deiodinase 3 decreases expression EXP Lidocaine results in decreased expression of DIO3 mRNA CTD PMID:35283115 NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660 		JBrowse link
G Dlgap5 DLG associated protein 5 increases expression EXP Lidocaine results in increased expression of DLGAP5 mRNA CTD PMID:35283115 NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518 		JBrowse link
G Dnajb7 DnaJ heat shock protein family (Hsp40) member B7 decreases expression EXP Lidocaine results in decreased expression of DNAJB7 mRNA CTD PMID:35283115 NCBI chr 7:112,932,736...112,934,050
Ensembl chr 7:112,932,616...112,945,537 		JBrowse link
G Dnajc22 DnaJ heat shock protein family (Hsp40) member C22 increases expression EXP Lidocaine results in increased expression of DNAJC22 mRNA CTD PMID:35283115 NCBI chr 7:130,257,504...130,262,880
Ensembl chr 7:130,257,851...130,263,230 		JBrowse link
G Dnase2 deoxyribonuclease 2, lysosomal increases expression EXP Lidocaine results in increased expression of DNASE2 mRNA CTD PMID:35283115 NCBI chr19:23,244,656...23,247,376
Ensembl chr19:23,244,664...23,247,376 		JBrowse link
G Dock8 dedicator of cytokinesis 8 increases expression EXP Lidocaine results in increased expression of DOCK8 mRNA CTD PMID:35283115 NCBI chr 1:222,649,309...222,842,474
Ensembl chr 1:222,649,309...222,842,474 		JBrowse link
G Dpep2 dipeptidase 2 increases expression EXP Lidocaine results in increased expression of DPEP2 mRNA CTD PMID:35283115 NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954 		JBrowse link
G Dph6 diphthamine biosynthesis 6 decreases expression EXP Lidocaine results in decreased expression of DPH6 mRNA CTD PMID:35283115 NCBI chr 3:101,307,229...101,437,463
Ensembl chr 3:101,307,231...101,534,603 		JBrowse link
G Dscc1 DNA replication and sister chromatid cohesion 1 increases expression EXP Lidocaine results in increased expression of DSCC1 mRNA CTD PMID:35283115 NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212 		JBrowse link
G Dtl denticleless E3 ubiquitin protein ligase homolog decreases expression EXP Lidocaine results in decreased expression of DTL mRNA CTD PMID:35283115 NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890 		JBrowse link
G Dtx4 deltex E3 ubiquitin ligase 4 increases expression EXP Lidocaine results in increased expression of DTX4 mRNA CTD PMID:35283115 NCBI chr 1:209,457,719...209,545,163
Ensembl chr 1:209,460,735...209,492,818 		JBrowse link
G E2f1 E2F transcription factor 1 affects expression ISO Lidocaine affects the expression of E2F1 mRNA CTD PMID:18931217 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G E2f2 E2F transcription factor 2 affects expression ISO Lidocaine affects the expression of E2F2 mRNA CTD PMID:18931217 NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217 		JBrowse link
G E2f3 E2F transcription factor 3 affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of E2F3 mRNA
Lidocaine results in increased expression of E2F3 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253 		JBrowse link
G E2f4 E2F transcription factor 4 affects expression ISO Lidocaine affects the expression of E2F4 mRNA CTD PMID:18931217 NCBI chr19:33,174,396...33,181,806
Ensembl chr19:33,174,410...33,181,806 		JBrowse link
G Ect2 epithelial cell transforming 2 increases expression EXP Lidocaine results in increased expression of ECT2 mRNA CTD PMID:35283115 NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911 		JBrowse link
G Efcab11 EF-hand calcium binding domain 11 increases expression EXP Lidocaine results in increased expression of EFCAB11 mRNA CTD PMID:35283115 NCBI chr 6:119,008,908...119,162,994
Ensembl chr 6:119,008,919...119,162,046 		JBrowse link
G Egr1 early growth response 1 increases expression EXP Lidocaine results in increased expression of EGR1 mRNA CTD PMID:35283115 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Egr2 early growth response 2 increases expression EXP Lidocaine results in increased expression of EGR2 mRNA CTD PMID:35283115 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562 		JBrowse link
G Eme1 essential meiotic structure-specific endonuclease 1 increases expression EXP Lidocaine results in increased expression of EME1 mRNA CTD PMID:35283115 NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435 		JBrowse link
G Emp1 epithelial membrane protein 1 increases expression EXP Lidocaine results in increased expression of EMP1 mRNA CTD PMID:35283115 NCBI chr 4:168,212,901...168,233,039
Ensembl chr 4:168,212,861...168,232,904 		JBrowse link
G Emp3 epithelial membrane protein 3 increases expression EXP Lidocaine results in increased expression of EMP3 mRNA CTD PMID:35283115 NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988 		JBrowse link
G Engase endo-beta-N-acetylglucosaminidase increases expression EXP Lidocaine results in increased expression of ENGASE mRNA CTD PMID:35283115 NCBI chr10:103,707,169...103,719,833
Ensembl chr10:103,707,169...103,719,819 		JBrowse link
G Epcam epithelial cell adhesion molecule increases expression EXP Lidocaine results in increased expression of EPCAM mRNA CTD PMID:35283115 NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127 		JBrowse link
G Epor erythropoietin receptor increases expression EXP Lidocaine results in increased expression of EPOR mRNA CTD PMID:35283115 NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257 		JBrowse link
G Epsti1 epithelial stromal interaction 1 increases expression EXP Lidocaine results in increased expression of EPSTI1 mRNA CTD PMID:35283115 NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191 		JBrowse link
G Ercc6l ERCC excision repair 6 like, spindle assembly checkpoint helicase increases expression EXP Lidocaine results in increased expression of ERCC6L mRNA CTD PMID:35283115 NCBI chr  X:67,245,414...67,261,222
Ensembl chr  X:67,245,414...67,280,756 		JBrowse link
G Esco2 establishment of sister chromatid cohesion N-acetyltransferase 2 increases expression EXP Lidocaine results in increased expression of ESCO2 mRNA CTD PMID:35283115 NCBI chr15:40,034,566...40,052,295
Ensembl chr15:40,034,568...40,055,306 		JBrowse link
G Esco2-ps1 establishment of cohesion 1 homolog 2 (S. cerevisiae), pseudogene 1 increases expression EXP Lidocaine results in increased expression of ESCO2-PS1 mRNA CTD PMID:35283115 NCBI chr 7:63,948,207...63,951,641 JBrowse link
G Esm1 endothelial cell-specific molecule 1 decreases expression EXP Lidocaine results in decreased expression of ESM1 mRNA CTD PMID:35283115 NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804 		JBrowse link
G Espl1 extra spindle pole bodies like 1, separase increases expression EXP Lidocaine results in increased expression of ESPL1 mRNA CTD PMID:35283115 NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984 		JBrowse link
G Esr1 estrogen receptor 1 increases expression ISO Lidocaine results in increased expression of ESR1 mRNA CTD PMID:22083529 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G F10 coagulation factor X increases expression EXP Lidocaine results in increased expression of F10 mRNA CTD PMID:35283115 NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141 		JBrowse link
G F2rl3 F2R like thrombin or trypsin receptor 3 increases expression EXP Lidocaine results in increased expression of F2RL3 mRNA CTD PMID:35283115 NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472 		JBrowse link
G Fam72a family with sequence similarity 72, member A increases expression EXP Lidocaine results in increased expression of FAM72A mRNA CTD PMID:35283115 NCBI chr13:42,967,701...42,979,083
Ensembl chr13:42,967,578...42,984,208 		JBrowse link
G Fancd2 FA complementation group D2 increases expression EXP Lidocaine results in increased expression of FANCD2 mRNA CTD PMID:35283115 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412 		JBrowse link
G Fbln2 fibulin 2 increases expression EXP Lidocaine results in increased expression of FBLN2 mRNA CTD PMID:35283115 NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948 		JBrowse link
G Fbxl21 F-box and leucine-rich repeat protein 21 increases expression EXP Lidocaine results in increased expression of FBXL21 mRNA CTD PMID:35283115 NCBI chr17:8,060,412...8,077,415
Ensembl chr17:8,060,414...8,073,359 		JBrowse link
G Fbxo5 F-box protein 5 increases expression EXP Lidocaine results in increased expression of FBXO5 mRNA CTD PMID:35283115 NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437 		JBrowse link
G Fcrl2 Fc receptor-like 2 increases expression EXP Lidocaine results in increased expression of FCRL2 mRNA CTD PMID:35283115 NCBI chr 2:172,694,308...172,707,261
Ensembl chr 2:172,694,308...172,707,051 		JBrowse link
G Fgd2 FYVE, RhoGEF and PH domain containing 2 increases expression EXP Lidocaine results in increased expression of FGD2 mRNA CTD PMID:35283115 NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603 		JBrowse link
G Fgf20 fibroblast growth factor 20 decreases expression EXP Lidocaine results in decreased expression of FGF20 mRNA CTD PMID:35283115 NCBI chr16:52,030,549...52,038,201
Ensembl chr16:52,010,194...52,038,204 		JBrowse link
G Fgfbp1 fibroblast growth factor binding protein 1 decreases expression EXP Lidocaine results in decreased expression of FGFBP1 mRNA CTD PMID:35283115 NCBI chr14:67,103,686...67,107,492
Ensembl chr14:67,104,545...67,107,496 		JBrowse link
G Fignl1 fidgetin-like 1 increases expression EXP Lidocaine results in increased expression of FIGNL1 mRNA CTD PMID:35283115 NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455 		JBrowse link
G Fitm1 fat storage-inducing transmembrane protein 1 increases expression EXP Lidocaine results in increased expression of FITM1 mRNA CTD PMID:35283115 NCBI chr15:29,064,746...29,066,015
Ensembl chr15:29,064,707...29,066,015 		JBrowse link
G Flnc filamin C increases expression EXP Lidocaine results in increased expression of FLNC mRNA CTD PMID:35283115 NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844 		JBrowse link
G Flt3 Fms related receptor tyrosine kinase 3 decreases expression EXP Lidocaine results in decreased expression of FLT3 mRNA CTD PMID:35283115 NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474 		JBrowse link
G Fmo13 flavin-containing monooxygenase 13 decreases expression EXP Lidocaine results in decreased expression of FMO13 mRNA CTD PMID:35283115 NCBI chr13:78,726,398...78,738,178
Ensembl chr13:78,726,398...78,738,178 		JBrowse link
G Folr2 folate receptor beta increases expression EXP Lidocaine results in increased expression of FOLR2 mRNA CTD PMID:35283115 NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
affects expression		 ISO
EXP		 Lidocaine inhibits the reaction [Bee Venoms promotes the reaction [Methamphetamine results in increased expression of FOS protein]]
Lidocaine inhibits the reaction [Propofol results in increased expression of FOS protein]
Lidocaine affects the expression of FOS protein		 CTD PMID:7887109 PMID:17136530 PMID:20950675 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Fscn3 fascin actin-bundling protein 3 increases expression EXP Lidocaine results in increased expression of FSCN3 mRNA CTD PMID:35283115 NCBI chr 4:57,042,797...57,052,224
Ensembl chr 4:57,042,797...57,052,404 		JBrowse link
G Ftl1l5 ferritin light chain 1 like 5 increases expression EXP Lidocaine results in increased expression of FTL1L5 mRNA CTD PMID:35283115 NCBI chr 7:12,220,109...12,221,018
Ensembl chr 7:12,220,103...12,221,023 		JBrowse link
G Galc galactosylceramidase increases expression EXP Lidocaine results in increased expression of GALC mRNA CTD PMID:35283115 NCBI chr 6:117,452,888...117,522,281
Ensembl chr 6:117,452,895...117,515,830 		JBrowse link
G Galnt3 polypeptide N-acetylgalactosaminyltransferase 3 increases expression EXP Lidocaine results in increased expression of GALNT3 mRNA CTD PMID:35283115 NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268 		JBrowse link
G Gask1b golgi associated kinase 1B increases expression EXP Lidocaine results in increased expression of FAM198B mRNA CTD PMID:35283115 NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477 		JBrowse link
G Gdf15 growth differentiation factor 15 increases expression EXP Lidocaine results in increased expression of GDF15 mRNA CTD PMID:35283115 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055 		JBrowse link
G Gdf3 growth differentiation factor 3 increases expression EXP Lidocaine results in increased expression of GDF3 mRNA CTD PMID:35283115 NCBI chr 4:155,831,572...155,835,953
Ensembl chr 4:155,830,909...155,835,937 		JBrowse link
G Gdf7 growth differentiation factor 7 decreases expression EXP Lidocaine results in decreased expression of GDF7 mRNA CTD PMID:35283115 NCBI chr 6:31,171,495...31,182,484
Ensembl chr 6:31,178,119...31,182,447 		JBrowse link
G Gdnf glial cell derived neurotrophic factor increases expression EXP Lidocaine results in increased expression of GDNF mRNA CTD PMID:35283115 NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209 		JBrowse link
G Gen1 GEN1 Holliday junction 5' flap endonuclease increases expression EXP Lidocaine results in increased expression of GEN1 mRNA CTD PMID:35283115 NCBI chr 6:33,947,599...33,978,461
Ensembl chr 6:33,948,206...33,978,401 		JBrowse link
G Gins1 GINS complex subunit 1 increases expression EXP Lidocaine results in increased expression of GINS1 mRNA CTD PMID:35283115 NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936 		JBrowse link
G Gldn gliomedin increases expression EXP Lidocaine results in increased expression of GLDN mRNA CTD PMID:35283115 NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:54,679,119...54,723,196 		JBrowse link
G Glipr1 GLI pathogenesis-related 1 increases expression EXP Lidocaine results in increased expression of GLIPR1 mRNA CTD PMID:35283115 NCBI chr 7:47,487,342...47,498,974
Ensembl chr 7:47,487,345...47,498,429 		JBrowse link
G Gnb2 G protein subunit beta 2 increases expression EXP Lidocaine results in increased expression of GNB2 mRNA; Lidocaine results in increased expression of GNB2 protein CTD PMID:27018092 NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019 		JBrowse link
G Gpnmb glycoprotein nmb increases expression EXP Lidocaine results in increased expression of GPNMB mRNA CTD PMID:35283115 NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367 		JBrowse link
G Gpr182 G protein-coupled receptor 182 decreases expression EXP Lidocaine results in decreased expression of GPR182 mRNA CTD PMID:35283115 NCBI chr 7:63,585,997...63,589,088
Ensembl chr 7:63,578,750...63,589,210 		JBrowse link
G Gpr31 G protein-coupled receptor 31 increases expression EXP Lidocaine results in increased expression of GPR31 mRNA CTD PMID:35283115 NCBI chr 1:52,926,953...52,927,912 JBrowse link
G Gpr34 G protein-coupled receptor 34 increases expression EXP Lidocaine results in increased expression of GPR34 mRNA CTD PMID:35283115 NCBI chr  X:9,104,829...9,113,796
Ensembl chr  X:9,104,565...9,148,601 		JBrowse link
G Gpr65 G-protein coupled receptor 65 increases expression EXP Lidocaine results in increased expression of GPR65 mRNA CTD PMID:35283115 NCBI chr 6:117,515,786...117,536,514
Ensembl chr 6:117,515,648...117,536,512 		JBrowse link
G Grn granulin precursor increases expression EXP Lidocaine results in increased expression of GRN mRNA CTD PMID:35283115 NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775 		JBrowse link
G Gsg1 germ cell associated 1 increases expression EXP Lidocaine results in increased expression of GSG1 mRNA CTD PMID:35283115 NCBI chr 4:168,090,773...168,107,039
Ensembl chr 4:168,090,776...168,107,039 		JBrowse link
G H19 H19 imprinted maternally expressed transcript increases expression EXP Lidocaine results in increased expression of H19 mRNA CTD PMID:35283115 NCBI chr 1:197,730,698...197,733,374
Ensembl chr 1:197,730,698...197,733,134 		JBrowse link
G H2ac25 H2A clustered histone 25 decreases expression EXP Lidocaine results in decreased expression of H2AC25 mRNA CTD PMID:35283115 NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874 		JBrowse link
G Haspin histone H3 associated protein kinase increases expression EXP Lidocaine results in increased expression of GSG2 mRNA CTD PMID:35283115 NCBI chr10:57,747,731...57,750,518
Ensembl chr10:57,747,573...57,750,512 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 increases expression EXP Lidocaine results in increased expression of HAVCR1 mRNA CTD PMID:35283115 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Havcr2 hepatitis A virus cellular receptor 2 increases expression EXP Lidocaine results in increased expression of HAVCR2 mRNA CTD PMID:35283115 NCBI chr10:30,882,484...30,914,018
Ensembl chr10:30,882,606...30,909,137 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor increases expression EXP Lidocaine results in increased expression of HBEGF mRNA CTD PMID:35283115 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441 		JBrowse link
G Hcls1 hematopoietic cell specific Lyn substrate 1 increases expression EXP Lidocaine results in increased expression of HCLS1 mRNA CTD PMID:35283115 NCBI chr11:63,817,482...63,840,943
Ensembl chr11:63,817,476...63,841,014 		JBrowse link
G Hcst hematopoietic cell signal transducer increases expression EXP Lidocaine results in increased expression of HCST mRNA CTD PMID:35283115 NCBI chr 1:85,676,976...85,679,083
Ensembl chr 1:85,676,979...85,679,012 		JBrowse link
G Hebp2 heme binding protein 2 decreases expression EXP Lidocaine results in decreased expression of HEBP2 mRNA CTD PMID:35283115 NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777 		JBrowse link
G Hgd homogentisate 1, 2-dioxygenase increases expression EXP Lidocaine results in increased expression of HGD mRNA CTD PMID:35283115 NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323 		JBrowse link
G Hils1 histone linker H1 domain, spermatid-specific 1 increases expression EXP Lidocaine results in increased expression of HILS1 mRNA CTD PMID:35283115 NCBI chr10:79,913,525...79,914,321
Ensembl chr10:79,913,480...79,914,321 		JBrowse link
G Hist1h2af histone cluster 1 H2A family member F increases expression EXP Lidocaine results in increased expression of HIST1H2AF mRNA CTD PMID:35283115 NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796 		JBrowse link
G Hist1h2ah histone cluster 1 H2A family member H increases expression EXP Lidocaine results in increased expression of HIST1H2AH mRNA CTD PMID:35283115 NCBI chr17:41,384,521...41,385,018 JBrowse link
G Hk3 hexokinase 3 increases expression EXP Lidocaine results in increased expression of HK3 mRNA CTD PMID:35283115 NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,599,865...9,614,863 		JBrowse link
G Hmgb1 high mobility group box 1 multiple interactions ISO Lidocaine inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased localization of HMGB1 protein]; Lidocaine inhibits the reaction [Lipopolysaccharides results in increased expression of HMGB1 mRNA] CTD PMID:21288974 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565 		JBrowse link
G Hmgb2 high mobility group box 2 increases expression EXP Lidocaine results in increased expression of HMGB2 mRNA CTD PMID:35283115 NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140 		JBrowse link
G Hmgb2-ps6 high mobility group box 2, pseudogene 6 increases expression EXP Lidocaine results in increased expression of HMGB2-PS6 mRNA CTD PMID:35283115 NCBI chr 1:19,409,161...19,410,260
Ensembl chr 1:19,409,539...19,410,168 		JBrowse link
G Hmgb2l1 high mobility group box 2-like 1 increases expression EXP Lidocaine results in increased expression of HMGB2L1 mRNA CTD PMID:35283115 NCBI chr11:47,252,583...47,253,646
Ensembl chr11:47,252,569...47,253,669 		JBrowse link
G Hmgb2l2 high mobility group box 2 like 2 increases expression EXP Lidocaine results in increased expression of HMGB2L2 mRNA CTD PMID:35283115 NCBI chr14:69,045,590...69,046,623
Ensembl chr14:69,045,641...69,046,640 		JBrowse link
G Hmmr hyaluronan-mediated motility receptor increases expression EXP Lidocaine results in increased expression of HMMR mRNA CTD PMID:35283115 NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression EXP Lidocaine results in increased expression of HMOX1 mRNA CTD PMID:35283115 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hormad2 HORMA domain containing 2 increases expression EXP Lidocaine results in increased expression of HORMAD2 mRNA CTD PMID:35283115 NCBI chr14:79,215,013...79,300,447
Ensembl chr14:79,214,998...79,299,910 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression EXP Lidocaine results in increased expression of HPGD mRNA CTD PMID:35283115 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228 		JBrowse link
G Hpgds hematopoietic prostaglandin D synthase increases expression EXP Lidocaine results in increased expression of HPGDS mRNA CTD PMID:35283115 NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883 		JBrowse link
G Hrh1 histamine receptor H 1 affects binding
multiple interactions		 ISO HRH1 protein binds to Lidocaine
[HRH1 protein binds to Lidocaine] which results in increased import of Calcium		 CTD PMID:32061592 NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455 		JBrowse link
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression EXP Lidocaine results in increased expression of HSPA1B mRNA CTD PMID:35283115 NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240 		JBrowse link
G Hvcn1 hydrogen voltage-gated channel 1 increases expression EXP Lidocaine results in increased expression of HVCN1 mRNA CTD PMID:35283115 NCBI chr12:34,341,673...34,370,010
Ensembl chr12:34,335,190...34,370,141 		JBrowse link
G Ifi30 IFI30, lysosomal thiol reductase increases expression EXP Lidocaine results in increased expression of IFI30 mRNA CTD PMID:35283115 NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175 		JBrowse link
G Ifi44l interferon-induced protein 44-like increases expression EXP Lidocaine results in increased expression of IFI44L mRNA CTD PMID:35283115 NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359 		JBrowse link
G Ifit1bl interferon-induced protein with tetratricopeptide repeats 1B-like decreases expression EXP Lidocaine results in decreased expression of IFIT1BL mRNA CTD PMID:35283115 NCBI chr 1:232,122,618...232,167,317
Ensembl chr 1:232,122,562...232,167,518 		JBrowse link
G Igf1 insulin-like growth factor 1 increases expression EXP Lidocaine results in increased expression of IGF1 mRNA CTD PMID:35283115 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296 		JBrowse link
G Igfbp2 insulin-like growth factor binding protein 2 increases expression EXP Lidocaine results in increased expression of IGFBP2 mRNA CTD PMID:35283115 NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937 		JBrowse link
G Il10ra interleukin 10 receptor subunit alpha increases expression EXP Lidocaine results in increased expression of IL10RA mRNA CTD PMID:35283115 NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061 		JBrowse link
G Il13 interleukin 13 decreases expression ISO Lidocaine results in decreased expression of IL13 protein CTD PMID:18382663 NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737 		JBrowse link
G Il16 interleukin 16 increases expression EXP Lidocaine results in increased expression of IL16 mRNA CTD PMID:35283115 NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130 		JBrowse link
G Il1rap interleukin 1 receptor accessory protein increases expression EXP Lidocaine results in increased expression of IL1RAP mRNA CTD PMID:35283115 NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530 		JBrowse link
G Il33 interleukin 33 increases expression EXP Lidocaine results in increased expression of IL33 mRNA CTD PMID:35283115 NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373 		JBrowse link
G Il4 interleukin 4 decreases expression ISO Lidocaine results in decreased expression of IL4 protein CTD PMID:18382663 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 decreases expression ISO Lidocaine results in decreased expression of IL6 protein CTD PMID:16378115 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Inava innate immunity activator increases expression EXP Lidocaine results in increased expression of INAVA mRNA CTD PMID:35283115 NCBI chr13:47,666,446...47,687,383
Ensembl chr13:47,666,447...47,686,729 		JBrowse link
G Insyn2b inhibitory synaptic factor family member 2B decreases expression EXP Lidocaine results in decreased expression of INSYN2B mRNA CTD PMID:35283115 NCBI chr10:18,916,721...19,023,859
Ensembl chr10:19,003,131...19,022,139 		JBrowse link
G Iqgap3 IQ motif containing GTPase activating protein 3 increases expression EXP Lidocaine results in increased expression of IQGAP3 mRNA CTD PMID:35283115 NCBI chr 2:173,542,151...173,583,956
Ensembl chr 2:173,542,110...173,583,956 		JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 increases expression EXP Lidocaine results in increased expression of IRAK2 mRNA CTD PMID:35283115 NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602 		JBrowse link
G Irf5 interferon regulatory factor 5 increases expression EXP Lidocaine results in increased expression of IRF5 mRNA CTD PMID:35283115 NCBI chr 4:58,127,577...58,140,665
Ensembl chr 4:58,127,640...58,139,267 		JBrowse link
G Irf8 interferon regulatory factor 8 increases expression EXP Lidocaine results in increased expression of IRF8 mRNA CTD PMID:35283115 NCBI chr19:48,790,581...48,812,363
Ensembl chr19:48,790,588...48,811,829 		JBrowse link
G Isg20 interferon stimulated exonuclease gene 20 increases expression EXP Lidocaine results in increased expression of ISG20 mRNA CTD PMID:35283115 NCBI chr 1:132,829,303...132,837,027
Ensembl chr 1:132,815,123...132,837,027 		JBrowse link
G Itga4 integrin subunit alpha 4 increases expression EXP Lidocaine results in increased expression of ITGA4 mRNA CTD PMID:35283115 NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715 		JBrowse link
G Itga5 integrin subunit alpha 5 increases expression EXP Lidocaine results in increased expression of ITGA5 mRNA CTD PMID:35283115 NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions
increases expression		 ISO
EXP		 Lidocaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]]
Lidocaine results in increased expression of ITGAM mRNA		 CTD PMID:9336308 PMID:35283115 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Itgax integrin subunit alpha X increases expression EXP Lidocaine results in increased expression of ITGAX mRNA CTD PMID:35283115 NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698 		JBrowse link
G Itgb2 integrin subunit beta 2 multiple interactions ISO Lidocaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] CTD PMID:9336308 NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600 		JBrowse link
G Itsn1 intersectin 1 increases expression EXP Lidocaine results in increased expression of ITSN1 mRNA CTD PMID:35283115 NCBI chr11:30,978,590...31,160,645
Ensembl chr11:30,978,590...31,160,645 		JBrowse link
G Izumo2 IZUMO family member 2 decreases expression EXP Lidocaine results in decreased expression of IZUMO2 mRNA CTD PMID:35283115 NCBI chr 1:95,196,459...95,209,131
Ensembl chr 1:95,196,459...95,209,092 		JBrowse link
G Jag1 jagged canonical Notch ligand 1 decreases expression EXP Lidocaine results in decreased expression of JAG1 mRNA CTD PMID:35283115 NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209 		JBrowse link
G Kcnb2 potassium voltage-gated channel subfamily B member 2 decreases expression EXP Lidocaine results in decreased expression of KCNB2 mRNA CTD PMID:35283115 NCBI chr 5:3,567,012...4,028,564
Ensembl chr 5:3,569,685...4,028,599 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Lidocaine results in decreased activity of KCNH2 protein CTD PMID:24052561 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008 		JBrowse link
G Kcnk18 potassium two pore domain channel subfamily K member 18 multiple interactions ISO Lidocaine inhibits the reaction [KCNK18 protein results in increased transport of Potassium] CTD PMID:12754259 NCBI chr 1:258,374,671...258,388,945
Ensembl chr 1:258,374,671...258,388,945 		JBrowse link
G Kcnk9 potassium two pore domain channel subfamily K member 9 multiple interactions EXP Lidocaine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] CTD PMID:10734076 NCBI chr 7:104,429,186...104,473,924
Ensembl chr 7:104,437,934...104,473,175 		JBrowse link
G Kcnn4 potassium calcium-activated channel subfamily N member 4 increases expression EXP Lidocaine results in increased expression of KCNN4 mRNA CTD PMID:35283115 NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340 		JBrowse link
G Kctd19 potassium channel tetramerization domain containing 19 decreases expression EXP Lidocaine results in decreased expression of KCTD19 mRNA CTD PMID:35283115 NCBI chr19:33,259,869...33,292,011
Ensembl chr19:33,259,970...33,292,006 		JBrowse link
G Kif11 kinesin family member 11 increases expression EXP Lidocaine results in increased expression of KIF11 mRNA CTD PMID:35283115 NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766 		JBrowse link
G Kif14 kinesin family member 14 increases expression EXP Lidocaine results in increased expression of KIF14 mRNA CTD PMID:35283115 NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164 		JBrowse link
G Kif18a kinesin family member 18A increases expression EXP Lidocaine results in increased expression of KIF18A mRNA CTD PMID:35283115 NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582 		JBrowse link
G Kif18b kinesin family member 18B increases expression EXP Lidocaine results in increased expression of KIF18B mRNA CTD PMID:35283115 NCBI chr10:87,870,424...87,889,895
Ensembl chr10:87,870,428...87,889,850 		JBrowse link
G Kif20a kinesin family member 20A increases expression EXP Lidocaine results in increased expression of KIF20A mRNA CTD PMID:35283115 NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780 		JBrowse link
G Kif22 kinesin family member 22 increases expression EXP Lidocaine results in increased expression of KIF22 mRNA CTD PMID:35283115 NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401 		JBrowse link
G Kif28p kinesin family member 28, pseudogene decreases expression EXP Lidocaine results in decreased expression of KIF28P mRNA CTD PMID:35283115 NCBI chr13:91,427,527...91,482,297
Ensembl chr13:91,427,736...91,482,237 		JBrowse link
G Kifc1 kinesin family member C1 increases expression EXP Lidocaine results in increased expression of KIFC1 mRNA CTD PMID:35283115 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105 		JBrowse link
G Klc1 kinesin light chain 1 decreases expression EXP Lidocaine results in decreased expression of KLC1 mRNA CTD PMID:35283115 NCBI chr 6:130,823,416...130,866,729
Ensembl chr 6:130,823,419...130,867,031 		JBrowse link
G Klhl38 kelch-like family member 38 increases expression EXP Lidocaine results in increased expression of KLHL38 mRNA CTD PMID:35283115 NCBI chr 7:89,854,015...89,864,352
Ensembl chr 7:89,855,148...89,864,276 		JBrowse link
G Klhl6 kelch-like family member 6 increases expression EXP Lidocaine results in increased expression of KLHL6 mRNA CTD PMID:35283115 NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677 		JBrowse link
G Kmo kynurenine 3-monooxygenase increases expression EXP Lidocaine results in increased expression of KMO mRNA CTD PMID:35283115 NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881 		JBrowse link
G Kng1 kininogen 1 multiple interactions
decreases activity		 ISO Lidocaine inhibits the reaction [[Propofol co-treated with Pharmaceutical Vehicles] results in increased expression of KNG1 protein modified form]
Lidocaine results in decreased activity of KNG1 protein		 CTD PMID:1371395 PMID:10655909 NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555 		JBrowse link
G Knstrn kinetochore-localized astrin/SPAG5 binding protein increases expression EXP Lidocaine results in increased expression of KNSTRN mRNA CTD PMID:35283115 NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715 		JBrowse link
G Kntc1 kinetochore associated 1 increases expression EXP Lidocaine results in increased expression of KNTC1 mRNA CTD PMID:35283115 NCBI chr12:32,769,020...32,839,617
Ensembl chr12:32,769,020...32,839,561 		JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression EXP Lidocaine results in increased expression of KPNA2 mRNA CTD PMID:35283115 NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150 		JBrowse link
G Kpna7 karyopherin subunit alpha 7 decreases expression EXP Lidocaine results in decreased expression of KPNA7 mRNA CTD PMID:35283115 NCBI chr12:9,576,378...9,635,247
Ensembl chr12:9,576,378...9,612,833 		JBrowse link
G Krt34 keratin 34 decreases expression EXP Lidocaine results in decreased expression of KRT34 mRNA CTD PMID:35283115 NCBI chr10:84,969,988...84,974,098
Ensembl chr10:84,970,017...84,974,040 		JBrowse link
G Krt8 keratin 8 increases expression EXP Lidocaine results in increased expression of KRT8 mRNA CTD PMID:35283115 NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728 		JBrowse link
G Lalba lactalbumin, alpha decreases expression EXP Lidocaine results in decreased expression of LALBA mRNA CTD PMID:35283115 NCBI chr 7:129,625,531...129,628,034
Ensembl chr 7:129,625,535...129,628,061 		JBrowse link
G Laptm5 lysosomal protein transmembrane 5 increases expression EXP Lidocaine results in increased expression of LAPTM5 mRNA CTD PMID:35283115 NCBI chr 5:143,087,759...143,109,807
Ensembl chr 5:143,087,759...143,109,807 		JBrowse link
G Lcp1 lymphocyte cytosolic protein 1 increases expression EXP Lidocaine results in increased expression of LCP1 mRNA CTD PMID:35283115 NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680 		JBrowse link
G Lcp2 lymphocyte cytosolic protein 2 increases expression EXP Lidocaine results in increased expression of LCP2 mRNA CTD PMID:35283115 NCBI chr10:18,642,600...18,689,562
Ensembl chr10:18,642,658...18,689,559 		JBrowse link
G Lgals1 galectin 1 decreases expression ISO Lidocaine results in decreased expression of LGALS1 protein CTD PMID:18382663 NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345 		JBrowse link
G Lgals12 galectin 12 decreases expression EXP Lidocaine results in decreased expression of LGALS12 mRNA CTD PMID:35283115 NCBI chr 1:204,832,065...204,842,759
Ensembl chr 1:204,832,065...204,842,759 		JBrowse link
G Lgals3bp galectin 3 binding protein increases expression EXP Lidocaine results in increased expression of LGALS3BP mRNA CTD PMID:35283115 NCBI chr10:103,619,912...103,629,251
Ensembl chr10:103,619,908...103,629,256 		JBrowse link
G Lilrc2 leukocyte immunoglobulin-like receptor, subfamily C, member 2 decreases expression EXP Lidocaine results in decreased expression of LILRC2 mRNA CTD PMID:35283115 NCBI chr 1:65,272,134...65,277,278
Ensembl chr 1:65,272,796...65,277,271 		JBrowse link
G Limk2 LIM domain kinase 2 increases expression EXP Lidocaine results in increased expression of LIMK2 mRNA CTD PMID:35283115 NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007 		JBrowse link
G Lpl lipoprotein lipase increases expression EXP Lidocaine results in increased expression of LPL mRNA CTD PMID:35283115 NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249 		JBrowse link
G Lpxn leupaxin increases expression EXP Lidocaine results in increased expression of LPXN mRNA CTD PMID:35283115 NCBI chr 1:209,928,297...209,963,085
Ensembl chr 1:209,929,202...209,963,084 		JBrowse link
G Lrr1 leucine rich repeat protein 1 increases expression EXP Lidocaine results in increased expression of LRR1 mRNA CTD PMID:35283115 NCBI chr 6:87,643,195...87,651,894
Ensembl chr 6:87,643,217...87,651,894 		JBrowse link
G Lrrc8e leucine rich repeat containing 8 VRAC subunit E increases expression EXP Lidocaine results in increased expression of LRRC8E mRNA CTD PMID:35283115 NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412 		JBrowse link
G Lsm2 LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated increases expression EXP Lidocaine results in increased expression of LSM2 mRNA CTD PMID:35283115 NCBI chr20:3,843,467...3,847,217
Ensembl chr20:3,843,466...3,847,266 		JBrowse link
G Lst1 leukocyte specific transcript 1 increases expression EXP Lidocaine results in increased expression of LST1 mRNA CTD PMID:35283115 NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997 		JBrowse link
G Ly49i9 Ly49 inhibitory receptor 9 increases expression EXP Lidocaine results in increased expression of LY49I9 mRNA CTD PMID:35283115
G Ly49s7 Ly49 stimulatory receptor 7 increases expression EXP Lidocaine results in increased expression of LY49S7 mRNA CTD PMID:35283115 NCBI chr 4:164,761,847...164,779,735
Ensembl chr 4:164,761,855...164,779,735 		JBrowse link
G Lyl1 LYL1, basic helix-loop-helix family member increases expression EXP Lidocaine results in increased expression of LYL1 mRNA CTD PMID:35283115 NCBI chr19:23,452,140...23,455,007
Ensembl chr19:23,452,140...23,455,007 		JBrowse link
G Mad2l1 mitotic arrest deficient 2 like 1 increases expression EXP Lidocaine results in increased expression of MAD2L1 mRNA CTD PMID:35283115 NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470 		JBrowse link
G Mageb11l1 MAGE family member B11 like 1 decreases expression EXP Lidocaine results in decreased expression of MAGEB11L1 mRNA CTD PMID:35283115 NCBI chr  X:56,619,858...56,621,033
Ensembl chr  X:56,619,985...56,621,013 		JBrowse link
G Malrd1 MAM and LDL receptor class A domain containing 1 increases expression EXP Lidocaine results in increased expression of MALRD1 mRNA CTD PMID:35283115 NCBI chr17:78,418,819...79,131,015
Ensembl chr17:78,418,819...79,131,016 		JBrowse link
G Man2b1 mannosidase, alpha, class 2B, member 1 increases expression EXP Lidocaine results in increased expression of MAN2B1 mRNA CTD PMID:35283115 NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389 		JBrowse link
G Man2b2 mannosidase, alpha, class 2B, member 2 increases expression EXP Lidocaine results in increased expression of MAN2B2 mRNA CTD PMID:35283115 NCBI chr14:73,969,079...73,994,089
Ensembl chr14:73,969,003...74,004,281 		JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha increases expression
multiple interactions		 EXP Lidocaine results in increased expression of MAP1LC3A protein
bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of MAP1LC3A protein]; dorsomorphin inhibits the reaction [Lidocaine results in increased expression of MAP1LC3A protein]; MK-8722 promotes the reaction [Lidocaine results in increased expression of MAP1LC3A protein]		 CTD PMID:37914286 NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670 		JBrowse link
G Map4k1 mitogen activated protein kinase kinase kinase kinase 1 increases expression EXP Lidocaine results in increased expression of MAP4K1 mRNA CTD PMID:35283115 NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions EXP Lidocaine inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of MAPK1 protein] CTD PMID:12196597 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions EXP Lidocaine inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:12196597 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mastl microtubule associated serine/threonine kinase-like increases expression EXP Lidocaine results in increased expression of MASTL mRNA CTD PMID:35283115 NCBI chr17:85,250,512...85,287,479
Ensembl chr17:85,251,997...85,287,353 		JBrowse link
G Mbp myelin basic protein decreases expression
multiple interactions		 EXP Lidocaine results in decreased expression of MBP mRNA; Lidocaine results in decreased expression of MBP protein
[Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MBP mRNA]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MBP protein]		 CTD PMID:33166664 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression EXP Lidocaine results in increased expression of MCL1 mRNA CTD PMID:35283115 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Mcm10 minichromosome maintenance 10 replication initiation factor increases expression EXP Lidocaine results in increased expression of MCM10 mRNA CTD PMID:35283115 NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364 		JBrowse link
G Mcm2 minichromosome maintenance complex component 2 increases expression EXP Lidocaine results in increased expression of MCM2 mRNA CTD PMID:35283115 NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847 		JBrowse link
G Mcm3 minichromosome maintenance complex component 3 increases expression EXP Lidocaine results in increased expression of MCM3 mRNA CTD PMID:35283115 NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314 		JBrowse link
G Mcm4 minichromosome maintenance complex component 4 increases expression EXP Lidocaine results in increased expression of MCM4 mRNA CTD PMID:35283115 NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144 		JBrowse link
G Mcm5 minichromosome maintenance complex component 5 increases expression EXP Lidocaine results in increased expression of MCM5 mRNA CTD PMID:35283115 NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389 		JBrowse link
G Mcm6 minichromosome maintenance complex component 6 increases expression EXP Lidocaine results in increased expression of MCM6 mRNA CTD PMID:35283115 NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960 		JBrowse link
G Meox1 mesenchyme homeobox 1 decreases expression EXP Lidocaine results in decreased expression of MEOX1 mRNA CTD PMID:35283115 NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660 		JBrowse link
G Mertk MER proto-oncogene, tyrosine kinase increases expression EXP Lidocaine results in increased expression of MERTK mRNA CTD PMID:35283115 NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554 		JBrowse link
G Milr1 mast cell immunoglobulin-like receptor 1 increases expression EXP Lidocaine results in increased expression of MILR1 mRNA CTD PMID:35283115 NCBI chr10:91,684,288...91,705,284
Ensembl chr10:91,687,831...91,705,282 		JBrowse link
G Mir199a2 microRNA 199a-2 multiple interactions
increases expression		 EXP [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MBP mRNA]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MBP protein]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MOG mRNA]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MYRF mRNA]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MYRF protein]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of PLP1 mRNA]
Lidocaine results in increased expression of MIR199A2 mRNA		 CTD PMID:33166664 NCBI chr13:74,582,954...74,583,063
Ensembl chr13:74,582,954...74,583,063 		JBrowse link
G Mis18a MIS18 kinetochore protein A increases expression EXP Lidocaine results in increased expression of MIS18A mRNA CTD PMID:35283115 NCBI chr11:29,968,030...29,981,058
Ensembl chr11:29,967,701...29,981,062 		JBrowse link
G Mis18bp1 MIS18 binding protein 1 increases expression EXP Lidocaine results in increased expression of MIS18BP1 mRNA CTD PMID:35283115 NCBI chr 6:83,182,497...83,231,978
Ensembl chr 6:83,182,499...83,231,383 		JBrowse link
G Mlst8 MTOR associated protein, LST8 homolog multiple interactions EXP bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; dorsomorphin inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]; MK-8722 promotes the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] CTD PMID:37914286 NCBI chr10:13,498,377...13,504,128
Ensembl chr10:13,498,388...13,504,128 		JBrowse link
G Mmp12 matrix metallopeptidase 12 increases expression EXP Lidocaine results in increased expression of MMP12 mRNA CTD PMID:35283115 NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611 		JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions
increases expression		 EXP cordycepin inhibits the reaction [Lidocaine results in increased expression of MMP3 mRNA]; cordycepin inhibits the reaction [Lidocaine results in increased expression of MMP3 protein]
Lidocaine results in increased expression of MMP3 mRNA; Lidocaine results in increased expression of MMP3 protein		 CTD PMID:29382532 NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961 		JBrowse link
G Mmp7 matrix metallopeptidase 7 increases expression EXP Lidocaine results in increased expression of MMP7 mRNA CTD PMID:35283115 NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902 		JBrowse link
G Mms22l MMS22-like, DNA repair protein increases expression EXP Lidocaine results in increased expression of MMS22L mRNA CTD PMID:35283115 NCBI chr 5:38,197,707...38,313,745
Ensembl chr 5:38,197,779...38,313,745 		JBrowse link
G Mobp myelin-associated oligodendrocyte basic protein decreases expression EXP Lidocaine results in decreased expression of MOBP mRNA CTD PMID:35283115 NCBI chr 8:119,869,504...119,899,605
Ensembl chr 8:119,869,626...119,899,563 		JBrowse link
G Mog myelin oligodendrocyte glycoprotein multiple interactions
decreases expression		 EXP [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MOG mRNA] CTD PMID:33166664 NCBI chr20:1,513,137...1,523,473
Ensembl chr20:1,513,239...1,523,474 		JBrowse link
G Ms4a1 membrane spanning 4-domains A1 decreases expression EXP Lidocaine results in decreased expression of MS4A1 mRNA CTD PMID:35283115 NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512 		JBrowse link
G Ms4a4a membrane spanning 4-domains A4A increases expression EXP Lidocaine results in increased expression of MS4A4A mRNA CTD PMID:35283115 NCBI chr 1:208,060,507...208,085,121
Ensembl chr 1:208,046,971...208,085,119 		JBrowse link
G Ms4a6bl1 membrane-spanning 4-domains, subfamily A, member 6B-like 1 increases expression EXP Lidocaine results in increased expression of MS4A6BL1 mRNA CTD PMID:35283115 NCBI chr 1:208,243,561...208,255,400
Ensembl chr 1:208,243,559...208,257,340 		JBrowse link
G Msr1 macrophage scavenger receptor 1 increases expression EXP Lidocaine results in increased expression of MSR1 mRNA CTD PMID:35283115 NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676 		JBrowse link
G Msx3 msh homeobox 3 decreases expression EXP Lidocaine results in decreased expression of MSX3 mRNA CTD PMID:35283115 NCBI chr 1:194,839,041...194,842,209
Ensembl chr 1:194,839,041...194,841,969 		JBrowse link
G Mtbp MDM2 binding protein increases expression EXP Lidocaine results in increased expression of MTBP mRNA CTD PMID:35283115 NCBI chr 7:86,973,215...87,055,775
Ensembl chr 7:86,973,069...87,050,827 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions EXP bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; dorsomorphin inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]; MK-8722 promotes the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] CTD PMID:37914286 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Mug2 murinoglobulin 2 increases expression EXP Lidocaine results in increased expression of PZP mRNA CTD PMID:35283115 NCBI chr 4:155,164,061...155,236,894
Ensembl chr 4:155,164,011...155,236,475 		JBrowse link
G Mxd3 Max dimerization protein 3 increases expression EXP Lidocaine results in increased expression of MXD3 mRNA CTD PMID:35283115 NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,301,399...9,305,157 		JBrowse link
G Mybl2 MYB proto-oncogene like 2 increases expression EXP Lidocaine results in increased expression of MYBL2 mRNA CTD PMID:35283115 NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708 		JBrowse link
G Mybpc2 myosin binding protein C2 increases expression EXP Lidocaine results in increased expression of MYBPC2 mRNA CTD PMID:35283115 NCBI chr 1:94,994,121...95,017,584
Ensembl chr 1:94,994,104...95,017,584 		JBrowse link
G Mylk3 myosin light chain kinase 3 increases expression EXP Lidocaine results in increased expression of MYLK3 mRNA CTD PMID:35283115 NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954 		JBrowse link
G Myo18b myosin XVIIIb increases expression EXP Lidocaine results in increased expression of MYO18B mRNA CTD PMID:35283115 NCBI chr12:43,747,003...43,953,694
Ensembl chr12:43,747,010...43,953,695 		JBrowse link
G Myo1f myosin IF increases expression EXP Lidocaine results in increased expression of MYO1F mRNA CTD PMID:35283115 NCBI chr 7:14,363,340...14,413,911
Ensembl chr 7:14,363,350...14,413,911 		JBrowse link
G Myo7a myosin VIIA increases expression EXP Lidocaine results in increased expression of MYO7A mRNA CTD PMID:35283115 NCBI chr 1:152,342,611...152,414,171
Ensembl chr 1:152,344,448...152,414,157 		JBrowse link
G Myrf myelin regulatory factor multiple interactions
decreases expression		 EXP [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MYRF mRNA]; [Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of MYRF protein]
Lidocaine results in decreased expression of MYRF mRNA; Lidocaine results in decreased expression of MYRF protein		 CTD PMID:33166664 NCBI chr 1:206,854,175...206,886,276
Ensembl chr 1:206,854,175...206,886,157 		JBrowse link
G Naglu N-acetyl-alpha-glucosaminidase increases expression EXP Lidocaine results in increased expression of NAGLU mRNA CTD PMID:35283115 NCBI chr10:86,001,545...86,009,049
Ensembl chr10:86,001,566...86,008,972 		JBrowse link
G Nav1 neuron navigator 1 decreases expression EXP Lidocaine results in decreased expression of NAV1 mRNA CTD PMID:35283115 NCBI chr13:46,866,972...47,119,368
Ensembl chr13:46,873,689...47,126,449 		JBrowse link
G Ncan neurocan increases expression EXP Lidocaine results in increased expression of NCAN mRNA CTD PMID:35283115 NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436 		JBrowse link
G Ncapg non-SMC condensin I complex, subunit G increases expression EXP Lidocaine results in increased expression of NCAPG mRNA CTD PMID:35283115 NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902 		JBrowse link
G Ncapg2 non-SMC condensin II complex, subunit G2 increases expression EXP Lidocaine results in increased expression of NCAPG2 mRNA CTD PMID:35283115 NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159 		JBrowse link
G Ncaph non-SMC condensin I complex, subunit H increases expression EXP Lidocaine results in increased expression of NCAPH mRNA CTD PMID:35283115 NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180 		JBrowse link
G Ncf1 neutrophil cytosolic factor 1 increases expression EXP Lidocaine results in increased expression of NCF1 mRNA CTD PMID:35283115 NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646 		JBrowse link
G Nckap1l NCK associated protein 1 like increases expression EXP Lidocaine results in increased expression of NCKAP1L mRNA CTD PMID:35283115 NCBI chr 7:134,577,470...134,622,928
Ensembl chr 7:134,577,482...134,622,934 		JBrowse link
G Ndc80 NDC80 kinetochore complex component increases expression EXP Lidocaine results in increased expression of NDC80 mRNA CTD PMID:35283115 NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924 		JBrowse link
G Nefm neurofilament medium chain multiple interactions
decreases expression		 ISO NGF protein inhibits the reaction [Lidocaine results in decreased expression of NEFM protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of NEFM protein] CTD PMID:34193770 NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755 		JBrowse link
G Neil3 nei-like DNA glycosylase 3 increases expression EXP Lidocaine results in increased expression of NEIL3 mRNA CTD PMID:35283115 NCBI chr16:38,359,305...38,418,528
Ensembl chr16:38,359,371...38,418,527 		JBrowse link
G Nek2 NIMA-related kinase 2 increases expression EXP Lidocaine results in increased expression of NEK2 mRNA CTD PMID:35283115 NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051 		JBrowse link
G Nes nestin increases expression EXP Lidocaine results in increased expression of NES mRNA CTD PMID:35283115 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777 		JBrowse link
G Nfasc neurofascin decreases expression EXP Lidocaine results in decreased expression of NFASC mRNA CTD PMID:35283115 NCBI chr13:43,997,223...44,183,863
Ensembl chr13:43,997,224...44,183,880 		JBrowse link
G Nfe2 nuclear factor, erythroid 2 decreases expression EXP Lidocaine results in decreased expression of NFE2 mRNA CTD PMID:35283115 NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108 		JBrowse link
G Nfkbid NFKB inhibitor delta increases expression EXP Lidocaine results in increased expression of NFKBID mRNA CTD PMID:35283115 NCBI chr 1:85,679,353...85,690,415
Ensembl chr 1:85,680,861...85,690,447 		JBrowse link
G Ngf nerve growth factor decreases expression
multiple interactions		 ISO Lidocaine results in decreased expression of NGF protein
NGF protein inhibits the reaction [Lidocaine results in decreased expression of NEFM protein]; NGF protein inhibits the reaction [Lidocaine results in decreased expression of NNAT protein]; NGF protein inhibits the reaction [Lidocaine results in decreased expression of UCHL1 protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of NGF protein]
NGF protein inhibits the reaction [Lidocaine results in decreased expression of NEFM protein]; NGF protein inhibits the reaction [Lidocaine results in decreased expression of NNAT protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of NGF protein]		 CTD PMID:34193770 NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452 		JBrowse link
G Ngfr nerve growth factor receptor increases expression EXP Lidocaine results in increased expression of NGFR mRNA CTD PMID:35283115 NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518 		JBrowse link
G Nkain1 Sodium/potassium transporting ATPase interacting 1 increases expression EXP Lidocaine results in increased expression of NKAIN1 mRNA CTD PMID:35283115 NCBI chr 5:142,747,702...142,792,665
Ensembl chr 5:142,747,505...142,791,863 		JBrowse link
G Nnat neuronatin multiple interactions
decreases expression		 ISO NGF protein inhibits the reaction [Lidocaine results in decreased expression of NNAT protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of NEFM protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of NGF protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of UCHL1 protein] CTD PMID:34193770 NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 increases activity ISO Lidocaine results in increased activity of NR1I2 protein CTD PMID:25455453 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nsl1 NSL1 component of MIS12 kinetochore complex increases expression EXP Lidocaine results in increased expression of NSL1 mRNA CTD PMID:35283115 NCBI chr13:102,649,050...102,674,059
Ensembl chr13:102,649,058...102,674,054 		JBrowse link
G Nt5dc2 5'-nucleotidase domain containing 2 increases expression EXP Lidocaine results in increased expression of NT5DC2 mRNA CTD PMID:35283115 NCBI chr16:6,322,485...6,330,538
Ensembl chr16:6,322,236...6,330,537 		JBrowse link
G Nuf2 NUF2 component of NDC80 kinetochore complex increases expression EXP Lidocaine results in increased expression of NUF2 mRNA CTD PMID:35283115 NCBI chr13:81,693,675...81,722,765
Ensembl chr13:81,693,598...81,722,766 		JBrowse link
G Nusap1 nucleolar and spindle associated protein 1 increases expression EXP Lidocaine results in increased expression of NUSAP1 mRNA CTD PMID:35283115 NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624 		JBrowse link
G Oasl 2'-5'-oligoadenylate synthetase-like increases expression EXP Lidocaine results in increased expression of OASL mRNA CTD PMID:35283115 NCBI chr12:41,682,900...41,695,641
Ensembl chr12:41,682,900...41,695,641 		JBrowse link
G Oip5 Opa interacting protein 5 increases expression EXP Lidocaine results in increased expression of OIP5 mRNA CTD PMID:35283115 NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250 		JBrowse link
G Olr1 oxidized low density lipoprotein receptor 1 increases expression EXP Lidocaine results in increased expression of OLR1 mRNA CTD PMID:35283115 NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523 		JBrowse link
G Oplah 5-oxoprolinase (ATP-hydrolysing) increases expression EXP Lidocaine results in increased expression of OPLAH mRNA CTD PMID:35283115 NCBI chr 7:108,011,472...108,051,751
Ensembl chr 7:108,011,475...108,035,297 		JBrowse link
G Or10a48 olfactory receptor family 10 subfamily A member 48B decreases expression EXP Lidocaine results in decreased expression of OR10A48 mRNA CTD PMID:35283115 NCBI chr 1:162,793,841...162,794,776
Ensembl chr 1:162,793,610...162,797,017 		JBrowse link
G Or1x2c olfactory receptor family 1 subfamily O member 2C decreases expression EXP Lidocaine results in decreased expression of OR1X2C mRNA CTD PMID:35283115 NCBI chr10:35,364,667...35,365,608
Ensembl chr10:35,364,667...35,365,608 		JBrowse link
G Or52e15c olfactory receptor family 52 subfamily E member 15C decreases expression EXP Lidocaine results in decreased expression of OR52E15C mRNA CTD PMID:35283115 NCBI chr 1:159,401,875...159,402,816
Ensembl chr 1:159,401,808...159,408,026 		JBrowse link
G Or6k2 olfactory receptor family 6 subfamily K member 2 increases expression EXP Lidocaine results in increased expression of OR6K2 mRNA CTD PMID:35283115 NCBI chr13:86,186,442...86,190,391
Ensembl chr13:86,185,529...86,190,815 		JBrowse link
G Or8g36b olfactory receptor family 8 subfamily G member 36B decreases expression EXP Lidocaine results in decreased expression of OR8G36B mRNA CTD PMID:35283115 NCBI chr 8:39,803,767...39,804,720
Ensembl chr 8:39,803,767...39,804,720 		JBrowse link
G Orc1 origin recognition complex, subunit 1 increases expression EXP Lidocaine results in increased expression of ORC1 mRNA CTD PMID:35283115 NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375 		JBrowse link
G Orm1 orosomucoid 1 affects binding
multiple interactions		 ISO Lidocaine binds to ORM1 protein alternative form
Lidocaine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]		 CTD PMID:8946472 NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154 		JBrowse link
G Otulinl OTU deubiquitinase with linear linkage specificity like increases expression EXP Lidocaine results in increased expression of FAM105A mRNA CTD PMID:35283115 NCBI chr 2:78,405,994...78,433,860
Ensembl chr 2:78,408,593...78,433,838 		JBrowse link
G Ovch2 ovochymase 2 decreases expression EXP Lidocaine results in decreased expression of OVCH2 mRNA CTD PMID:35283115 NCBI chr 1:161,693,619...161,713,952
Ensembl chr 1:161,693,647...161,713,952 		JBrowse link
G Parp10 poly (ADP-ribose) polymerase family, member 10 increases expression EXP Lidocaine results in increased expression of PARP10 mRNA CTD PMID:35283115 NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304 		JBrowse link
G Parp14 poly (ADP-ribose) polymerase family, member 14 increases expression EXP Lidocaine results in increased expression of PARP14 mRNA CTD PMID:35283115 NCBI chr11:64,902,848...64,934,916
Ensembl chr11:64,902,785...64,934,916 		JBrowse link
G Pcdh15 protocadherin related 15 decreases expression EXP Lidocaine results in decreased expression of PCDH15 mRNA CTD PMID:35283115 NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719 		JBrowse link
G Pcdha12 protocadherin alpha 12 increases expression EXP Lidocaine results in increased expression of PCDHA12 mRNA CTD PMID:35283115 Ensembl chr18:28,581,225...28,846,211 JBrowse link
G Pclaf PCNA clamp associated factor increases expression EXP Lidocaine results in increased expression of PCLAF mRNA CTD PMID:35283115 NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994 		JBrowse link
G Pdcd1 programmed cell death 1 increases expression EXP Lidocaine results in increased expression of PDCD1 mRNA CTD PMID:35283115 NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937 		JBrowse link
G Pde6b phosphodiesterase 6B increases expression EXP Lidocaine results in increased expression of PDE6B mRNA CTD PMID:35283115 NCBI chr14:1,323,310...1,366,450
Ensembl chr14:1,323,310...1,366,450 		JBrowse link
G Pf4 platelet factor 4 increases expression EXP Lidocaine results in increased expression of PF4 mRNA CTD PMID:35283115 NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365 		JBrowse link
G Pgap1 post-GPI attachment to proteins inositol deacylase 1 increases expression EXP Lidocaine results in increased expression of PGAP1 mRNA CTD PMID:35283115 NCBI chr 9:55,975,574...56,044,325
Ensembl chr 9:55,975,667...56,044,464 		JBrowse link
G Phldb3 pleckstrin homology-like domain, family B, member 3 increases expression EXP Lidocaine results in increased expression of PHLDB3 mRNA CTD PMID:35283115 NCBI chr 1:80,201,083...80,219,541
Ensembl chr 1:80,201,578...80,219,534 		JBrowse link
G Pi15 peptidase inhibitor 15 decreases expression EXP Lidocaine results in decreased expression of PI15 mRNA CTD PMID:35283115 NCBI chr 5:1,395,094...1,423,213
Ensembl chr 5:1,395,094...1,423,213 		JBrowse link
G Pik3cg phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma increases expression EXP Lidocaine results in increased expression of PIK3CG mRNA CTD PMID:35283115 NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043 		JBrowse link
G Pimreg PICALM interacting mitotic regulator increases expression EXP Lidocaine results in increased expression of FAM64A mRNA CTD PMID:35283115 NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791 		JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
increases expression		 EXP bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of PINK1 protein]; dorsomorphin inhibits the reaction [Lidocaine results in increased expression of PINK1 protein]; MK-8722 promotes the reaction [Lidocaine results in increased expression of PINK1 protein] CTD PMID:37914286 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Pip prolactin induced protein increases expression EXP Lidocaine results in increased expression of PIP mRNA CTD PMID:35283115 NCBI chr 4:70,787,627...70,791,921
Ensembl chr 4:70,787,627...70,791,921 		JBrowse link
G Pla2g2a phospholipase A2 group IIA decreases expression EXP Lidocaine results in decreased expression of PLA2G2A mRNA CTD PMID:35283115 NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014 		JBrowse link
G Plac8 placenta associated 8 decreases expression EXP Lidocaine results in decreased expression of PLAC8 mRNA CTD PMID:35283115 NCBI chr14:9,052,601...9,074,264
Ensembl chr14:9,063,048...9,074,264 		JBrowse link
G Plau plasminogen activator, urokinase increases expression EXP Lidocaine results in increased expression of PLAU mRNA CTD PMID:35283115 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plaur plasminogen activator, urokinase receptor increases expression EXP Lidocaine results in increased expression of PLAUR mRNA CTD PMID:35283115 NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595 		JBrowse link
G Plbd1 phospholipase B domain containing 1 increases expression EXP Lidocaine results in increased expression of PLBD1 mRNA CTD PMID:35283115 NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277 		JBrowse link
G Plcb2 phospholipase C, beta 2 increases expression EXP Lidocaine results in increased expression of PLCB2 mRNA CTD PMID:35283115 NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:105,684,815...105,704,302 		JBrowse link
G Pld4 phospholipase D family, member 4 increases expression EXP Lidocaine results in increased expression of PLD4 mRNA CTD PMID:35283115 NCBI chr 6:131,818,860...131,827,457
Ensembl chr 6:131,818,860...131,826,376 		JBrowse link
G Plek2 pleckstrin 2 decreases expression EXP Lidocaine results in decreased expression of PLEK2 mRNA CTD PMID:35283115 NCBI chr 6:97,700,123...97,719,417
Ensembl chr 6:97,701,106...97,719,326 		JBrowse link
G Plekha2 pleckstrin homology domain containing A2 increases expression EXP Lidocaine results in increased expression of PLEKHA2 mRNA CTD PMID:35283115 NCBI chr16:66,938,684...67,000,661
Ensembl chr16:66,939,109...66,999,395 		JBrowse link
G Plin2 perilipin 2 increases expression EXP Lidocaine results in increased expression of PLIN2 mRNA CTD PMID:35283115 NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319 		JBrowse link
G Pln phospholamban decreases expression EXP Lidocaine results in decreased expression of PLN mRNA CTD PMID:35283115 NCBI chr20:32,629,537...32,639,559 JBrowse link
G Plp1 proteolipid protein 1 decreases expression
multiple interactions		 EXP Lidocaine results in decreased expression of PLP1 mRNA
[Antagomirs results in decreased expression of MIR199A2 mRNA] inhibits the reaction [Lidocaine results in decreased expression of PLP1 mRNA]		 CTD PMID:33166664 NCBI chr  X:100,184,039...100,201,035
Ensembl chr  X:100,185,767...100,201,032 		JBrowse link
G Pm20d2 peptidase M20 domain containing 2 increases expression EXP Lidocaine results in increased expression of PM20D2 mRNA CTD PMID:35283115 NCBI chr 5:47,566,059...47,586,334
Ensembl chr 5:47,566,072...47,586,212 		JBrowse link
G Pmf1 polyamine-modulated factor 1 increases expression EXP Lidocaine results in increased expression of PMF1 mRNA CTD PMID:35283115 NCBI chr 2:173,848,074...173,868,272
Ensembl chr 2:173,848,074...173,868,270 		JBrowse link
G Pof1b POF1B, actin binding protein decreases expression EXP Lidocaine results in decreased expression of POF1B mRNA CTD PMID:35283115 NCBI chr  X:77,683,128...77,749,827
Ensembl chr  X:77,683,128...77,749,688 		JBrowse link
G Pola1 DNA polymerase alpha 1, catalytic subunit increases expression EXP Lidocaine results in increased expression of POLA1 mRNA CTD PMID:35283115 NCBI chr  X:58,034,617...58,348,612
Ensembl chr  X:58,034,619...58,348,536 		JBrowse link
G Pole DNA polymerase epsilon, catalytic subunit increases expression EXP Lidocaine results in increased expression of POLE mRNA CTD PMID:35283115 NCBI chr12:46,345,420...46,393,984
Ensembl chr12:46,345,420...46,393,939 		JBrowse link
G Pole2 DNA polymerase epsilon 2, accessory subunit increases expression EXP Lidocaine results in increased expression of POLE2 mRNA CTD PMID:35283115 NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305 		JBrowse link
G Polq DNA polymerase theta increases expression EXP Lidocaine results in increased expression of POLQ mRNA CTD PMID:35283115 NCBI chr11:63,673,796...63,775,905
Ensembl chr11:63,673,816...63,775,878 		JBrowse link
G Pomc proopiomelanocortin multiple interactions EXP Lidocaine inhibits the reaction [Capsaicin results in increased secretion of POMC protein] CTD PMID:8925284 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664 		JBrowse link
G Postn periostin increases expression EXP Lidocaine results in increased expression of POSTN mRNA CTD PMID:35283115 NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099 		JBrowse link
G Ppp4r3c protein phosphatase 4 regulatory subunit 3C decreases expression EXP Lidocaine results in decreased expression of PPP4R3C mRNA CTD PMID:35283115 NCBI chr  X:53,630,250...53,722,658 JBrowse link
G Prc1 protein regulator of cytokinesis 1 increases expression EXP Lidocaine results in increased expression of PRC1 mRNA CTD PMID:35283115 NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765 		JBrowse link
G Primpol primase and DNA directed polymerase increases expression EXP Lidocaine results in increased expression of PRIMPOL mRNA CTD PMID:35283115 NCBI chr16:45,681,252...45,715,758
Ensembl chr16:45,681,326...45,715,565 		JBrowse link
G Prkaa1 protein kinase AMP-activated catalytic subunit alpha 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein]; MK-8722 promotes the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein] CTD PMID:37914286 NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978 		JBrowse link
G Prkcb protein kinase C, beta increases expression
multiple interactions		 EXP Lidocaine results in increased expression of PRKCB protein
Dexmedetomidine inhibits the reaction [Lidocaine results in increased expression of PRKCB protein]		 CTD PMID:30240660 NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536 		JBrowse link
G Prkcg protein kinase C, gamma multiple interactions EXP Lidocaine inhibits the reaction [remifentanil affects the localization of PRKCG protein] CTD PMID:19955894 NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384 		JBrowse link
G Prok2 prokineticin 2 decreases expression EXP Lidocaine results in decreased expression of PROK2 mRNA CTD PMID:35283115 NCBI chr 4:132,346,681...132,361,754
Ensembl chr 4:132,347,103...132,361,385 		JBrowse link
G Prph2 peripherin 2 decreases expression EXP Lidocaine results in decreased expression of PRPH2 mRNA CTD PMID:35283115 NCBI chr 9:14,066,149...14,081,454
Ensembl chr 9:14,066,156...14,081,454 		JBrowse link
G Prr11 proline rich 11 increases expression EXP Lidocaine results in increased expression of PRR11 mRNA CTD PMID:35283115 NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012 		JBrowse link
G Prrg4 proline rich and Gla domain 4 increases expression EXP Lidocaine results in increased expression of PRRG4 mRNA CTD PMID:35283115 NCBI chr 3:91,214,646...91,243,347
Ensembl chr 3:91,214,653...91,243,273 		JBrowse link
G Prss56 serine protease 56 increases expression EXP Lidocaine results in increased expression of PRSS56 mRNA CTD PMID:35283115 NCBI chr 9:87,842,806...87,859,978
Ensembl chr 9:87,854,805...87,859,978 		JBrowse link
G Ptges prostaglandin E synthase decreases expression EXP Lidocaine results in decreased expression of PTGES mRNA CTD PMID:35283115 NCBI chr 3:14,177,892...14,189,236 JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression EXP Lidocaine results in decreased expression of PTGS2 mRNA CTD PMID:35283115 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptpn18 protein tyrosine phosphatase, non-receptor type 18 increases expression EXP Lidocaine results in increased expression of PTPN18 mRNA CTD PMID:35283115 NCBI chr 9:36,672,325...36,689,963
Ensembl chr 9:36,672,362...36,690,995 		JBrowse link
G Ptpn6 protein tyrosine phosphatase, non-receptor type 6 increases expression EXP Lidocaine results in increased expression of PTPN6 mRNA CTD PMID:35283115 NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984 		JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin increases expression EXP Lidocaine results in increased expression of PTTG1 mRNA CTD PMID:35283115 NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837 		JBrowse link
G Ptx3 pentraxin 3 decreases expression EXP Lidocaine results in decreased expression of PTX3 mRNA CTD PMID:35283115 NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323 		JBrowse link
G Pvr PVR cell adhesion molecule increases expression EXP Lidocaine results in increased expression of PVR mRNA CTD PMID:35283115 NCBI chr 1:79,561,294...79,576,700
Ensembl chr 1:79,546,879...79,576,715 		JBrowse link
G Pvt1 Pvt1 oncogene increases expression EXP Lidocaine results in increased expression of PVT1 mRNA CTD PMID:35283115 NCBI chr 7:93,656,528...93,879,938 JBrowse link
G Pycard PYD and CARD domain containing increases expression EXP Lidocaine results in increased expression of PYCARD mRNA CTD PMID:35283115 NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955 		JBrowse link
G Pyy peptide YY increases expression EXP Lidocaine results in increased expression of PYY mRNA CTD PMID:35283115 NCBI chr10:87,061,155...87,062,278
Ensembl chr10:87,061,161...87,061,815 		JBrowse link
G Qprt quinolinate phosphoribosyltransferase increases expression EXP Lidocaine results in increased expression of QPRT mRNA CTD PMID:35283115 NCBI chr 1:181,718,189...181,733,486
Ensembl chr 1:181,718,190...181,733,486 		JBrowse link
G Rab7b Rab7b, member RAS oncogene family increases expression EXP Lidocaine results in increased expression of RAB7B mRNA CTD PMID:35283115 NCBI chr13:43,121,168...43,147,581
Ensembl chr13:43,121,226...43,147,581 		JBrowse link
G Rab8a RAB8A, member RAS oncogene family increases expression EXP Lidocaine results in increased expression of RAB8A mRNA CTD PMID:35283115 NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678 		JBrowse link
G Racgap1 Rac GTPase-activating protein 1 increases expression EXP Lidocaine results in increased expression of RACGAP1 mRNA CTD PMID:35283115 NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831 		JBrowse link
G Rad51 RAD51 recombinase increases expression EXP Lidocaine results in increased expression of RAD51 mRNA CTD PMID:35283115 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035 		JBrowse link
G Rad54l RAD54 like increases expression EXP Lidocaine results in increased expression of RAD54L mRNA CTD PMID:35283115 NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070 		JBrowse link
G Rbl1 RB transcriptional corepressor like 1 affects expression
increases expression		 ISO
EXP		 Lidocaine affects the expression of RBL1 mRNA
Lidocaine results in increased expression of RBL1 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330 		JBrowse link
G Rbl2 RB transcriptional corepressor like 2 affects expression ISO Lidocaine affects the expression of RBL2 mRNA CTD PMID:18931217 NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572 		JBrowse link
G Rbm47 RNA binding motif protein 47 increases expression EXP Lidocaine results in increased expression of RBM47 mRNA CTD PMID:35283115 NCBI chr14:42,053,290...42,191,572
Ensembl chr14:42,154,142...42,189,431 		JBrowse link
G Recql4 RecQ like helicase 4 increases expression EXP Lidocaine results in increased expression of RECQL4 mRNA CTD PMID:35283115 NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619 		JBrowse link
G Reg3b regenerating family member 3 beta increases expression EXP Lidocaine results in increased expression of REG3B mRNA CTD PMID:35283115 NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015 		JBrowse link
G RGD1559545 similar to ATPase inhibitory factor 1 decreases expression EXP Lidocaine results in decreased expression of RGD1559545 mRNA CTD PMID:35283115 NCBI chr 6:89,821,916...89,842,882 JBrowse link
G RGD1560225 similar to nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 increases expression EXP Lidocaine results in increased expression of RGD1560225 mRNA CTD PMID:35283115
G Rgs18 regulator of G-protein signaling 18 increases expression EXP Lidocaine results in increased expression of RGS18 mRNA CTD PMID:35283115 NCBI chr13:56,493,134...56,516,045
Ensembl chr13:56,494,010...56,516,098 		JBrowse link
G Rn28s 28S ribosomal RNA decreases expression EXP Lidocaine results in decreased expression of RN28S mRNA CTD PMID:35283115
G Rptor regulatory associated protein of MTOR, complex 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; dorsomorphin inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]]; Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]; MK-8722 promotes the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] CTD PMID:37914286 NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983 		JBrowse link
G Rrm1 ribonucleotide reductase catalytic subunit M1 increases expression EXP Lidocaine results in increased expression of RRM1 mRNA CTD PMID:35283115 NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261 		JBrowse link
G Rrm2 ribonucleotide reductase regulatory subunit M2 increases expression EXP Lidocaine results in increased expression of RRM2 mRNA CTD PMID:35283115 NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773 		JBrowse link
G Rsad2 radical S-adenosyl methionine domain containing 2 increases expression EXP Lidocaine results in increased expression of RSAD2 mRNA CTD PMID:35283115 NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699 		JBrowse link
G RT1-CE10 RT1 class I, locus CE10 decreases expression EXP Lidocaine results in decreased expression of RT1-CE10 mRNA CTD PMID:35283115 NCBI chr20:3,377,284...3,380,301 JBrowse link
G RT1-CE2 RT1 class I, locus CE2 decreases expression EXP Lidocaine results in decreased expression of RT1-CE2 mRNA CTD PMID:35283115 NCBI chr20:3,538,452...3,541,841
Ensembl chr20:3,537,809...3,541,790 		JBrowse link
G RT1-CE5 RT1 class I, locus CE5 decreases expression EXP Lidocaine results in decreased expression of RT1-CE5 mRNA CTD PMID:35283115 NCBI chr20:3,403,418...3,479,476 JBrowse link
G RT1-DMb RT1 class II, locus DMb increases expression EXP Lidocaine results in increased expression of RT1-DMB mRNA CTD PMID:35283115 NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340 		JBrowse link
G RT1-N2 RT1 class Ib, locus N2 increases expression EXP Lidocaine results in increased expression of RT1-N2 mRNA CTD PMID:35283115 NCBI chr20:2,641,157...2,645,439
Ensembl chr20:2,641,202...2,644,900 		JBrowse link
G RT1-T24-3 RT1 class I, locus T24, gene 3 increases expression EXP Lidocaine results in increased expression of RT1-T24-3 mRNA CTD PMID:35283115 NCBI chr20:2,718,210...2,730,604
Ensembl chr20:2,718,279...2,776,154 		JBrowse link
G S100a11 S100 calcium binding protein A11 increases expression EXP Lidocaine results in increased expression of S100A11 mRNA CTD PMID:35283115 NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044 		JBrowse link
G S100a3 S100 calcium binding protein A3 increases expression EXP Lidocaine results in increased expression of S100A3 mRNA CTD PMID:35283115 NCBI chr 2:176,034,283...176,089,702
Ensembl chr 2:176,049,520...176,089,702 		JBrowse link
G S100a8 S100 calcium binding protein A8 increases expression
decreases expression		 ISO
EXP		 Lidocaine results in increased expression of S100A8 protein
Lidocaine results in decreased expression of S100A8 mRNA		 CTD PMID:18382663 PMID:35283115 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643 		JBrowse link
G S100a9 S100 calcium binding protein A9 increases expression ISO Lidocaine results in increased expression of S100A9 protein CTD PMID:18382663 NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230 		JBrowse link
G Sapcd2 suppressor APC domain containing 2 increases expression EXP Lidocaine results in increased expression of SAPCD2 mRNA CTD PMID:35283115 NCBI chr 3:8,186,089...8,195,119
Ensembl chr 3:8,187,266...8,192,546 		JBrowse link
G Sc5d sterol-C5-desaturase decreases expression EXP Lidocaine results in decreased expression of SC5D mRNA CTD PMID:35283115 NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273 		JBrowse link
G Scgb1a1 secretoglobin family 1A member 1 increases expression EXP Lidocaine results in increased expression of SCGB1A1 mRNA CTD PMID:35283115 NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610 		JBrowse link
G Scn4a sodium voltage-gated channel alpha subunit 4 multiple interactions ISO Lidocaine binds to and results in decreased activity of SCN4A protein CTD PMID:14662728 NCBI chr10:91,246,936...91,296,670
Ensembl chr10:91,246,936...91,296,545 		JBrowse link
G Scn5a sodium voltage-gated channel alpha subunit 5 affects response to substance ISO SCN5A protein mutant form affects the susceptibility to Lidocaine CTD PMID:18599870 NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769 		JBrowse link
G Sct secretin increases expression EXP Lidocaine results in increased expression of SCT mRNA CTD PMID:35283115 NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658 		JBrowse link
G Scube1 signal peptide, CUB domain and EGF like domain containing 1 increases expression EXP Lidocaine results in increased expression of SCUBE1 mRNA CTD PMID:35283115 NCBI chr 7:114,759,016...114,880,995
Ensembl chr 7:114,759,010...114,880,940 		JBrowse link
G Sdf2l1 stromal cell-derived factor 2-like 1 increases expression EXP Lidocaine results in increased expression of SDF2L1 mRNA CTD PMID:35283115 NCBI chr11:83,872,659...83,874,902
Ensembl chr11:83,872,659...83,874,902 		JBrowse link
G Sell selectin L multiple interactions ISO Lidocaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein] CTD PMID:9336308 NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456 		JBrowse link
G Sema5b semaphorin 5B increases expression EXP Lidocaine results in increased expression of SEMA5B mRNA CTD PMID:35283115 NCBI chr11:65,102,532...65,225,456
Ensembl chr11:65,102,031...65,225,311 		JBrowse link
G Sgo2 shugoshin 2 increases expression EXP Lidocaine results in increased expression of SGO2 mRNA CTD PMID:35283115 NCBI chr 9:59,548,605...59,573,229
Ensembl chr 9:59,548,683...59,573,229 		JBrowse link
G Sgsm3 small G protein signaling modulator 3 decreases expression EXP Lidocaine results in decreased expression of SGSM3 mRNA CTD PMID:35283115 NCBI chr 7:112,514,453...112,544,109
Ensembl chr 7:112,514,630...112,544,108 		JBrowse link
G Shc4 SHC adaptor protein 4 increases expression EXP Lidocaine results in increased expression of SHC4 mRNA CTD PMID:35283115 NCBI chr 3:112,880,598...112,974,216
Ensembl chr 3:112,880,600...112,974,366 		JBrowse link
G Shcbp1 SHC binding and spindle associated 1 increases expression EXP Lidocaine results in increased expression of SHCBP1 mRNA CTD PMID:35283115 NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844 		JBrowse link
G Shmt1 serine hydroxymethyltransferase 1 increases expression EXP Lidocaine results in increased expression of SHMT1 mRNA CTD PMID:35283115 NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820 		JBrowse link
G Sirt4 sirtuin 4 decreases expression EXP Lidocaine results in decreased expression of SIRT4 mRNA CTD PMID:35283115 NCBI chr12:41,125,533...41,139,440
Ensembl chr12:41,131,262...41,139,439 		JBrowse link
G Ska1 spindle and kinetochore associated complex subunit 1 increases expression EXP Lidocaine results in increased expression of SKA1 mRNA CTD PMID:35283115 NCBI chr18:67,794,722...67,805,037
Ensembl chr18:67,794,725...67,805,037 		JBrowse link
G Ska3 spindle and kinetochore associated complex subunit 3 increases expression EXP Lidocaine results in increased expression of SKA3 mRNA CTD PMID:35283115 NCBI chr15:31,951,812...31,971,010
Ensembl chr15:31,951,825...31,971,010 		JBrowse link
G Slamf7 SLAM family member 7 increases expression EXP Lidocaine results in increased expression of SLAMF7 mRNA CTD PMID:35283115 NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105 		JBrowse link
G Slamf9 SLAM family member 9 increases expression EXP Lidocaine results in increased expression of SLAMF9 mRNA CTD PMID:35283115 NCBI chr13:84,941,896...84,944,749
Ensembl chr13:84,941,982...84,944,748 		JBrowse link
G Slc10a6 solute carrier family 10 member 6 increases expression EXP Lidocaine results in increased expression of SLC10A6 mRNA CTD PMID:35283115 NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,080,717...6,103,037 		JBrowse link
G Slc13a3 solute carrier family 13 member 3 decreases expression EXP Lidocaine results in decreased expression of SLC13A3 mRNA CTD PMID:35283115 NCBI chr 3:154,141,878...154,204,604
Ensembl chr 3:154,141,872...154,204,606 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions ISO Lidocaine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:21641380 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO Lidocaine inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Lidocaine inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] CTD PMID:23770354 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Slc22a3 solute carrier family 22 member 3 multiple interactions ISO Lidocaine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:21641380 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612 		JBrowse link
G Slc22a4 solute carrier family 22 member 4 multiple interactions ISO Lidocaine inhibits the reaction [SLC22A4 protein results in increased uptake of Tetraethylammonium] CTD PMID:21641380 NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720 		JBrowse link
G Slc22a5 solute carrier family 22 member 5 multiple interactions ISO Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] CTD PMID:21641380 NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309 		JBrowse link
G Slc26a2 solute carrier family 26 member 2 decreases expression EXP Lidocaine results in decreased expression of SLC26A2 mRNA CTD PMID:35283115 NCBI chr18:54,648,276...54,666,627
Ensembl chr18:54,652,951...54,666,626 		JBrowse link
G Slc28a1 solute carrier family 28 member 1 decreases expression EXP Lidocaine results in decreased expression of SLC28A1 mRNA CTD PMID:35283115 NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464 		JBrowse link
G Slc39a12 solute carrier family 39 member 12 increases expression EXP Lidocaine results in increased expression of SLC39A12 mRNA CTD PMID:35283115 NCBI chr17:77,353,761...77,440,384
Ensembl chr17:77,353,805...77,440,353 		JBrowse link
G Slc41a2 solute carrier family 41 member 2 decreases expression EXP Lidocaine results in decreased expression of SLC41A2 mRNA CTD PMID:35283115 NCBI chr 7:20,383,714...20,491,178
Ensembl chr 7:20,383,757...20,491,166 		JBrowse link
G Slc6a2 solute carrier family 6 member 2 multiple interactions ISO Lidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] CTD PMID:16725121 NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357 		JBrowse link
G Slc7a7 solute carrier family 7 member 7 increases expression EXP Lidocaine results in increased expression of SLC7A7 mRNA CTD PMID:35283115 NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648 		JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 increases expression EXP Lidocaine results in increased expression of SLCO2B1 mRNA CTD PMID:35283115 NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353 		JBrowse link
G Smc2 structural maintenance of chromosomes 2 increases expression EXP Lidocaine results in increased expression of SMC2 mRNA CTD PMID:35283115 NCBI chr 5:66,806,882...66,853,478
Ensembl chr 5:66,807,011...66,853,242 		JBrowse link
G Snx20 sorting nexin 20 increases expression EXP Lidocaine results in increased expression of SNX20 mRNA CTD PMID:35283115 NCBI chr19:18,435,935...18,445,108
Ensembl chr19:18,435,935...18,445,107 		JBrowse link
G Soat1 sterol O-acyltransferase 1 increases expression EXP Lidocaine results in increased expression of SOAT1 mRNA CTD PMID:35283115 NCBI chr13:68,552,274...68,597,529
Ensembl chr13:68,552,317...68,597,494 		JBrowse link
G SPATA45 spermatogenesis associated 45 increases expression EXP Lidocaine results in increased expression of PYHIN1 mRNA CTD PMID:35283115 NCBI chr13:102,624,298...102,631,191
Ensembl chr13:102,625,273...102,631,191 		JBrowse link
G Spc24 SPC24 component of NDC80 kinetochore complex increases expression EXP Lidocaine results in increased expression of SPC24 mRNA CTD PMID:35283115 NCBI chr 8:20,300,315...20,305,354
Ensembl chr 8:20,300,319...20,305,310 		JBrowse link
G Spc25 SPC25 component of NDC80 kinetochore complex increases expression EXP Lidocaine results in increased expression of SPC25 mRNA CTD PMID:35283115 NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959 		JBrowse link
G Spi1 Spi-1 proto-oncogene increases expression EXP Lidocaine results in increased expression of SPI1 mRNA CTD PMID:35283115 NCBI chr 3:77,059,744...77,093,730
Ensembl chr 3:77,073,012...77,092,393 		JBrowse link
G Spink2 serine peptidase inhibitor, Kazal type 2 increases expression EXP Lidocaine results in increased expression of SPINK2 mRNA CTD PMID:35283115 NCBI chr14:30,967,682...30,974,326
Ensembl chr14:30,967,714...30,974,326 		JBrowse link
G Spp1 secreted phosphoprotein 1 increases expression EXP Lidocaine results in increased expression of SPP1 mRNA CTD PMID:35283115 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162 		JBrowse link
G Srd5a2 steroid 5 alpha-reductase 2 decreases expression EXP Lidocaine results in decreased expression of SRD5A2 mRNA CTD PMID:35283115 NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112 		JBrowse link
G St14 ST14 transmembrane serine protease matriptase increases expression EXP Lidocaine results in increased expression of ST14 mRNA CTD PMID:35283115 NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517 		JBrowse link
G Stap1 signal transducing adaptor family member 1 increases expression EXP Lidocaine results in increased expression of STAP1 mRNA CTD PMID:35283115 NCBI chr14:21,950,466...21,981,395
Ensembl chr14:21,952,496...21,981,245 		JBrowse link
G Stat6 signal transducer and activator of transcription 6 increases expression EXP Lidocaine results in increased expression of STAT6 mRNA CTD PMID:35283115 NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495 		JBrowse link
G Steap4 STEAP4 metalloreductase decreases expression EXP Lidocaine results in decreased expression of STEAP4 mRNA CTD PMID:35283115 NCBI chr 4:26,077,182...26,099,859
Ensembl chr 4:26,054,671...26,099,859 		JBrowse link
G Stfa2l3 stefin A2-like 3 decreases expression EXP Lidocaine results in decreased expression of STFA2L3 mRNA CTD PMID:35283115 NCBI chr11:64,588,401...64,593,418
Ensembl chr11:64,588,465...64,593,327 		JBrowse link
G Stfa3l1 stefin A3-like 1 decreases expression EXP Lidocaine results in decreased expression of STFA3L1 mRNA CTD PMID:35283115 NCBI chr11:64,608,683...64,615,902
Ensembl chr11:64,608,683...64,615,902 		JBrowse link
G Stil STIL, centriolar assembly protein increases expression EXP Lidocaine results in increased expression of STIL mRNA CTD PMID:35283115 NCBI chr 5:128,520,837...128,573,732
Ensembl chr 5:128,520,953...128,573,730 		JBrowse link
G Stkld1 serine/threonine kinase-like domain containing 1 decreases expression EXP Lidocaine results in decreased expression of STKLD1 mRNA CTD PMID:35283115 NCBI chr 3:10,261,583...10,280,850
Ensembl chr 3:10,261,828...10,280,566 		JBrowse link
G Stmn1 stathmin 1 increases expression EXP Lidocaine results in increased expression of STMN1 mRNA; Lidocaine results in increased expression of STMN1 protein CTD PMID:27018092 NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154 		JBrowse link
G Stxbp2 syntaxin binding protein 2 increases expression EXP Lidocaine results in increased expression of STXBP2 mRNA CTD PMID:35283115 NCBI chr12:1,689,364...1,701,145
Ensembl chr12:1,689,410...1,700,458 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 increases sulfation ISO SULT1A1 protein results in increased sulfation of Lidocaine metabolite CTD PMID:10460806 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Sult1b1 sulfotransferase family 1B member 1 increases sulfation ISO SULT1B1 protein results in increased sulfation of Lidocaine metabolite CTD PMID:10460806 NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483 		JBrowse link
G Syk spleen associated tyrosine kinase increases expression EXP Lidocaine results in increased expression of SYK mRNA CTD PMID:35283115 NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410 		JBrowse link
G Sypl2 synaptophysin-like 2 increases expression EXP Lidocaine results in increased expression of SYPL2 mRNA CTD PMID:35283115 NCBI chr 2:195,849,062...195,863,794
Ensembl chr 2:195,849,062...195,863,794 		JBrowse link
G Tac1 tachykinin, precursor 1 increases expression EXP Lidocaine results in increased expression of TAC1 mRNA CTD PMID:35283115 NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178 		JBrowse link
G Tacc3 transforming, acidic coiled-coil containing protein 3 increases expression EXP Lidocaine results in increased expression of TACC3 mRNA CTD PMID:35283115 NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219 		JBrowse link
G Tagap T-cell activation RhoGTPase activating protein increases expression EXP Lidocaine results in increased expression of TAGAP mRNA CTD PMID:35283115 NCBI chr 1:47,170,725...47,179,705
Ensembl chr 1:47,170,725...47,179,792 		JBrowse link
G Tcf19 transcription factor 19 increases expression EXP Lidocaine results in increased expression of TCF19 mRNA CTD PMID:35283115 NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271 		JBrowse link
G Tchhl1 trichohyalin-like 1 decreases expression EXP Lidocaine results in decreased expression of TCHHL1 mRNA CTD PMID:35283115 NCBI chr 2:179,134,941...179,138,467
Ensembl chr 2:179,135,796...179,138,202 		JBrowse link
G Tcim transcriptional and immune response regulator increases expression EXP Lidocaine results in increased expression of TCIM mRNA CTD PMID:35283115 NCBI chr16:67,595,762...67,597,055
Ensembl chr16:67,593,410...67,597,581 		JBrowse link
G Tec tec protein tyrosine kinase increases expression EXP Lidocaine results in increased expression of TEC mRNA CTD PMID:35283115 NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557 		JBrowse link
G Tent5a terminal nucleotidyltransferase 5A increases expression EXP Lidocaine results in increased expression of FAM46A mRNA CTD PMID:35283115 NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045 		JBrowse link
G Tent5c terminal nucleotidyltransferase 5C increases expression EXP Lidocaine results in increased expression of FAM46C mRNA CTD PMID:35283115 NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744 		JBrowse link
G Tex56p testis expressed 56 increases expression EXP Lidocaine results in increased expression of TEX56P mRNA CTD PMID:35283115 NCBI chr17:29,929,855...29,966,578
Ensembl chr17:29,929,780...29,966,579 		JBrowse link
G Tff3 trefoil factor 3 increases expression EXP Lidocaine results in increased expression of TFF3 mRNA CTD PMID:35283115 NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054 		JBrowse link
G Tgfa transforming growth factor alpha decreases expression ISO Lidocaine results in decreased expression of TGFA protein CTD PMID:18382663 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression EXP Lidocaine results in increased expression of TGFB1 mRNA CTD PMID:35283115 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tgif2 TGFB-induced factor homeobox 2 increases expression EXP Lidocaine results in increased expression of TGIF2 mRNA CTD PMID:35283115 NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596 		JBrowse link
G Thbs2 thrombospondin 2 increases expression EXP Lidocaine results in increased expression of THBS2 mRNA CTD PMID:35283115 NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789 		JBrowse link
G Thbs4 thrombospondin 4 increases expression EXP Lidocaine results in increased expression of THBS4 mRNA CTD PMID:35283115 NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313 		JBrowse link
G Ticam2 TIR domain containing adaptor molecule 2 increases expression EXP Lidocaine results in increased expression of TICAM2 mRNA CTD PMID:35283115 NCBI chr18:39,289,902...39,311,462
Ensembl chr18:39,294,453...39,311,462 		JBrowse link
G Ticrr TOPBP1-interacting checkpoint and replication regulator increases expression EXP Lidocaine results in increased expression of TICRR mRNA CTD PMID:35283115 NCBI chr 1:133,597,618...133,639,513
Ensembl chr 1:133,597,716...133,639,523 		JBrowse link
G Tifab TIFA inhibitor increases expression EXP Lidocaine results in increased expression of TIFAB mRNA CTD PMID:35283115 NCBI chr17:8,433,406...8,436,541
Ensembl chr17:8,431,635...8,436,592 		JBrowse link
G Timd2 T-cell immunoglobulin and mucin domain containing 2 increases expression EXP Lidocaine results in increased expression of TIMD2 mRNA CTD PMID:35283115 NCBI chr10:31,060,308...31,101,262
Ensembl chr10:31,060,326...31,094,623 		JBrowse link
G Tk1 thymidine kinase 1 increases expression EXP Lidocaine results in increased expression of TK1 mRNA CTD PMID:35283115 NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920 		JBrowse link
G Tln1 talin 1 increases expression EXP Lidocaine results in increased expression of TLN1 mRNA CTD PMID:35283115 NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900 		JBrowse link
G Tlr3 toll-like receptor 3 increases expression EXP Lidocaine results in increased expression of TLR3 mRNA CTD PMID:35283115 NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545 		JBrowse link
G Tlr4 toll-like receptor 4 increases expression EXP Lidocaine results in increased expression of TLR4 mRNA CTD PMID:35283115 NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628 		JBrowse link
G Tlr8 toll-like receptor 8 increases expression EXP Lidocaine results in increased expression of TLR8 mRNA CTD PMID:35283115 NCBI chr  X:27,091,780...27,116,092
Ensembl chr  X:27,091,778...27,116,549 		JBrowse link
G Tlr9 toll-like receptor 9 increases expression EXP Lidocaine results in increased expression of TLR9 mRNA CTD PMID:35283115 NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796 		JBrowse link
G Tmem119 transmembrane protein 119 increases expression EXP Lidocaine results in increased expression of TMEM119 mRNA CTD PMID:35283115 NCBI chr12:42,828,621...42,835,678
Ensembl chr12:42,828,418...42,835,689 		JBrowse link
G Tmem176b transmembrane protein 176B increases expression EXP Lidocaine results in increased expression of TMEM176B mRNA CTD PMID:35283115 NCBI chr 4:77,766,928...77,774,740
Ensembl chr 4:77,766,928...77,774,384 		JBrowse link
G Tmprss7 transmembrane serine protease 7 decreases expression EXP Lidocaine results in decreased expression of TMPRSS7 mRNA CTD PMID:35283115 NCBI chr11:55,127,992...55,166,597
Ensembl chr11:55,128,998...55,164,882 		JBrowse link
G Tmprss9 transmembrane serine protease 9 increases expression EXP Lidocaine results in increased expression of TMPRSS9 mRNA CTD PMID:35283115 NCBI chr 7:8,810,321...8,831,177
Ensembl chr 7:8,810,320...8,831,177 		JBrowse link
G Tnc tenascin C increases expression EXP Lidocaine results in increased expression of TNC mRNA CTD PMID:35283115 NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Lidocaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein]; Lidocaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]]
Lidocaine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Lidocaine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]		 CTD PMID:9336308 PMID:32471037 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfaip8l2 TNF alpha induced protein 8 like 2 increases expression EXP Lidocaine results in increased expression of TNFAIP8L2 mRNA CTD PMID:35283115 NCBI chr 2:182,710,433...182,726,724
Ensembl chr 2:182,709,378...182,726,760 		JBrowse link
G Tnfrsf12a TNF receptor superfamily member 12A increases expression EXP Lidocaine results in increased expression of TNFRSF12A mRNA CTD PMID:35283115 NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045 		JBrowse link
G Tnni2 troponin I2, fast skeletal type increases expression EXP Lidocaine results in increased expression of TNNI2 mRNA CTD PMID:35283115 NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:197,594,813...197,597,560 		JBrowse link
G Top6bl TOP6B like initiator of meiotic double strand breaks decreases expression EXP Lidocaine results in decreased expression of TOP6BL mRNA CTD PMID:35283115 NCBI chr 1:201,902,564...201,989,945 JBrowse link
G Tp53 tumor protein p53 affects expression
decreases expression		 ISO
EXP		 Lidocaine affects the expression of TRP53 mRNA
Lidocaine results in decreased expression of TP53 mRNA		 CTD PMID:18931217 PMID:35283115 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tpbgl trophoblast glycoprotein-like increases expression EXP Lidocaine results in increased expression of TPBGL mRNA CTD PMID:35283115 NCBI chr 1:153,923,722...153,926,548
Ensembl chr 1:153,925,098...153,926,252 		JBrowse link
G Tph1 tryptophan hydroxylase 1 increases expression EXP Lidocaine results in increased expression of TPH1 mRNA CTD PMID:35283115 NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344 		JBrowse link
G Tpx2 TPX2, microtubule nucleation factor increases expression EXP Lidocaine results in increased expression of TPX2 mRNA CTD PMID:35283115 NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468 		JBrowse link
G Traip TRAF-interacting protein increases expression EXP Lidocaine results in increased expression of TRAIP mRNA CTD PMID:35283115 NCBI chr 8:108,641,860...108,661,640
Ensembl chr 8:108,641,852...108,661,638 		JBrowse link
G Tram2 translocation associated membrane protein 2 increases expression EXP Lidocaine results in increased expression of TRAM2 mRNA CTD PMID:35283115 NCBI chr 9:23,419,204...23,498,745
Ensembl chr 9:23,424,232...23,498,689 		JBrowse link
G Trav12-3 T cell receptor alpha variable 12-3 decreases expression EXP Lidocaine results in decreased expression of TRAV12-3 mRNA CTD PMID:35283115 NCBI chr15:25,503,871...25,504,883
Ensembl chr15:25,503,985...25,504,565 		JBrowse link
G Trim7 tripartite motif-containing 7 decreases expression EXP Lidocaine results in decreased expression of TRIM7 mRNA CTD PMID:35283115 NCBI chr10:33,205,491...33,221,482
Ensembl chr10:33,205,491...33,221,468 		JBrowse link
G Trip13 thyroid hormone receptor interactor 13 increases expression EXP Lidocaine results in increased expression of TRIP13 mRNA CTD PMID:35283115 NCBI chr 1:29,357,093...29,402,078
Ensembl chr 1:29,357,130...29,402,074 		JBrowse link
G Troap trophinin associated protein increases expression EXP Lidocaine results in increased expression of TROAP mRNA CTD PMID:35283115 NCBI chr 7:130,233,534...130,242,369
Ensembl chr 7:130,234,544...130,242,365 		JBrowse link
G Trpa1 transient receptor potential cation channel, subfamily A, member 1 increases activity ISO
EXP		 Lidocaine results in increased activity of TRPA1 protein CTD PMID:18172555 NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 increases activity
multiple interactions		 ISO
EXP		 Lidocaine results in increased activity of TRPV1 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Lidocaine results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [Lidocaine results in increased activity of TRPV1 protein]; Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein]; Lidocaine promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]; Lidocaine promotes the reaction [TRPV1 protein results in increased abundance of Calcium]; N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide inhibits the reaction [Lidocaine results in increased activity of TRPV1 protein]; oxophenylarsine inhibits the reaction [Lidocaine promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]]; oxophenylarsine inhibits the reaction [Lidocaine results in increased activity of TRPV1 protein]; Ruthenium Red inhibits the reaction [Lidocaine results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Lidocaine results in increased activity of TRPV1 protein]
TRPV1 protein affects the reaction [Lidocaine results in increased secretion of CALCA protein]		 CTD PMID:18172555 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513 		JBrowse link
G Ttk Ttk protein kinase increases expression EXP Lidocaine results in increased expression of TTK mRNA CTD PMID:35283115 NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651 		JBrowse link
G Tyms thymidylate synthetase increases expression EXP Lidocaine results in increased expression of TYMS mRNA CTD PMID:35283115 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
G Tyrobp transmembrane immune signaling adaptor Tyrobp increases expression EXP Lidocaine results in increased expression of TYROBP mRNA CTD PMID:35283115 NCBI chr 1:85,672,931...85,676,856
Ensembl chr 1:85,672,994...85,676,848 		JBrowse link
G Ubd ubiquitin D decreases expression EXP Lidocaine results in decreased expression of UBD mRNA CTD PMID:35283115 NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
Ensembl chr20:1,385,864...1,408,639 		JBrowse link
G Ube2c ubiquitin-conjugating enzyme E2C increases expression EXP Lidocaine results in increased expression of UBE2C mRNA CTD PMID:35283115 NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339 		JBrowse link
G Ube2t ubiquitin-conjugating enzyme E2T increases expression EXP Lidocaine results in increased expression of UBE2T mRNA CTD PMID:35283115 NCBI chr13:46,403,352...46,413,854
Ensembl chr13:46,403,375...46,414,835 		JBrowse link
G Ubl7 ubiquitin-like 7 decreases expression EXP Lidocaine results in decreased expression of UBL7 protein CTD PMID:27018092 NCBI chr 8:58,321,279...58,340,353
Ensembl chr 8:58,320,866...58,340,344 		JBrowse link
G Uchl1 ubiquitin C-terminal hydrolase L1 multiple interactions
decreases expression		 ISO NGF protein inhibits the reaction [Lidocaine results in decreased expression of UCHL1 protein]; NNAT protein inhibits the reaction [Lidocaine results in decreased expression of UCHL1 protein] CTD PMID:34193770 NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590 		JBrowse link
G Ucn urocortin increases expression EXP Lidocaine results in increased expression of UCN mRNA CTD PMID:35283115 NCBI chr 6:25,238,120...25,238,950
Ensembl chr 6:25,238,120...25,238,950 		JBrowse link
G Ucp2 uncoupling protein 2 increases expression EXP Lidocaine results in increased expression of UCP2 mRNA CTD PMID:35283115 NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611 		JBrowse link
G Unc5cl unc-5 family C-terminal like increases expression EXP Lidocaine results in increased expression of UNC5CL mRNA CTD PMID:35283115 NCBI chr 9:12,528,109...12,543,382
Ensembl chr 9:12,528,246...12,542,233 		JBrowse link
G Unc93b1 unc-93 homolog B1, TLR signaling regulator increases expression EXP Lidocaine results in increased expression of UNC93B1 mRNA CTD PMID:35283115 NCBI chr 1:201,167,388...201,178,343
Ensembl chr 1:201,152,693...201,178,338 		JBrowse link
G Usp18 ubiquitin specific peptidase 18 increases expression EXP Lidocaine results in increased expression of USP18 mRNA CTD PMID:35283115 NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144 		JBrowse link
G Uts2 urotensin 2 increases expression EXP Lidocaine results in increased expression of UTS2 mRNA CTD PMID:35283115 NCBI chr 5:161,450,846...161,456,235
Ensembl chr 5:161,450,846...161,456,237 		JBrowse link
G Vav1 vav guanine nucleotide exchange factor 1 increases expression EXP Lidocaine results in increased expression of VAV1 mRNA CTD PMID:35283115 NCBI chr 9:2,161,985...2,209,951
Ensembl chr 9:2,157,900...2,208,937 		JBrowse link
G Vcan versican increases expression EXP Lidocaine results in increased expression of VCAN mRNA CTD PMID:35283115 NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637 		JBrowse link
G Vgf VGF nerve growth factor inducible increases expression EXP Lidocaine results in increased expression of VGF mRNA CTD PMID:35283115 NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341 		JBrowse link
G Vwa5al1 von Willebrand factor A domain containing 5A like 1 decreases expression EXP Lidocaine results in decreased expression of VWA5AL1 mRNA CTD PMID:35283115 NCBI chr 8:39,869,937...39,890,669
Ensembl chr 8:39,870,563...39,893,187 		JBrowse link
G Wdfy4 WDFY family member 4 increases expression EXP Lidocaine results in increased expression of WDFY4 mRNA CTD PMID:35283115 NCBI chr16:8,221,853...8,450,494
Ensembl chr16:8,221,719...8,450,491 		JBrowse link
G Zbp1 Z-DNA binding protein 1 increases expression EXP Lidocaine results in increased expression of ZBP1 mRNA CTD PMID:35283115 NCBI chr 3:161,993,351...162,009,297
Ensembl chr 3:161,993,351...162,003,870 		JBrowse link
G Zc3hav1 zinc finger CCCH-type containing, antiviral 1 increases expression EXP Lidocaine results in increased expression of ZC3HAV1 mRNA CTD PMID:35283115 NCBI chr 4:67,012,129...67,062,428
Ensembl chr 4:67,012,185...67,062,428 		JBrowse link
G Zfp281 zinc finger protein 281 decreases expression EXP Lidocaine results in decreased expression of ZFP281 mRNA CTD PMID:35283115 NCBI chr13:48,096,103...48,104,265
Ensembl chr13:48,037,286...48,104,888 		JBrowse link
G Zfp597 zinc finger protein 597 decreases expression EXP Lidocaine results in decreased expression of ZFP597 mRNA CTD PMID:35283115 NCBI chr10:11,653,169...11,658,843
Ensembl chr10:11,653,127...11,660,675 		JBrowse link
midodrine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slc47a1 solute carrier family 47 member 1 multiple interactions ISO Midodrine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637 		JBrowse link
G Slc47a2 solute carrier family 47 member 2 multiple interactions ISO Midodrine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] CTD PMID:22419765 NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904 		JBrowse link
monoethylglycinexylidide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ces1d carboxylesterase 1D increases hydrolysis EXP CES1D protein results in increased hydrolysis of monoethylglycinexylidide CTD PMID:12019189 NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects chemical synthesis ISO CYP3A4 protein affects the chemical synthesis of monoethylglycinexylidide CTD PMID:15887009 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
PF-00477736 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO PF 00477736 inhibits the reaction [Mustard Gas results in increased phosphorylation of CDK1 protein] CTD PMID:25448276 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Chek1 checkpoint kinase 1 decreases activity
multiple interactions		 ISO PF 00477736 results in decreased activity of CHEK1 protein
PF 00477736 inhibits the reaction [Mustard Gas results in increased phosphorylation of CHEK1 protein]		 CTD PMID:21707865 PMID:25448276 NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009 		JBrowse link
prilocaine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO Prilocaine results in increased phosphorylation of AKT1 protein CTD PMID:37561044 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Il6 interleukin 6 increases expression ISO Prilocaine results in increased expression of IL6 protein CTD PMID:37561044 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Nos2 nitric oxide synthase 2 increases expression ISO Prilocaine results in increased expression of NOS2 protein CTD PMID:37561044 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Prilocaine results in increased expression of and results in increased phosphorylation of RELA protein CTD PMID:37561044 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
vildagliptin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] CTD PMID:32956689 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP [dapagliflozin co-treated with Vildagliptin] inhibits the reaction [Dietary Fats results in decreased phosphorylation of AKT1 protein]; Vildagliptin inhibits the reaction [Dietary Fats results in decreased phosphorylation of AKT1 protein] CTD PMID:28807765 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Atf4 activating transcription factor 4 decreases expression EXP Vildagliptin results in decreased expression of ATF4 protein CTD PMID:34081941 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atf6 activating transcription factor 6 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of ATF6 protein] CTD PMID:34081941 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP [Vildagliptin co-treated with dapagliflozin] inhibits the reaction [Dietary Fats results in increased expression of BAX protein]; Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of BAX protein] CTD PMID:28807765 PMID:34081941 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP [dapagliflozin co-treated with Vildagliptin] inhibits the reaction [Dietary Fats results in decreased expression of BCL2 protein]; Vildagliptin inhibits the reaction [Dietary Fats results in decreased expression of BCL2 protein] CTD PMID:28807765 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Capn2 calpain 2 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of CAPN2 protein] CTD PMID:34081941 NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969 		JBrowse link
G Casp12 caspase 12 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased cleavage of CASP12 protein] CTD PMID:34081941 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA] CTD PMID:32956689 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of DDIT3 protein] CTD PMID:34081941 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dpp4 dipeptidylpeptidase 4 decreases activity ISO vildagliptin results in decreased activity of DPP4 protein CTD PMID:17287297 PMID:21388136 NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901 		JBrowse link
G Dpp8 dipeptidylpeptidase 8 decreases activity ISO vildagliptin results in decreased activity of DPP8 protein CTD PMID:17287297 NCBI chr 8:65,550,620...65,605,828
Ensembl chr 8:65,550,677...65,605,825 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased phosphorylation of EIF2AK3 protein] CTD PMID:34081941 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased phosphorylation of EIF2S1 protein] CTD PMID:34081941 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased phosphorylation of ERN1 protein] CTD PMID:34081941 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] CTD PMID:32956689 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of HAVCR1 protein] CTD PMID:34081941 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of HSPA5 protein] CTD PMID:34081941 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Ins1 insulin 1 multiple interactions EXP dapagliflozin promotes the reaction [Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of INS1 protein]]; Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of INS1 protein] CTD PMID:28807765 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536 		JBrowse link
G Insr insulin receptor multiple interactions EXP [dapagliflozin co-treated with Vildagliptin] inhibits the reaction [Dietary Fats results in decreased phosphorylation of INSR protein]; Vildagliptin inhibits the reaction [Dietary Fats results in decreased phosphorylation of INSR protein] CTD PMID:28807765 NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883 		JBrowse link
G Lcn2 lipocalin 2 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in increased expression of LCN2 protein] CTD PMID:34081941 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of MAPK1 protein] CTD PMID:32956689 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of MAPK3 protein] CTD PMID:32956689 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of NFKBIA mRNA] CTD PMID:32956689 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Pdgfb platelet derived growth factor subunit B multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFB protein] CTD PMID:32956689 NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP
ISO		 [dapagliflozin co-treated with Vildagliptin] inhibits the reaction [Dietary Fats results in increased phosphorylation of RELA protein]; Vildagliptin inhibits the reaction [Dietary Fats results in increased phosphorylation of RELA protein]
Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA mRNA]; Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of RELA protein]		 CTD PMID:28807765 PMID:32956689 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Slc22a8 solute carrier family 22 member 8 multiple interactions EXP Vildagliptin inhibits the reaction [Dietary Fats results in decreased expression of SLC22A8 protein] CTD PMID:34081941 NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] CTD PMID:32956689 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein] CTD PMID:32956689 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Vildagliptin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] CTD PMID:32956689 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19808
    chemical entity 19806
      atom 19806
        nonmetal atom 19744
          nitrogen atom 18933
            nitrogen molecular entity 18933
              organonitrogen compound 18783
                carboxamide 17526
                  amino acid amide 1457
                    (-)-14-o-malonylindolactam V 0
                    (-)-7-Geranylindolactam V 0
                    (-)-spiromalbramide 0
                    (2R)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide 0
                    (2R,3R)-3-Methylglutamyl-5-semialdehyde-N6-lysine 0
                    (2R,3R,3aS,9bS)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-(cyclohexylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-N-(1,3-thiazol-2-yl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[(4-methyl-1-piperazinyl)-oxomethyl]-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-2-(morpholine-4-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-acetyl-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-acetyl-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-1-acetyl-N-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-2-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-3-(hydroxymethyl)-6-oxo-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-[(2-methoxyphenyl)methyl]-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methyl-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1R)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1S)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-3-(hydroxymethyl)-N2-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-N1-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-(cyclopropylmethyl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-(cyclopropylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-[2-(dimethylamino)-1-oxoethyl]-3-(hydroxymethyl)-6-oxo-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(cyclohexen-1-yl)-3-(hydroxymethyl)-1-(1,3-oxazol-4-ylmethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(cyclohexen-1-yl)-3-(hydroxymethyl)-1-(2-methoxyacetyl)-2-(morpholine-4-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-7-(cyclohexen-1-yl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-1-(cyclopropanecarbonyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-2-(morpholine-4-carbonyl)-1-(1,3-thiazol-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-N-(cyclopropylmethyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-1-methyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1-(pyrimidin-5-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-[oxo(3-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-benzyl-3-(hydroxymethyl)-1-(2-methoxyacetyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2R,3R,3aS,9bS)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                    (2S,3S,3aR,9bR)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-(cyclohexylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-(cyclopropanecarbonyl)-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[(4-methyl-1-piperazinyl)-oxomethyl]-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-2-[4-morpholinyl(oxo)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-acetyl-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-acetyl-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-1-acetyl-N-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-6-oxo-N-(phenylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-[(2-methoxyphenyl)methyl]-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methyl-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1R)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1S)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-3-(hydroxymethyl)-N2-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-N1-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-1-[2-(dimethylamino)-1-oxoethyl]-3-(hydroxymethyl)-6-oxo-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2-[4-morpholinyl(oxo)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-1-(4-oxazolylmethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-[cyclopropyl(oxo)methyl]-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(cyclohexen-1-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(cyclohexen-1-yl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-2-(morpholine-4-carbonyl)-1-(1,3-thiazol-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                    (2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-N-(cyclopropylmethyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-1-methyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1-(5-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-[oxo(3-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                    (2S,3S,3aR,9bR)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                    (3S,3'aR,8'aS,8'bS)-5-ethyl-2'-(phenylmethyl)spiro[1H-indole-3,4'-3a,6,7,8,8a,8b-hexahydropyrrolo[3,4-a]pyrrolizine]-1',2,3'-trione 0
                    (3S,4aR,8aR)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide 0
                    (3aR,4S,9aR,9bS)-N,2-bis(4-chlorophenyl)-1,3-dioxo-3a,4,9a,9b-tetrahydropyrrolo[1,2]pyrrolo[3,5-b]pyridazine-4-carboxamide 0
                    (3aR,4S,9aR,9bS)-N-(4-chlorophenyl)-2-(4-fluorophenyl)-1,3-dioxo-3a,4,9a,9b-tetrahydropyrrolo[1,2]pyrrolo[3,5-b]pyridazine-4-carboxamide 0
                    (R)-2-Amino-N-(2,2,4,4-tetramethyl-3-thietanyl)propanamide 0
                    (R)-carnitinamide + 0
                    (R,S)-piperazin-4-ium-2-tert-butylcarboxamide(1+) 0
                    (S)-2',6'-Pipecoloxylidide 0
                    (S)-Piperidine-2-carboxamide 0
                    1-(4-benzylpiperazino)-2-(pyridin-2-ylamino)propan-1-one 0
                    1-(4-methyl-1-piperazinyl)-2-[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]ethanone 0
                    1-(4-tert-butylphenyl)sulfonyl-N-(2-pyridinylmethyl)-2-piperidinecarboxamide 0
                    1-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxo-1-phenylethyl]-4-piperidinecarboxylic acid ethyl ester 0
                    12-epi-lyngbyatoxin A 0
                    2,3-seco-2,3-dioxo-lyngbyatoxin A 0
                    2,6-Pipecoloxylidide 0
                    2-(1,3-benzodioxol-5-ylamino)-N-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetamide 0
                    2-(1,3-benzodioxol-5-ylmethylamino)-N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)acetamide 0
                    2-(1-azepanyl)-N-[4-(dimethylsulfamoyl)phenyl]acetamide 0
                    2-(2,3-dimethylanilino)-N-(2,3-dimethylphenyl)acetamide 0
                    2-(2-chloro-4-methylanilino)-N-[3-(dimethylsulfamoyl)phenyl]acetamide 0
                    2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-(1-phenylethyl)acetamide 0
                    2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-(3-pyridinylmethyl)acetamide 0
                    2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide 0
                    2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-N-(4-propan-2-ylphenyl)acetamide 0
                    2-(4-methyl-1-piperazinyl)-N-(5-thiophen-2-yl-1,3,4-thiadiazol-2-yl)acetamide 0
                    2-(4-methyl-1-piperidinyl)-N-[2-(phenylthio)phenyl]acetamide 0
                    2-(5-chloro-2,4-dimethoxyanilino)-1-(4-ethyl-1-piperazinyl)-1-propanone 0
                    2-(benzenesulfonamido)-N-[(2-methoxyphenyl)methyl]propanamide 0
                    2-(butan-2-ylamino)-N-[4-[5-[[2-(butan-2-ylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide 0
                    2-(butylamino)-N-[4-[5-[[2-(butylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide 0
                    2-(cyclohexylamino)-N-(4-ethylphenyl)-2-sulfanylideneacetamide 0
                    2-(dimethylamino)-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2R,3R,6S)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2R,3S,6R)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[oxo-(propan-2-ylamino)methyl]amino]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3R,6S)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3S,6R)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                    2-(dimethylamino)-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                    2-(p-hydroxyphenyl)glycinamide + 0
                    2-Piperidinecarboxamide, 1-butyl-N-(4-hydroxy-2,6-dimethylphenyl)- 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                    2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                    2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                    2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,3R,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2R,3R,6R)-3-[[2-(dimethylamino)acetyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,3R,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,3R,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2R,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2R,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,3R,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,3R,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,3R,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2S,3R,6S)-3-[[2-(dimethylamino)acetyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                    2-[(2S,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(2S,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                    2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                    2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                    2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(3-methoxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylhydrazo]-2-oxo-N-(3-pyridinylmethyl)acetamide 0
                    2-[(5-bromo-2-thiophenyl)sulfonylamino]-N-cyclopentyl-2-phenylacetamide 0
                    2-[1-[(2-chloro-6-fluorophenyl)methyl]-3-oxo-2-piperazinyl]-N-prop-2-enylacetamide 0
                    2-[2-(difluoromethoxy)anilino]-1-(2,3-dihydroindol-1-yl)ethanone 0
                    2-[4-[2-(3,5-dimethoxyanilino)-2-oxoethyl]-1-piperazinyl]-N-(4-ethoxyphenyl)acetamide 0
                    2-[[2-(2,4-dichlorophenoxy)-1-oxopropyl]hydrazo]-N-(4-methoxyphenyl)-2-oxoacetamide 0
                    2-[[2-(3-chloro-4-fluoroanilino)-2-oxoethyl]-methylamino]-N-(4-methylphenyl)acetamide 0
                    2-[[2-(4-chlorophenoxy)-1-oxoethyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide 0
                    2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid methyl ester 0
                    2-[[2-[(2,5-dimethylphenyl)sulfonylamino]-1-oxoethyl]amino]-6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide 0
                    2-[[2-[3-(1-azepanylsulfonyl)-4-methylanilino]-2-oxoethyl]-methylamino]-N-(3-fluorophenyl)acetamide 0
                    2-[[2-furanyl(oxo)methyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide 0
                    2-[[3-Cyclohexyl-1-[2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid 0
                    2-[[4-amino-6-(2-methylanilino)-1,3,5-triazin-2-yl]methyl-methylamino]-N-(2-ethylphenyl)acetamide 0
                    2-[carboxymethyl-[2-(2,6-diethylanilino)-2-oxoethyl]amino]acetic acid 0
                    2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]-N-(3-fluorophenyl)acetamide 0
                    2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]-N-[2-(methylthio)phenyl]acetamide 0
                    2-\{6-Oxo-6-[4-(L-phenylalanyl)-1-piperazinyl]hexyl\}guanidine 0
                    2-amino-2',6'-butyroxylidide 0
                    2-amino-4-(methylsulfanyl)-N-(2-naphthyl)butanamide + 0
                    2-amino-N-(2'-(cyclohex-2''-enyl)acetyl)acetimide 0
                    2-amino-N-2'-(phenylacetyl)propanimide 0
                    2-aminohexano-6-lactam + 0
                    2-anilino-N-(3,5-dimethylphenyl)-2-phenylacetamide 0
                    2-anilino-N-(4-fluorophenyl)acetamide 0
                    2-anilino-N-(4-methylphenyl)-2-phenylacetamide 0
                    2-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                    2-oxo-2-[(6-oxo-1-cyclohexa-2,4-dienylidene)methylhydrazo]-N-(2-pyridinyl)acetamide 0
                    2-oxo-3(R)-hydroxy-lyngbyatoxin A 0
                    3'-Hydroxyropivacaine 0
                    3,4-dihydro-1H-isoquinolin-2-yl-[1-(8-quinolinylsulfonyl)-2-pyrrolidinyl]methanone 0
                    3-(3-bromoanilino)-2-oxo-1H-indole-3-carbonitrile 0
                    3-Hydroxylidocaine 0
                    3-Hydroxymonoethylglycinexylidide 0
                    3-[(3aR,6aS)-6'-chloro-5-(4-chlorophenyl)-7'-methyl-2',4,6-trioxo-1-spiro[1,2,3a,6a-tetrahydropyrrolo[3,4-c]pyrrole-3,3'-1H-indole]yl]propanamide 0
                    3-[(4-methoxyphenyl)hydrazo]-2-nitroso-N-phenyl-2-butenamide 0
                    3-[[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]-2-benzofurancarboxylic acid ethyl ester 0
                    3-chloro-N-[1-[[2-(dimethylamino)-1-oxoethyl]amino]-3-[4-[8-(1-hydroxyethyl)-2-imidazo[1,2-a]pyridinyl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide 0
                    3-chloro-N-[1-[[2-(dimethylamino)-1-oxoethyl]amino]-3-[4-[8-[(1S)-1-hydroxyethyl]-2-imidazo[1,2-a]pyridinyl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide 0
                    3-fluoro-N-[1-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-4-piperidinyl]benzamide 0
                    3-methyl-5-[[1-oxo-2-(2-pyridinylmethylamino)ethyl]amino]thiophene-2,4-dicarboxylic acid diethyl ester 0
                    4'-Hydroxyropivacaine 0
                    4-(5-methyl-2-furanyl)-2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3-thiophenecarboxylic acid ethyl ester 0
                    4-Hydroxylidocaine 0
                    4-amino-5-[(2R)-2-borono-1-pyrrolidinyl]-5-oxopentanoic acid 0
                    5-(alpha-Phenylethyl)semioxamazide 0
                    5-bromo-3-[[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]-2-benzofurancarboxylic acid ethyl ester 0
                    5-carbamoyl-4-methyl-2-[[1-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester 0
                    5-hydroxy saxagliptin 0
                    5-oxo-L-proline 2-naphthylamide 0
                    6-methyl-2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester 0
                    8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one 0
                    A 80987 0
                    BILA 2185BS 0
                    BY-81 0
                    Bactobolin 0
                    Blastmycetin A 0
                    Blastmycetin B 0
                    Blastmycetin C 0
                    Blastmycetin D 0
                    Blastmycetin E 0
                    Blastmycetin F 0
                    Calpeptin 26
                    Chrysogenamide A 0
                    Citrinalin C 0
                    Collacyclumin B 0
                    Cycloexpansamine A 0
                    Cytoblastin 0
                    Descarbonyl-lacosamide 0
                    Dl-norleucinamide 0
                    Etidocaine hydrochloride 0
                    Eusynstyelamide D 0
                    Eusynstyelamide E 0
                    Eusynstyelamide F 0
                    FR900452 0
                    Fasoracetam 0
                    Glycyl-H-1152 0
                    HEHEAA 0
                    Hoiamide D 0
                    Hydroxy-lacosamide 0
                    Iprofenin 0
                    L-alaninamide 0
                    L-alanine 2-naphthylamide 0
                    L-arginine 2-naphthylamide 0
                    L-arginine amide 0
                    L-asparagine 2-naphthylamide 0
                    L-asparagine amide 0
                    L-cysteine 2-naphthylamide 0
                    L-cystine di-2-naphthylamide 0
                    L-cystine mono-2-naphthylamide 0
                    L-glutamine 2-naphthylamide 0
                    L-glutamine amide + 0
                    L-histidine 2-naphthylamide 0
                    L-histidine amide 0
                    L-hydroxyproline 2-naphthylamide 0
                    L-isoleucinamide 0
                    L-isoleucine 2-naphthylamide 0
                    L-leucinamide 0
                    L-leucine 2-naphthylamide 0
                    L-leucine 4-methoxy-2-naphthylamide 0
                    L-lysinamide + 0
                    L-lysine 2-naphthylamide 0
                    L-methioninamide + 0
                    L-ornithine 2-naphthylamide 0
                    L-phenylalanine 2-naphthylamide 0
                    L-phenylalanine amide + 0
                    L-prolinamide 0
                    L-proline 2-naphthylamide 0
                    L-serine 2-naphthylamide 0
                    L-serine amide 0
                    L-threonine 2-naphthylamide 0
                    L-threonine amide 0
                    L-tryptophan 2-naphthylamide 0
                    L-tryptophanamide + 0
                    L-tyrosinamide 0
                    L-tyrosine 2-naphthylamide 0
                    L-valine 2-naphthylamide 0
                    L-valine amide 0
                    LSM-10083 0
                    LSM-10230 0
                    LSM-10322 0
                    LSM-11913 0
                    LSM-12220 0
                    LSM-14484 0
                    LSM-14577 0
                    LSM-14579 0
                    LSM-14581 0
                    LSM-14585 0
                    LSM-14589 0
                    LSM-14591 0
                    LSM-14592 0
                    LSM-14593 0
                    LSM-14594 0
                    LSM-14597 0
                    LSM-14601 0
                    LSM-14603 0
                    LSM-14605 0
                    LSM-14606 0
                    LSM-14607 0
                    LSM-14609 0
                    LSM-14610 0
                    LSM-14612 0
                    LSM-14613 0
                    LSM-14614 0
                    LSM-14618 0
                    LSM-14621 0
                    LSM-14625 0
                    LSM-14626 0
                    LSM-14629 0
                    LSM-14631 0
                    LSM-14633 0
                    LSM-14634 0
                    LSM-14636 0
                    LSM-14640 0
                    LSM-14641 0
                    LSM-14650 0
                    LSM-14651 0
                    LSM-14657 0
                    LSM-14663 0
                    LSM-14664 0
                    LSM-14666 0
                    LSM-14667 0
                    LSM-14672 0
                    LSM-24595 0
                    LSM-26278 0
                    LSM-33227 0
                    LSM-36762 0
                    LSM-42687 0
                    LSM-4274 0
                    LSM-4415 0
                    LSM-8595 0
                    LSM-8885 0
                    LSM-9109 0
                    LSM-9223 0
                    LSM-9303 0
                    LSM-9808 0
                    LSM-9820 0
                    Lipoxamycin 0
                    Lycomarasmine B 0
                    Lyngbyatoxin C 0
                    Majusculamide A/B 0
                    Marcfortine C 0
                    Milacainide tartrate 0
                    N'-(4-phenyl-2-thiazolyl)-N-(2-pyridinylmethyl)oxamide 0
                    N'-[(2,5-dimethyl-1-phenyl-3-pyrrolyl)methylideneamino]-N-(2-pyridinylmethyl)oxamide 0
                    N'-[(4-chlorophenyl)methyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]oxamide 0
                    N'-[2-[1-(4-fluoro-2-methylphenyl)sulfonyl-2-piperidinyl]ethyl]-N-methyloxamide 0
                    N'-[4-(1-adamantyl)-2-thiazolyl]-N-[(4-fluorophenyl)methyl]oxamide 0
                    N'-[4-(dimethylamino)phenyl]-N-propyloxamide 0
                    N(2)-(cyclohexylsulfonyl)-N-[(1R)-1-(piperidin-1-ylcarbonyl)-3-(pyridinium-4-ylamino)propyl]glycinamide 0
                    N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-alaninamide 0
                    N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-cysteinamide 0
                    N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-serinamide 0
                    N(2)-\{3-[2-(2-\{[(1-\{3-[2-(2-\{[4-(indol-3-yl)butanoyl]amino\}ethoxy)ethoxy]propanoyl\}piperidin-4-yl)carbonyl]amino\}ethoxy)ethoxy]propanoyl\}-N(6)-(5-nitro-2-furoyl)lysinamide 0
                    N(6)-Dnp-Lys-NH2 0
                    N(6)-carbamoylmethyl-2'-deoxyadenosine 0
                    N(6)-carbamoylmethyl-2'-deoxyadenosine 5'-monophosphate 0
                    N(6)-carbamoylmethyladenine 0
                    N,N'-diisobutyloxalamide 0
                    N-(1,3-benzodioxol-5-yl)-2-(3-methyl-1-piperidinyl)-2-phenylacetamide 0
                    N-(1,3-benzodioxol-5-yl)-2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]acetamide 0
                    N-(1,3-benzodioxol-5-yl)-2-[4-(4-phenyl-2-thiazolyl)-1-piperazinyl]acetamide 0
                    N-(1,3-benzodioxol-5-yl)-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide 0
                    N-(1,3-benzothiazol-2-yl)-2-(2,6-dimethyl-4-morpholinyl)acetamide 0
                    N-(1,3-benzothiazol-2-yl)-2-ethylsulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-1-piperidinyl)-2-phenylacetamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(3-methoxyphenyl)methylamino]propanamide 0
                    N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[4-(2,5-dimethylphenyl)sulfonyl-1-piperazinyl]acetamide 0
                    N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)-2-(propan-2-ylamino)acetamide 0
                    N-(2,5-difluorophenyl)-2-(1-pyrrolidinyl)acetamide 0
                    N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide 0
                    N-(2-bromophenyl)-2-[5-(dimethylsulfamoyl)-2-(ethylamino)anilino]acetamide 0
                    N-(2-bromophenyl)-2-[[2-(2,6-dimethylanilino)-2-oxoethyl]-methylamino]acetamide 0
                    N-(2-butan-2-ylphenyl)-2-[(3-methoxyphenyl)methyl-methylamino]propanamide 0
                    N-(2-fluorophenyl)-N'-[[2-[2-oxo-2-(1-pyrrolidinyl)ethoxy]phenyl]methylideneamino]oxamide 0
                    N-(2-furanylmethyl)-2-[(5-methoxy-6-oxo-1-cyclohexa-2,4-dienylidene)methylhydrazo]-2-oxoacetamide 0
                    N-(2-methylphenyl)-N'-[[4-oxo-4-(2-pyridinylamino)butan-2-ylidene]amino]oxamide 0
                    N-(3,4-dichlorophenyl)-2-[4-(1-piperidinylsulfonyl)-1-piperazinyl]acetamide 0
                    N-(3-chloro-2-methylphenyl)-2-[(2-fluorophenyl)methylamino]acetamide 0
                    N-(3-chloro-2-methylphenyl)-2-[3-(dimethylsulfamoyl)anilino]acetamide 0
                    N-(3-chloro-4-fluorophenyl)-2-[5-(dimethylsulfamoyl)-2-(ethylamino)anilino]acetamide 0
                    N-(3-chloro-4-methylphenyl)-2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)acetamide 0
                    N-(3-chlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide 0
                    N-(3-cyano-2-thiophenyl)-2-[4-(2,5-dimethylphenyl)sulfonyl-1-piperazinyl]acetamide 0
                    N-(3-fluorophenyl)-2-oxo-4,10-dihydro-3H-pyrimido[1,2-a]benzimidazole-4-carboxamide 0
                    N-(4-Chloro-3-cyanophenyl)-N'-[2-(4-methoxyphenyl)ethyl]ethanediamide 0
                    N-(4-bromo-2-fluorophenyl)-2-(2,4-dimethoxyanilino)acetamide 0
                    N-(4-cyano-1-phenyl-1H-pyrazol-5-yl)-2-(4-methylpiperazino)acetamide 0
                    N-(4-fluorophenyl)-2-[4-[oxo(1-piperidinyl)methyl]-1-piperazinyl]acetamide 0
                    N-(4-methoxyphenyl)-2-(N-methylanilino)-2-(6-nitro-1,3-benzodioxol-5-yl)acetamide 0
                    N-(4-nitrophenyl)-2-(1-pyrrolidinyl)acetamide 0
                    N-(5-chloro-2-methoxyphenyl)-2-[4-(3-phenylprop-2-enyl)-1-piperazinyl]propanamide 0
                    N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-(2-fluorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxamide 0
                    N-(6-acetyl-1,3-benzodioxol-5-yl)-2-(2-methyl-1-piperidinyl)acetamide 0
                    N-(6-acetyl-1,3-benzodioxol-5-yl)-2-(4-ethyl-1-piperazinyl)acetamide 0
                    N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[4-[5-(trifluoromethyl)-1-benzotriazolyl]-1-piperidinyl]acetamide 0
                    N-(alpha-L-aspartyl)-2-naphthylamine 0
                    N-(alpha-L-glutamyl)-2-naphthylamine 0
                    N-(gamma-L-glutamyl)-2-naphthylamine 0
                    N-Demethylteleocidin B-4 0
                    N-Tert-butyl-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide 0
                    N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-(2-oxo-2-piperidin-1-ylethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3R,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3R,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3S,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1R,3S,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3R,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3R,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3S,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(1S,3S,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                    N-[(2R,3R,4aS,6S,8aS)-2-[2-[4-(1-cyclohexenyl)phenyl]ethyl]-6-(hydroxymethyl)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-3-yl]-2-(dimethylamino)acetamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2R,3R,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3R,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2R,3R,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3R,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2R,3S,6R)-6-[2-(4-cyclohexyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-2-morpholin-4-ylacetamide 0
                    N-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3S,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2R,3S,6S)-6-[2-(4-cyclohexyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-2-morpholin-4-ylacetamide 0
                    N-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2R,3S,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2S,3R,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3R,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2S,3R,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3R,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2S,3S,6R)-6-[2-(4-cyclohexyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-2-morpholin-4-ylacetamide 0
                    N-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3S,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                    N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                    N-[(2S,3S,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(2S,3S,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(3-fluorophenyl)methyl]-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-[(4-chlorophenyl)methyl]-2-[[[(2-fluorophenyl)methyl-(phenylmethyl)amino]-sulfanylidenemethyl]amino]acetamide 0
                    N-[2-(1H-benzimidazol-2-yl)ethyl]-2-[4-(5-fluoro-1-benzotriazolyl)-1-piperidinyl]acetamide 0
                    N-[2-(2-ethyl-1-piperidinyl)ethyl]-2-[(2-methyl-1,3-benzothiazol-6-yl)sulfonylamino]acetamide 0
                    N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)oxamide 0
                    N-[2-(4-chlorophenyl)ethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide 0
                    N-[2-(cyclopentylamino)-2-oxoethyl]-4,7-dimethyl-N-(2-methylphenyl)-2-oxo-3H-pyrido[1,2-a]pyrimidine-4-carboxamide 0
                    N-[2-(diethylamino)-5-(4-morpholinylsulfonyl)phenyl]-2-[(phenylmethyl)amino]acetamide 0
                    N-[2-[(2R,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2S,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2S,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-[(2S,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-2-morpholin-4-ylacetamide 0
                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                    N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                    N-[2-chloro-5-[ethyl(phenyl)sulfamoyl]phenyl]-2-[methyl-(1-methyl-4-piperidinyl)amino]acetamide 0
                    N-[4-(1,3-benzothiazol-2-yl)phenyl]-2-[(4-tert-butylphenyl)sulfonylamino]acetamide 0
                    N-[4-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-2-thiazolyl]-2-(4-morpholinyl)acetamide 0
                    N-[4-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-5-methyl-2-thiazolyl]-2-(4-morpholinyl)acetamide 0
                    N-[4-chloro-3-(dimethylsulfamoyl)phenyl]-2-[(phenylmethyl)amino]acetamide 0
                    N-[5-[[2-(4-methylanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-2-(4-morpholinyl)acetamide 0
                    N-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                    N-[[(2R,3R,4S)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                    N-[[(2R,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                    N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                    N-[[(2R,3S,4S)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                    N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                    N-[[(2S,3R,4R)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                    N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                    N-[[(2S,3S,4R)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                    N-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                    N-[[3-(4-nitrophenyl)sulfonyl-2-oxazolidinyl]methyl]-N'-(2-pyridinylmethyl)oxamide 0
                    N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide 0
                    N-acetylglycine-N-methylamide 0
                    N-cycloheptyl-2-(cyclohexylamino)-2-sulfanylideneacetamide 0
                    N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                    N-cyclohexyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclohexyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                    N-cyclopentyl-2-(2,3-dihydroindol-1-yl)-2-(4-methoxyphenyl)acetamide 0
                    N-decyl-N'-(2-pyridinyl)oxamide 0
                    N-propan-2-yl-2-[4-(2-pyrimidinyl)-1-piperazinyl]acetamide 0
                    N-tert-butyl-2-[[(3-nitrophenyl)-oxomethyl]hydrazo]-2-oxoacetamide 0
                    N1-(2,4-Dimethoxybenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide 0
                    N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(5-methylpyridin-2-yl)ethyl)oxalamide 0
                    N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide 0
                    N1-(4-butyl-2-methylphenyl)-2-(benzylamino)-2-thioxoacetamide 0
                    N1-(4-nitrophenyl)-2-amino-3-(benzylthio)propanamide 0
                    N2,N6-Diacetyl-N-\{4-[hydroxy(phenyl)methyl]phenyl\}lysinamide 0
                    Neoenactin B1 0
                    Neoenactin B2 0
                    Neoenactin M2 0
                    Neoenactin NL1 0
                    Neoenactin NL2 0
                    Olivoretin A 0
                    Olivoretin B 0
                    Olivoretin E 0
                    Oxethazaine 0
                    PF-00477736 2
                    Pantocin B 0
                    Peniciherquamide A 0
                    Penicimutide 0
                    Penioxalamine A 0
                    Phenylacetylglycine dimethylamide 0
                    Prumycin 0
                    Pyrronamycin A 0
                    Pyrronamycin B 0
                    SB200437 0
                    Safracin A 0
                    Saframycin Mx1 0
                    Serratiochelin C 0
                    Teleocidin A-2 0
                    Teleocidin B-1 0
                    Teleocidin B-2 0
                    Teleocidin B-3 0
                    Teleocidin B4 0
                    VM-55595 0
                    Y-14556 0
                    [(3R)-3-aMino-4-[(3-hexylphenyl)aMino]-4-oxobutyl]-phosphonic acid 0
                    [2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium 0
                    [2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-methylammonium 0
                    [2-(2,6-dimethylanilino)-2-oxoethyl]-trimethylammonium 0
                    alpha-N-(9-beta-D-ribofuranosylpurin-6-yl)glycinamide 0
                    ambucetamide 0
                    aminopropylone 0
                    amoxicilloyl polylysine 0
                    anagliptin 11
                    aspartic 1-amide + 0
                    benzylpenicilloyl polylysine 0
                    beta-alaninamide 0
                    beta-alanine 2-naphthylamide 0
                    beta-alanine, n-[2-[(3-hexylphenyl)amino]-2-oxoethyl]- 0
                    biocytinamide 0
                    bortezomib 833
                    butanilicaine 0
                    cefatrizine 0
                    disofenin 0
                    eluxadoline 1
                    ent-Eusynstyelamide B, (rel)- 0
                    etidocaine 0
                    glycinamide + 645
                    glycine 2-naphthylamide 0
                    glycinexylidide + 0
                    gosogliptin 0
                    isoglutamine + 0
                    isopropyl (3-methyl-1-\{[1-(4-methylphenyl)ethyl]amino\}-1-oxobutan-2-yl)carbamate + 0
                    lidofenin 0
                    lisdexamfetamine 0
                    majusculamide A 0
                    majusculamide B 0
                    mebrofenin 0
                    methyl 2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetate 0
                    midodrine 2
                    monoethylglycinexylidide + 2
                    phenamine 0
                    prilocaine + 4
                    proline 2-naphthylamide 0
                    pyrrocaine 0
                    safinamide 0
                    teneligliptin 0
                    trimecaine 0
                    trimethyl-[2-oxo-2-[(2,2,3-trimethyl-3-bicyclo[2.2.1]heptanyl)amino]ethyl]ammonium 0
                    tryparsamide 0
                    versetamide 0
                    vildagliptin 30
Path 2
Term Annotations click to browse term
  CHEBI ontology 19808
    subatomic particle 19806
      composite particle 19806
        hadron 19806
          baryon 19806
            nucleon 19806
              atomic nucleus 19806
                atom 19806
                  main group element atom 19756
                    p-block element atom 19756
                      carbon group element atom 19705
                        carbon atom 19702
                          organic molecular entity 19702
                            heteroorganic entity 19460
                              organochalcogen compound 19224
                                organooxygen compound 19141
                                  carbon oxoacid 18612
                                    carboxylic acid 18609
                                      carboacyl group 17677
                                        univalent carboacyl group 17677
                                          carbamoyl group 17526
                                            carboxamide 17526
                                              amino acid amide 1457
                                                (-)-14-o-malonylindolactam V 0
                                                (-)-7-Geranylindolactam V 0
                                                (-)-spiromalbramide 0
                                                (2R)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide 0
                                                (2R,3R)-3-Methylglutamyl-5-semialdehyde-N6-lysine 0
                                                (2R,3R,3aS,9bS)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-(cyclohexylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-(cyclopentylmethyl)-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-N-(1,3-thiazol-2-yl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[(4-methyl-1-piperazinyl)-oxomethyl]-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-2-(morpholine-4-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-[cyclopropyl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-acetyl-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-acetyl-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-1-acetyl-N-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-2-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-3-(hydroxymethyl)-6-oxo-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-[(2-methoxyphenyl)methyl]-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methyl-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1R)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1S)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-2-(piperidine-1-carbonyl)-1-propanoyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-3-(hydroxymethyl)-N2-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-N1-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-(cyclopropylmethyl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-(cyclopropylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-1-[2-(dimethylamino)-1-oxoethyl]-3-(hydroxymethyl)-6-oxo-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(1-cyclopentenyl)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(cyclohexen-1-yl)-3-(hydroxymethyl)-1-(1,3-oxazol-4-ylmethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(cyclohexen-1-yl)-3-(hydroxymethyl)-1-(2-methoxyacetyl)-2-(morpholine-4-carbonyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-7-(cyclohexen-1-yl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-1-(cyclopropanecarbonyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-2-(morpholine-4-carbonyl)-1-(1,3-thiazol-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2R,3R,3aS,9bS)-7-(cyclopenten-1-yl)-N-(cyclopropylmethyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-1-methyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1-(pyrimidin-5-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-[oxo(3-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-benzyl-3-(hydroxymethyl)-1-(2-methoxyacetyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2R,3R,3aS,9bS)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                                (2S,3S,3aR,9bR)-1-(1,3-benzodioxol-5-ylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-(cyclohexylmethyl)-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-(cyclopropanecarbonyl)-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[(4-methyl-1-piperazinyl)-oxomethyl]-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-2-[4-morpholinyl(oxo)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-1-[(2,5-difluorophenyl)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-7-pyrimidin-5-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-1-[(3-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-(2,2,2-trifluoroethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-[cyclobutyl(oxo)methyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-acetyl-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-acetyl-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-1-acetyl-N-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-2-[3,4-dihydro-1H-isoquinolin-2-yl(oxo)methyl]-3-(hydroxymethyl)-6-oxo-N-propan-2-yl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-6-oxo-N-(phenylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-[(2-methoxyphenyl)methyl]-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methyl-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1R)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-[(1S)-1-phenylethyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-3-(hydroxymethyl)-N2-[2-(1-methyl-4-imidazolyl)ethyl]-6-oxo-N1-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-N-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-1-[2-(dimethylamino)-1-oxoethyl]-3-(hydroxymethyl)-6-oxo-N-(2-thiazolyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-2-[4-morpholinyl(oxo)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-1-(4-oxazolylmethyl)-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-1-(2-pyridinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(1-oxopropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-(cyclopropylmethyl)-3-(hydroxymethyl)-2-[oxo(1-piperidinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-[(2-fluorophenyl)-oxomethyl]-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-[cyclopropyl(oxo)methyl]-N-ethyl-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-1-ethyl-3-(hydroxymethyl)-N-[(3-methoxyphenyl)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-1-methylsulfonyl-6-oxo-N-(2-pyridin-4-ylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-3-(hydroxymethyl)-6-oxo-N-[(1R)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(1-cyclopentenyl)-N-[3-(dimethylamino)propyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(cyclohexen-1-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(cyclohexen-1-yl)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-2-(morpholine-4-carbonyl)-1-(1,3-thiazol-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizin-6-one 0
                                                (2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-3-(hydroxymethyl)-6-oxo-N-[(1S)-1-phenylethyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-7-(cyclopenten-1-yl)-N-(cyclopropylmethyl)-1-[(2-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-1-methyl-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-[oxo(2-pyrazinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-(cyclohexylmethyl)-1-(2-cyclopropyl-1-oxoethyl)-3-(hydroxymethyl)-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-1-(5-pyrimidinylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-(3,3,3-trifluoropropyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)-6-oxo-1-[oxo(3-pyridinyl)methyl]-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide 0
                                                (2S,3S,3aR,9bR)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide 0
                                                (3S,3'aR,8'aS,8'bS)-5-ethyl-2'-(phenylmethyl)spiro[1H-indole-3,4'-3a,6,7,8,8a,8b-hexahydropyrrolo[3,4-a]pyrrolizine]-1',2,3'-trione 0
                                                (3S,4aR,8aR)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide 0
                                                (3aR,4S,9aR,9bS)-N,2-bis(4-chlorophenyl)-1,3-dioxo-3a,4,9a,9b-tetrahydropyrrolo[1,2]pyrrolo[3,5-b]pyridazine-4-carboxamide 0
                                                (3aR,4S,9aR,9bS)-N-(4-chlorophenyl)-2-(4-fluorophenyl)-1,3-dioxo-3a,4,9a,9b-tetrahydropyrrolo[1,2]pyrrolo[3,5-b]pyridazine-4-carboxamide 0
                                                (R)-2-Amino-N-(2,2,4,4-tetramethyl-3-thietanyl)propanamide 0
                                                (R)-carnitinamide + 0
                                                (R,S)-piperazin-4-ium-2-tert-butylcarboxamide(1+) 0
                                                (S)-2',6'-Pipecoloxylidide 0
                                                (S)-Piperidine-2-carboxamide 0
                                                1-(4-benzylpiperazino)-2-(pyridin-2-ylamino)propan-1-one 0
                                                1-(4-methyl-1-piperazinyl)-2-[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]ethanone 0
                                                1-(4-tert-butylphenyl)sulfonyl-N-(2-pyridinylmethyl)-2-piperidinecarboxamide 0
                                                1-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxo-1-phenylethyl]-4-piperidinecarboxylic acid ethyl ester 0
                                                12-epi-lyngbyatoxin A 0
                                                2,3-seco-2,3-dioxo-lyngbyatoxin A 0
                                                2,6-Pipecoloxylidide 0
                                                2-(1,3-benzodioxol-5-ylamino)-N-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetamide 0
                                                2-(1,3-benzodioxol-5-ylmethylamino)-N-(1,5-dimethyl-3-oxo-2-phenyl-4-pyrazolyl)acetamide 0
                                                2-(1-azepanyl)-N-[4-(dimethylsulfamoyl)phenyl]acetamide 0
                                                2-(2,3-dimethylanilino)-N-(2,3-dimethylphenyl)acetamide 0
                                                2-(2-chloro-4-methylanilino)-N-[3-(dimethylsulfamoyl)phenyl]acetamide 0
                                                2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-(1-phenylethyl)acetamide 0
                                                2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-(3-pyridinylmethyl)acetamide 0
                                                2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide 0
                                                2-(3-oxo-2,4-dihydroquinoxalin-1-yl)-2-phenyl-N-(4-propan-2-ylphenyl)acetamide 0
                                                2-(4-methyl-1-piperazinyl)-N-(5-thiophen-2-yl-1,3,4-thiadiazol-2-yl)acetamide 0
                                                2-(4-methyl-1-piperidinyl)-N-[2-(phenylthio)phenyl]acetamide 0
                                                2-(5-chloro-2,4-dimethoxyanilino)-1-(4-ethyl-1-piperazinyl)-1-propanone 0
                                                2-(benzenesulfonamido)-N-[(2-methoxyphenyl)methyl]propanamide 0
                                                2-(butan-2-ylamino)-N-[4-[5-[[2-(butan-2-ylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide 0
                                                2-(butylamino)-N-[4-[5-[[2-(butylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide 0
                                                2-(cyclohexylamino)-N-(4-ethylphenyl)-2-sulfanylideneacetamide 0
                                                2-(dimethylamino)-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2R,3R,6S)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2R,3S,6R)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[oxo-(propan-2-ylamino)methyl]amino]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3R,6S)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3S,6R)-6-[2-[[(4-fluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]acetamide 0
                                                2-(dimethylamino)-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[4-(3-methoxyphenyl)-1-triazolyl]ethyl]-3-oxanyl]acetamide 0
                                                2-(p-hydroxyphenyl)glycinamide + 0
                                                2-Piperidinecarboxamide, 1-butyl-N-(4-hydroxy-2,6-dimethylphenyl)- 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1R,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                                                2-[(1R,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1R,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1S,3R,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aR,9aS)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(cyclopropylmethyl)acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(pyridin-4-ylmethyl)acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2,5-difluorophenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(3-fluorophenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-chlorophenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-cyclohexylacetamide 0
                                                2-[(1S,3S,4aS,9aR)-6-[[2-(dimethylamino)-1-oxoethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]acetic acid methyl ester 0
                                                2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,3R,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2R,3R,6R)-3-[[2-(dimethylamino)acetyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,3R,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,3R,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2R,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2R,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,3R,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,3R,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,3R,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2S,3R,6S)-3-[[2-(dimethylamino)acetyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,3S,6R)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[(2-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,3S,6S)-3-[[2-(dimethylamino)-1-oxoethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-[2-(1-piperidinyl)ethyl]acetamide 0
                                                2-[(2S,5R,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,5R,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,5S,6R)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(2S,5S,6S)-5-[[2-(dimethylamino)-1-oxoethyl]amino]-6-(hydroxymethyl)-2-oxanyl]-N-[(4-methoxyphenyl)methyl]acetamide 0
                                                2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-(2-pyridin-4-ylethyl)acetamide 0
                                                2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide 0
                                                2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide 0
                                                2-[(3-methoxy-4-oxo-1-cyclohexa-2,5-dienylidene)methylhydrazo]-2-oxo-N-(3-pyridinylmethyl)acetamide 0
                                                2-[(5-bromo-2-thiophenyl)sulfonylamino]-N-cyclopentyl-2-phenylacetamide 0
                                                2-[1-[(2-chloro-6-fluorophenyl)methyl]-3-oxo-2-piperazinyl]-N-prop-2-enylacetamide 0
                                                2-[2-(difluoromethoxy)anilino]-1-(2,3-dihydroindol-1-yl)ethanone 0
                                                2-[4-[2-(3,5-dimethoxyanilino)-2-oxoethyl]-1-piperazinyl]-N-(4-ethoxyphenyl)acetamide 0
                                                2-[[2-(2,4-dichlorophenoxy)-1-oxopropyl]hydrazo]-N-(4-methoxyphenyl)-2-oxoacetamide 0
                                                2-[[2-(3-chloro-4-fluoroanilino)-2-oxoethyl]-methylamino]-N-(4-methylphenyl)acetamide 0
                                                2-[[2-(4-chlorophenoxy)-1-oxoethyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide 0
                                                2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-4-thiophen-2-yl-3-thiophenecarboxylic acid methyl ester 0
                                                2-[[2-[(2,5-dimethylphenyl)sulfonylamino]-1-oxoethyl]amino]-6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide 0
                                                2-[[2-[3-(1-azepanylsulfonyl)-4-methylanilino]-2-oxoethyl]-methylamino]-N-(3-fluorophenyl)acetamide 0
                                                2-[[2-furanyl(oxo)methyl]hydrazo]-N-(2-methoxy-5-methylphenyl)-2-oxoacetamide 0
                                                2-[[3-Cyclohexyl-1-[2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid 0
                                                2-[[4-amino-6-(2-methylanilino)-1,3,5-triazin-2-yl]methyl-methylamino]-N-(2-ethylphenyl)acetamide 0
                                                2-[carboxymethyl-[2-(2,6-diethylanilino)-2-oxoethyl]amino]acetic acid 0
                                                2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]-N-(3-fluorophenyl)acetamide 0
                                                2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]-N-[2-(methylthio)phenyl]acetamide 0
                                                2-\{6-Oxo-6-[4-(L-phenylalanyl)-1-piperazinyl]hexyl\}guanidine 0
                                                2-amino-2',6'-butyroxylidide 0
                                                2-amino-4-(methylsulfanyl)-N-(2-naphthyl)butanamide + 0
                                                2-amino-N-(2'-(cyclohex-2''-enyl)acetyl)acetimide 0
                                                2-amino-N-2'-(phenylacetyl)propanimide 0
                                                2-aminohexano-6-lactam + 0
                                                2-anilino-N-(3,5-dimethylphenyl)-2-phenylacetamide 0
                                                2-anilino-N-(4-fluorophenyl)acetamide 0
                                                2-anilino-N-(4-methylphenyl)-2-phenylacetamide 0
                                                2-fluoro-N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-fluoro-N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]benzamide 0
                                                2-oxo-2-[(6-oxo-1-cyclohexa-2,4-dienylidene)methylhydrazo]-N-(2-pyridinyl)acetamide 0
                                                2-oxo-3(R)-hydroxy-lyngbyatoxin A 0
                                                3'-Hydroxyropivacaine 0
                                                3,4-dihydro-1H-isoquinolin-2-yl-[1-(8-quinolinylsulfonyl)-2-pyrrolidinyl]methanone 0
                                                3-(3-bromoanilino)-2-oxo-1H-indole-3-carbonitrile 0
                                                3-Hydroxylidocaine 0
                                                3-Hydroxymonoethylglycinexylidide 0
                                                3-[(3aR,6aS)-6'-chloro-5-(4-chlorophenyl)-7'-methyl-2',4,6-trioxo-1-spiro[1,2,3a,6a-tetrahydropyrrolo[3,4-c]pyrrole-3,3'-1H-indole]yl]propanamide 0
                                                3-[(4-methoxyphenyl)hydrazo]-2-nitroso-N-phenyl-2-butenamide 0
                                                3-[[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]-2-benzofurancarboxylic acid ethyl ester 0
                                                3-chloro-N-[1-[[2-(dimethylamino)-1-oxoethyl]amino]-3-[4-[8-(1-hydroxyethyl)-2-imidazo[1,2-a]pyridinyl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide 0
                                                3-chloro-N-[1-[[2-(dimethylamino)-1-oxoethyl]amino]-3-[4-[8-[(1S)-1-hydroxyethyl]-2-imidazo[1,2-a]pyridinyl]phenyl]propan-2-yl]-4-propan-2-yloxybenzamide 0
                                                3-fluoro-N-[1-[2-[(2-fluorophenyl)methylamino]-2-oxoethyl]-4-piperidinyl]benzamide 0
                                                3-methyl-5-[[1-oxo-2-(2-pyridinylmethylamino)ethyl]amino]thiophene-2,4-dicarboxylic acid diethyl ester 0
                                                4'-Hydroxyropivacaine 0
                                                4-(5-methyl-2-furanyl)-2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3-thiophenecarboxylic acid ethyl ester 0
                                                4-Hydroxylidocaine 0
                                                4-amino-5-[(2R)-2-borono-1-pyrrolidinyl]-5-oxopentanoic acid 0
                                                5-(alpha-Phenylethyl)semioxamazide 0
                                                5-bromo-3-[[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]-2-benzofurancarboxylic acid ethyl ester 0
                                                5-carbamoyl-4-methyl-2-[[1-oxo-2-(1,2,3,4-tetrahydronaphthalen-1-ylamino)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester 0
                                                5-hydroxy saxagliptin 0
                                                5-oxo-L-proline 2-naphthylamide 0
                                                6-methyl-2-[[2-(4-morpholinyl)-1-oxoethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester 0
                                                8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one 0
                                                A 80987 0
                                                BILA 2185BS 0
                                                BY-81 0
                                                Bactobolin 0
                                                Blastmycetin A 0
                                                Blastmycetin B 0
                                                Blastmycetin C 0
                                                Blastmycetin D 0
                                                Blastmycetin E 0
                                                Blastmycetin F 0
                                                Calpeptin 26
                                                Chrysogenamide A 0
                                                Citrinalin C 0
                                                Collacyclumin B 0
                                                Cycloexpansamine A 0
                                                Cytoblastin 0
                                                Descarbonyl-lacosamide 0
                                                Dl-norleucinamide 0
                                                Etidocaine hydrochloride 0
                                                Eusynstyelamide D 0
                                                Eusynstyelamide E 0
                                                Eusynstyelamide F 0
                                                FR900452 0
                                                Fasoracetam 0
                                                Glycyl-H-1152 0
                                                HEHEAA 0
                                                Hoiamide D 0
                                                Hydroxy-lacosamide 0
                                                Iprofenin 0
                                                L-alaninamide 0
                                                L-alanine 2-naphthylamide 0
                                                L-arginine 2-naphthylamide 0
                                                L-arginine amide 0
                                                L-asparagine 2-naphthylamide 0
                                                L-asparagine amide 0
                                                L-cysteine 2-naphthylamide 0
                                                L-cystine di-2-naphthylamide 0
                                                L-cystine mono-2-naphthylamide 0
                                                L-glutamine 2-naphthylamide 0
                                                L-glutamine amide + 0
                                                L-histidine 2-naphthylamide 0
                                                L-histidine amide 0
                                                L-hydroxyproline 2-naphthylamide 0
                                                L-isoleucinamide 0
                                                L-isoleucine 2-naphthylamide 0
                                                L-leucinamide 0
                                                L-leucine 2-naphthylamide 0
                                                L-leucine 4-methoxy-2-naphthylamide 0
                                                L-lysinamide + 0
                                                L-lysine 2-naphthylamide 0
                                                L-methioninamide + 0
                                                L-ornithine 2-naphthylamide 0
                                                L-phenylalanine 2-naphthylamide 0
                                                L-phenylalanine amide + 0
                                                L-prolinamide 0
                                                L-proline 2-naphthylamide 0
                                                L-serine 2-naphthylamide 0
                                                L-serine amide 0
                                                L-threonine 2-naphthylamide 0
                                                L-threonine amide 0
                                                L-tryptophan 2-naphthylamide 0
                                                L-tryptophanamide + 0
                                                L-tyrosinamide 0
                                                L-tyrosine 2-naphthylamide 0
                                                L-valine 2-naphthylamide 0
                                                L-valine amide 0
                                                LSM-10083 0
                                                LSM-10230 0
                                                LSM-10322 0
                                                LSM-11913 0
                                                LSM-12220 0
                                                LSM-14484 0
                                                LSM-14577 0
                                                LSM-14579 0
                                                LSM-14581 0
                                                LSM-14585 0
                                                LSM-14589 0
                                                LSM-14591 0
                                                LSM-14592 0
                                                LSM-14593 0
                                                LSM-14594 0
                                                LSM-14597 0
                                                LSM-14601 0
                                                LSM-14603 0
                                                LSM-14605 0
                                                LSM-14606 0
                                                LSM-14607 0
                                                LSM-14609 0
                                                LSM-14610 0
                                                LSM-14612 0
                                                LSM-14613 0
                                                LSM-14614 0
                                                LSM-14618 0
                                                LSM-14621 0
                                                LSM-14625 0
                                                LSM-14626 0
                                                LSM-14629 0
                                                LSM-14631 0
                                                LSM-14633 0
                                                LSM-14634 0
                                                LSM-14636 0
                                                LSM-14640 0
                                                LSM-14641 0
                                                LSM-14650 0
                                                LSM-14651 0
                                                LSM-14657 0
                                                LSM-14663 0
                                                LSM-14664 0
                                                LSM-14666 0
                                                LSM-14667 0
                                                LSM-14672 0
                                                LSM-24595 0
                                                LSM-26278 0
                                                LSM-33227 0
                                                LSM-36762 0
                                                LSM-42687 0
                                                LSM-4274 0
                                                LSM-4415 0
                                                LSM-8595 0
                                                LSM-8885 0
                                                LSM-9109 0
                                                LSM-9223 0
                                                LSM-9303 0
                                                LSM-9808 0
                                                LSM-9820 0
                                                Lipoxamycin 0
                                                Lycomarasmine B 0
                                                Lyngbyatoxin C 0
                                                Majusculamide A/B 0
                                                Marcfortine C 0
                                                Milacainide tartrate 0
                                                N'-(4-phenyl-2-thiazolyl)-N-(2-pyridinylmethyl)oxamide 0
                                                N'-[(2,5-dimethyl-1-phenyl-3-pyrrolyl)methylideneamino]-N-(2-pyridinylmethyl)oxamide 0
                                                N'-[(4-chlorophenyl)methyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]oxamide 0
                                                N'-[2-[1-(4-fluoro-2-methylphenyl)sulfonyl-2-piperidinyl]ethyl]-N-methyloxamide 0
                                                N'-[4-(1-adamantyl)-2-thiazolyl]-N-[(4-fluorophenyl)methyl]oxamide 0
                                                N'-[4-(dimethylamino)phenyl]-N-propyloxamide 0
                                                N(2)-(cyclohexylsulfonyl)-N-[(1R)-1-(piperidin-1-ylcarbonyl)-3-(pyridinium-4-ylamino)propyl]glycinamide 0
                                                N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-alaninamide 0
                                                N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-cysteinamide 0
                                                N(2)-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]-N-butyl-L-serinamide 0
                                                N(2)-\{3-[2-(2-\{[(1-\{3-[2-(2-\{[4-(indol-3-yl)butanoyl]amino\}ethoxy)ethoxy]propanoyl\}piperidin-4-yl)carbonyl]amino\}ethoxy)ethoxy]propanoyl\}-N(6)-(5-nitro-2-furoyl)lysinamide 0
                                                N(6)-Dnp-Lys-NH2 0
                                                N(6)-carbamoylmethyl-2'-deoxyadenosine 0
                                                N(6)-carbamoylmethyl-2'-deoxyadenosine 5'-monophosphate 0
                                                N(6)-carbamoylmethyladenine 0
                                                N,N'-diisobutyloxalamide 0
                                                N-(1,3-benzodioxol-5-yl)-2-(3-methyl-1-piperidinyl)-2-phenylacetamide 0
                                                N-(1,3-benzodioxol-5-yl)-2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]acetamide 0
                                                N-(1,3-benzodioxol-5-yl)-2-[4-(4-phenyl-2-thiazolyl)-1-piperazinyl]acetamide 0
                                                N-(1,3-benzodioxol-5-yl)-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide 0
                                                N-(1,3-benzothiazol-2-yl)-2-(2,6-dimethyl-4-morpholinyl)acetamide 0
                                                N-(1,3-benzothiazol-2-yl)-2-ethylsulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxamide 0
                                                N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(3-methyl-1-piperidinyl)-2-phenylacetamide 0
                                                N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(3-methoxyphenyl)methylamino]propanamide 0
                                                N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[4-(2,5-dimethylphenyl)sulfonyl-1-piperazinyl]acetamide 0
                                                N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)-2-(propan-2-ylamino)acetamide 0
                                                N-(2,5-difluorophenyl)-2-(1-pyrrolidinyl)acetamide 0
                                                N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide 0
                                                N-(2-bromophenyl)-2-[5-(dimethylsulfamoyl)-2-(ethylamino)anilino]acetamide 0
                                                N-(2-bromophenyl)-2-[[2-(2,6-dimethylanilino)-2-oxoethyl]-methylamino]acetamide 0
                                                N-(2-butan-2-ylphenyl)-2-[(3-methoxyphenyl)methyl-methylamino]propanamide 0
                                                N-(2-fluorophenyl)-N'-[[2-[2-oxo-2-(1-pyrrolidinyl)ethoxy]phenyl]methylideneamino]oxamide 0
                                                N-(2-furanylmethyl)-2-[(5-methoxy-6-oxo-1-cyclohexa-2,4-dienylidene)methylhydrazo]-2-oxoacetamide 0
                                                N-(2-methylphenyl)-N'-[[4-oxo-4-(2-pyridinylamino)butan-2-ylidene]amino]oxamide 0
                                                N-(3,4-dichlorophenyl)-2-[4-(1-piperidinylsulfonyl)-1-piperazinyl]acetamide 0
                                                N-(3-chloro-2-methylphenyl)-2-[(2-fluorophenyl)methylamino]acetamide 0
                                                N-(3-chloro-2-methylphenyl)-2-[3-(dimethylsulfamoyl)anilino]acetamide 0
                                                N-(3-chloro-4-fluorophenyl)-2-[5-(dimethylsulfamoyl)-2-(ethylamino)anilino]acetamide 0
                                                N-(3-chloro-4-methylphenyl)-2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)acetamide 0
                                                N-(3-chlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide 0
                                                N-(3-cyano-2-thiophenyl)-2-[4-(2,5-dimethylphenyl)sulfonyl-1-piperazinyl]acetamide 0
                                                N-(3-fluorophenyl)-2-oxo-4,10-dihydro-3H-pyrimido[1,2-a]benzimidazole-4-carboxamide 0
                                                N-(4-Chloro-3-cyanophenyl)-N'-[2-(4-methoxyphenyl)ethyl]ethanediamide 0
                                                N-(4-bromo-2-fluorophenyl)-2-(2,4-dimethoxyanilino)acetamide 0
                                                N-(4-cyano-1-phenyl-1H-pyrazol-5-yl)-2-(4-methylpiperazino)acetamide 0
                                                N-(4-fluorophenyl)-2-[4-[oxo(1-piperidinyl)methyl]-1-piperazinyl]acetamide 0
                                                N-(4-methoxyphenyl)-2-(N-methylanilino)-2-(6-nitro-1,3-benzodioxol-5-yl)acetamide 0
                                                N-(4-nitrophenyl)-2-(1-pyrrolidinyl)acetamide 0
                                                N-(5-chloro-2-methoxyphenyl)-2-[4-(3-phenylprop-2-enyl)-1-piperazinyl]propanamide 0
                                                N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-2-(2-fluorophenyl)sulfonyl-3,4-dihydro-1H-isoquinoline-3-carboxamide 0
                                                N-(6-acetyl-1,3-benzodioxol-5-yl)-2-(2-methyl-1-piperidinyl)acetamide 0
                                                N-(6-acetyl-1,3-benzodioxol-5-yl)-2-(4-ethyl-1-piperazinyl)acetamide 0
                                                N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[4-[5-(trifluoromethyl)-1-benzotriazolyl]-1-piperidinyl]acetamide 0
                                                N-(alpha-L-aspartyl)-2-naphthylamine 0
                                                N-(alpha-L-glutamyl)-2-naphthylamine 0
                                                N-(gamma-L-glutamyl)-2-naphthylamine 0
                                                N-Demethylteleocidin B-4 0
                                                N-Tert-butyl-2-[2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide 0
                                                N-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-(2-oxo-2-piperidin-1-ylethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3R,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3R,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3S,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1R,3S,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3R,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3R,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3S,4aR,9aS)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-oxo-2-(1-piperidinyl)ethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(1S,3S,4aS,9aR)-3-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-2-(dimethylamino)acetamide 0
                                                N-[(2R,3R,4aS,6S,8aS)-2-[2-[4-(1-cyclohexenyl)phenyl]ethyl]-6-(hydroxymethyl)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-3-yl]-2-(dimethylamino)acetamide 0
                                                N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2R,3R,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3R,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2R,3R,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3R,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2R,3S,6R)-6-[2-(4-cyclohexyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-2-morpholin-4-ylacetamide 0
                                                N-[(2R,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3S,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2R,3S,6S)-6-[2-(4-cyclohexyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-2-morpholin-4-ylacetamide 0
                                                N-[(2R,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2R,3S,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2S,3R,6R)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3R,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3R,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2S,3R,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3R,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3R,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2S,3S,6R)-6-[2-(4-cyclohexyltriazol-1-yl)ethyl]-2-(hydroxymethyl)oxan-3-yl]-2-morpholin-4-ylacetamide 0
                                                N-[(2S,3S,6R)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3S,6R)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-1,3-benzodioxole-5-carboxamide 0
                                                N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-[[2-(4-morpholinyl)-1-oxoethyl]amino]ethyl]-3-oxanyl]-2-(2-pyridinyl)acetamide 0
                                                N-[(2S,3S,6S)-6-[2-(4-cyclohexyl-1-triazolyl)ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3S,6S)-6-[2-[(2-fluorophenyl)sulfonylamino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(2S,3S,6S)-6-[2-[[(2,5-difluoroanilino)-oxomethyl]amino]ethyl]-2-(hydroxymethyl)-3-oxanyl]-2-(4-morpholinyl)acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(3-fluorophenyl)methyl]-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-[(4-chlorophenyl)methyl]-2-[[[(2-fluorophenyl)methyl-(phenylmethyl)amino]-sulfanylidenemethyl]amino]acetamide 0
                                                N-[2-(1H-benzimidazol-2-yl)ethyl]-2-[4-(5-fluoro-1-benzotriazolyl)-1-piperidinyl]acetamide 0
                                                N-[2-(2-ethyl-1-piperidinyl)ethyl]-2-[(2-methyl-1,3-benzothiazol-6-yl)sulfonylamino]acetamide 0
                                                N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)oxamide 0
                                                N-[2-(4-chlorophenyl)ethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide 0
                                                N-[2-(cyclopentylamino)-2-oxoethyl]-4,7-dimethyl-N-(2-methylphenyl)-2-oxo-3H-pyrido[1,2-a]pyrimidine-4-carboxamide 0
                                                N-[2-(diethylamino)-5-(4-morpholinylsulfonyl)phenyl]-2-[(phenylmethyl)amino]acetamide 0
                                                N-[2-[(2R,5R,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2S,5R,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(2-morpholin-4-ylacetyl)amino]oxan-2-yl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2S,5S,6R)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-[(2S,5S,6S)-5-[(4-fluorophenyl)sulfonylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-2-morpholin-4-ylacetamide 0
                                                N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]ethyl]cyclobutanecarboxamide 0
                                                N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[oxo-[4-(trifluoromethyl)anilino]methyl]amino]-2-oxanyl]ethyl]-2-(4-morpholinyl)acetamide 0
                                                N-[2-chloro-5-[ethyl(phenyl)sulfamoyl]phenyl]-2-[methyl-(1-methyl-4-piperidinyl)amino]acetamide 0
                                                N-[4-(1,3-benzothiazol-2-yl)phenyl]-2-[(4-tert-butylphenyl)sulfonylamino]acetamide 0
                                                N-[4-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-2-thiazolyl]-2-(4-morpholinyl)acetamide 0
                                                N-[4-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-5-methyl-2-thiazolyl]-2-(4-morpholinyl)acetamide 0
                                                N-[4-chloro-3-(dimethylsulfamoyl)phenyl]-2-[(phenylmethyl)amino]acetamide 0
                                                N-[5-[[2-(4-methylanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-2-(4-morpholinyl)acetamide 0
                                                N-[[(2R,3R,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                                                N-[[(2R,3R,4S)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                                                N-[[(2R,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                                                N-[[(2R,3S,4R)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                                                N-[[(2R,3S,4S)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                                                N-[[(2R,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                                                N-[[(2S,3R,4R)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                                                N-[[(2S,3R,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                                                N-[[(2S,3S,4R)-1-acetyl-3-[4-(1-cyclohexenyl)phenyl]-4-(hydroxymethyl)-2-azetidinyl]methyl]-2-(dimethylamino)acetamide 0
                                                N-[[(2S,3S,4S)-1-acetyl-4-(hydroxymethyl)-3-phenyl-2-azetidinyl]methyl]-2-(4-morpholinyl)acetamide 0
                                                N-[[3-(4-nitrophenyl)sulfonyl-2-oxazolidinyl]methyl]-N'-(2-pyridinylmethyl)oxamide 0
                                                N-acetyl-L-phenylalanyl-4-[difluoro(phosphono)methyl]-L-phenylalaninamide 0
                                                N-acetylglycine-N-methylamide 0
                                                N-cycloheptyl-2-(cyclohexylamino)-2-sulfanylideneacetamide 0
                                                N-cyclohexyl-2-[(2R,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2R,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2R,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2R,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2S,3R,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2S,3R,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2S,3S,6R)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2S,3S,6S)-2-(hydroxymethyl)-3-[[2-(4-morpholinyl)-1-oxoethyl]amino]-3,6-dihydro-2H-pyran-6-yl]acetamide 0
                                                N-cyclohexyl-2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclohexyl-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[2-(4-morpholinyl)-1-oxoethyl]amino]-2-oxanyl]acetamide 0
                                                N-cyclopentyl-2-(2,3-dihydroindol-1-yl)-2-(4-methoxyphenyl)acetamide 0
                                                N-decyl-N'-(2-pyridinyl)oxamide 0
                                                N-propan-2-yl-2-[4-(2-pyrimidinyl)-1-piperazinyl]acetamide 0
                                                N-tert-butyl-2-[[(3-nitrophenyl)-oxomethyl]hydrazo]-2-oxoacetamide 0
                                                N1-(2,4-Dimethoxybenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide 0
                                                N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(5-methylpyridin-2-yl)ethyl)oxalamide 0
                                                N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide 0
                                                N1-(4-butyl-2-methylphenyl)-2-(benzylamino)-2-thioxoacetamide 0
                                                N1-(4-nitrophenyl)-2-amino-3-(benzylthio)propanamide 0
                                                N2,N6-Diacetyl-N-\{4-[hydroxy(phenyl)methyl]phenyl\}lysinamide 0
                                                Neoenactin B1 0
                                                Neoenactin B2 0
                                                Neoenactin M2 0
                                                Neoenactin NL1 0
                                                Neoenactin NL2 0
                                                Olivoretin A 0
                                                Olivoretin B 0
                                                Olivoretin E 0
                                                Oxethazaine 0
                                                PF-00477736 2
                                                Pantocin B 0
                                                Peniciherquamide A 0
                                                Penicimutide 0
                                                Penioxalamine A 0
                                                Phenylacetylglycine dimethylamide 0
                                                Prumycin 0
                                                Pyrronamycin A 0
                                                Pyrronamycin B 0
                                                SB200437 0
                                                Safracin A 0
                                                Saframycin Mx1 0
                                                Serratiochelin C 0
                                                Teleocidin A-2 0
                                                Teleocidin B-1 0
                                                Teleocidin B-2 0
                                                Teleocidin B-3 0
                                                Teleocidin B4 0
                                                VM-55595 0
                                                Y-14556 0
                                                [(3R)-3-aMino-4-[(3-hexylphenyl)aMino]-4-oxobutyl]-phosphonic acid 0
                                                [2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-(phenylmethyl)ammonium 0
                                                [2-(2,6-dimethylanilino)-2-oxoethyl]-diethyl-methylammonium 0
                                                [2-(2,6-dimethylanilino)-2-oxoethyl]-trimethylammonium 0
                                                alpha-N-(9-beta-D-ribofuranosylpurin-6-yl)glycinamide 0
                                                ambucetamide 0
                                                aminopropylone 0
                                                amoxicilloyl polylysine 0
                                                anagliptin 11
                                                aspartic 1-amide + 0
                                                benzylpenicilloyl polylysine 0
                                                beta-alaninamide 0
                                                beta-alanine 2-naphthylamide 0
                                                beta-alanine, n-[2-[(3-hexylphenyl)amino]-2-oxoethyl]- 0
                                                biocytinamide 0
                                                bortezomib 833
                                                butanilicaine 0
                                                cefatrizine 0
                                                disofenin 0
                                                eluxadoline 1
                                                ent-Eusynstyelamide B, (rel)- 0
                                                etidocaine 0
                                                glycinamide + 645
                                                glycine 2-naphthylamide 0
                                                glycinexylidide + 0
                                                gosogliptin 0
                                                isoglutamine + 0
                                                isopropyl (3-methyl-1-\{[1-(4-methylphenyl)ethyl]amino\}-1-oxobutan-2-yl)carbamate + 0
                                                lidofenin 0
                                                lisdexamfetamine 0
                                                majusculamide A 0
                                                majusculamide B 0
                                                mebrofenin 0
                                                methyl 2-[(1R,3R,4aS,9aR)-6-[[2-(dimethylamino)acetyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]acetate 0
                                                midodrine 2
                                                monoethylglycinexylidide + 2
                                                phenamine 0
                                                prilocaine + 4
                                                proline 2-naphthylamide 0
                                                pyrrocaine 0
                                                safinamide 0
                                                teneligliptin 0
                                                trimecaine 0
                                                trimethyl-[2-oxo-2-[(2,2,3-trimethyl-3-bicyclo[2.2.1]heptanyl)amino]ethyl]ammonium 0
                                                tryparsamide 0
                                                versetamide 0
                                                vildagliptin 30
paths to the root